0001558370-21-004303 | 20-F | XBRL Viewer

Print Document View Excel Document

Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2020 shares
Document and Entity Information
Entity Registrant Name	Centogene N.V.
Entity Central Index Key	0001757097
Document Type	20-F
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Common Units, Units Outstanding	22,117,643
Entity Emerging Growth Company	true
Entity Shell Company	false
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Interactive Data Current	Yes
Document Registration Statement	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false

Consolidated statements of comprehensive loss - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Consolidated statements of comprehensive loss
Revenue	€ 128,381	€ 48,780	€ 40,478
Cost of sales	86,378	26,005	19,941
Gross profit	42,003	22,775	20,537
Research and development expenses	14,935	9,590	6,300
General administrative expenses	37,665	23,160	18,610
Selling expenses	7,580	9,254	7,474
Impairment of financial assets	3,738	752	792
Other operating income	2,394	3,781	2,306
Other operating expenses	182	1,284	273
Real estate transfer tax expenses		1,200	0
Operating loss	(19,703)	(18,684)	(10,606)
Interest and similar income	6	16	33
Interest and similar expenses	1,400	2,029	1,075
Financial costs, net	(1,394)	(2,013)	(1,042)
Loss before taxes	(21,097)	(20,697)	(11,648)
Income taxes expenses/(benefits)	281	158	(310)
Loss for the year	(21,378)	(20,855)	(11,338)
Other comprehensive income, all attributable to equity holders of the parent	(48)	16	(8)
Total comprehensive loss	(21,426)	(20,839)	(11,346)
Attributable to:
Equity holders of the parent	(21,486)	(20,658)	(10,971)
Non‑controlling interests	60	(181)	(375)
Total comprehensive loss	€ (21,426)	€ (20,839)	€ (11,346)
Loss per share - Basic and diluted	€ (1.02)	€ (1.27)	€ (0.8)

Consolidated statements of financial position - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Non‑current assets
Intangible assets	€ 12,407	€ 14,145
Property, plant and equipment	16,590	8,376
Right-of-use assets	22,120	24,932
Other assets	1,967	1,948
Non-current assets	53,084	49,401
Current assets
Inventories	11,405	1,809
Trade receivables and contract assets	29,199	16,593
Other assets	8,286	8,612
Cash and cash equivalents	48,156	41,095
Current assets	97,046	68,109
Total assets	150,130	117,510
Equity
Issued capital	2,654	2,383
Capital reserve	125,916	98,099
Retained earnings and other reserves	(62,888)	(40,622)
Non‑controlling interests	95	(938)
Equity	65,777	58,922
Non‑current liabilities
Non‑current loans	401	1,578
Lease liabilities	17,677	18,069
Deferred tax liabilities	207
Government grants	8,950	9,941
Non-current liabilities	27,235	29,588
Current liabilities
Government grants	1,342	1,348
Current loans	2,492	3,688
Lease liabilities	3,528	3,635
Liabilities from income taxes	58
Trade payables	31,736	8,554
Other liabilities	17,962	11,775
Current liabilities	57,118	29,000
Equity and liabilities	€ 150,130	€ 117,510

Consolidated statements of cash flows - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating activities
Loss before taxes	€ (21,097)	€ (20,697)	€ (11,648)
Adjustments to reconcile earnings to cash flow from operating activities
Amortization (including impairments) and depreciation	15,128	6,579	5,175
Interest income	(6)	(16)	(33)
Interest expense	1,400	2,029	1,075
Loss/(gain) on the disposal of non‑current assets		(532)
Expected credit loss allowances on trade receivables and contract assets	3,738	752	792
Share‑based payment expenses	5,658	6,418	5,521
Real estate transfer tax expenses		1,200	0
Other non‑cash items	(915)	(1,856)	(966)
Changes in operating assets and liabilities:
Inventories	(9,596)	(463)	(567)
Trade receivables and contract assets	(16,344)	(6,444)	(4,701)
Other assets	255	(1,169)	(919)
Trade payables	23,996	3,125	140
Other liabilities	6,245	3,299	1,554
Cash flow (used in)/from operating activities	8,462	(7,775)	(4,577)
Investing activities
Cash paid for investments in intangible assets	(6,657)	(7,280)	(3,059)
Cash paid for investments in property, plant and equipment	(9,890)	(296)	(8,710)
Grants received for investment in property, plant and equipment	390	793	3,042
Grants refunded related to disposed property, plant and equipment		(358)
Cash received from disposals of property, plant and equipment		21,300
Interest received	6	16	33
Cash flow (used in)/from investing activities	(16,151)	14,175	(8,694)
Financing activities
Cash received from issuance of shares	22,430	41,899	20,073
Cash paid for acquisition of non-wholly owned subsidiary	(75)
Cash received from loans	438	721	3,631
Cash repayments of loans	(2,760)	(12,072)	(2,851)
Cash repayments of lease liabilities	(5,018)	(3,046)	(442)
Interest paid	(173)	(2,029)	(1,075)
Cash flow from financing activities	14,842	25,473	19,336
Changes in cash and cash equivalents	7,153	31,873	6,065
Cash and cash equivalents at the beginning of the period	41,095	9,222	3,157
Effect of movements in exchange rates on cash held	(92)
Cash and cash equivalents at the end of the period	€ 48,156	€ 41,095	€ 9,222

Consolidated statements of changes in equity - EUR (€) € in Thousands	Total	Issued capital	Capital reserve	Currency translation reserve	Retained earnings	Non-controlling interests	Total
Balance at beginning of the period at Dec. 31, 2017	€ 16,736	€ 1,546	€ 24,183	€ (8)	€ (8,985)	€ (382)	€ 16,354
Loss for the year	(10,963)				(10,963)	(375)	(11,338)
Other comprehensive loss	(8)			(8)			(8)
Total comprehensive loss	(10,971)			(8)	(10,963)	(375)	(11,346)
Share-based payments	1,443		1,443				1,443
Issuance of shares	20,073	357	19,716				20,073
Transaction costs							0
Balance at end of the period at Dec. 31, 2018	27,281	1,903	45,342	(16)	(19,948)	(757)	26,524
Loss for the year	(20,674)				(20,674)	(181)	(20,855)
Other comprehensive loss	16			16			16
Total comprehensive loss	(20,658)			16	(20,674)	(181)	(20,839)
Share-based payments	1,300		1,300				1,300
Issuance of shares	46,798	480	46,318				46,798
Transaction costs	(4,899)		(4,899)				(4,899)
Share-based payments - modification at IPO	10,038		10,038				10,038
Balance at end of the period at Dec. 31, 2019	59,860	2,383	98,099		(40,622)	(938)	58,922
Loss for the year	(21,438)				(21,438)	60	(21,378)
Other comprehensive loss	(48)			(48)			(48)
Total comprehensive loss	(21,486)			(48)	(21,438)	60	(21,426)
Share-based payments	5,658		5,658				5,658
Issuance of shares	23,209	240	22,969				23,209
Exercise of options		31	(31)
Transaction costs	(779)		(779)				(779)
Disposal of non-wholly owned subsidiary						268	268
Acquisition of non-wholly owned subsidiary	(780)				(780)	705	(75)
Balance at end of the period at Dec. 31, 2020	€ 65,682	€ 2,654	€ 125,916	€ (48)	€ (62,840)	€ 95	€ 65,777

General company information	12 Months Ended
General company information	Dec. 31, 2020
General company information
General company information	1 General company information Centogene N.V. (“the Company”) and its subsidiaries focus on rare diseases that transforms real-world clinical and genetic or other data into actionable information for patients, physicians and pharmaceutical companies. The mission of the Company is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. On November 7, 2019, the Company completed an initial public offering (“IPO”) and has since been listed on Nasdaq Global Market under stock code “CNTG”. We have historically conducted our business through Centogene AG (which is now known as Centogene GmbH), and therefore our historical financial statements present the results of operations and financial condition of Centogene AG and its controlled subsidiaries. In connection with our initial public offering, Centogene N.V. became the holding company of Centogene AG on November 12, 2019, and the historical consolidated financial statements of Centogene AG became the historical consolidated financial statements of Centogene N.V. Centogene N.V. is a public company with limited liability incorporated in the Netherlands, with registered office located at Am Strande 7 in 18055 Rostock, Germany and Dutch trade register number 72822872. On March 5, 2020, the Company resolved that Centogene AG shall be converted into a German limited liability company and renamed Centogene GmbH. Such conversion became effective upon the registration in the German commercial register on June 29, 2020. Unless otherwise stated, “Centogene GmbH” also refers to the historical operations of Centogene AG throughout the notes. In July 2020, the Company completed a follow-on public offering of 3,500,000 common shares of the Company (the “July 2020 Offering”), consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of USD 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts, commissions and transaction costs, were EUR 22 million to the Company.

Basis of preparation	12 Months Ended
Basis of preparation	Dec. 31, 2020
Basis of preparation
Basis of preparation	2 Basis of preparation Unless otherwise specified, “the Company” refers to Centogene N.V. and Centogene GmbH throughout the remainder of these notes, while “the Group” refers to Centogene N.V., Centogene GmbH and its subsidiaries. The consolidated financial statements of the Group were prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (the “IASB”). The accounting policies used in the fiscal year 2020 generally correspond to the policies applied in the prior year, except for certain amendments to the standards which are effective for annual periods beginning on or after January 1, 2020 (see note 3). In addition, certain prior period information has been reclassified to conform with current year presentation (see note 17). These consolidated financial statements are presented in euro, which is the Group’s functional currency. Unless otherwise specified, all financial information presented in euro is rounded to the nearest thousand (EUR k) in line with customary commercial practice. COVID-19 Pandemic The COVID-19 pandemic, which began in December 2019, has spread worldwide and continues to cause many governments to maintain measures to slow the spread of the outbreak through quarantines, travel restrictions, closures of borders and requiring maintenance of physical distance between individuals. As part of the Group’s initiative to assist local, national and international authorities as well as other partners in their efforts to facilitate the earliest possible diagnosis of COVID-19 and thereby contribute to allowing society to return to a “new” normal, the Group commenced testing for COVID-19 in March 2020. The Group offers a COVID-19 testing solution to the community. This includes the COVID-19 tests, which received Emergency Use Authorizations (“EUA”) from the FDA in July 2020; the CentoKit-19, a fully validated sample collection kit which can either be used by healthcare professionals or self-administered by individuals; and the Corona Test Portal, a secure digital platform allowing seamless registration and result notification. The Group has leveraged its core competency of providing precise medical diagnoses, as well as its infrastructure, to help prevent further outbreaks of SARS-CoV-2 (COVID-19). As part of this initiative, the Group has become a large COVID-19 testing company in Europe, with a leading role in providing testing services at airports in Germany. The positive financial contribution from COVID-19 testing will enable the Group to make strategic investments to further solidify its leading position in the rare disease space. Furthermore, new virus variants have emerged since mid-December 2020. How these mutations develop and their impact on the effectiveness of vaccines have not yet been determined. However, this could potentially prolong the need for testing on a broader scale. Due to the growth and significance of the COVID-19 business in relation to the total activities of the Group, the COVID-19 testing business is managed and reported as a separate segment beginning in the third quarter of 2020. In the second quarter 2020 report, furnished to the SEC on Form 6-K on September 23, 2020, the financial impact of the COVID-19 business has been reported as a part of our Diagnostics segment, whereas it has been separated from the Diagnostics segment and included in the full year COVID-19 financials in these financial statements.

Effects of new accounting standards

12 Months Ended

Dec. 31, 2020

Effects of new accounting standards

Effects of new accounting standards

3 Effects of new accounting standards

(a)New standards adopted by the Group as of January 1, 2020

The following amendments and interpretations apply for the first time in 2020 and had no impact on the consolidated financial statements of the Group:

Amendments to IAS 1 and IAS 8 – Definition of Material

Amendments to IFRS 3 – Definition of a Business

Amendments to IFRS 7, IFRS 9 and IAS 39 – Interest Rate Benchmark Reform

Revised Conceptual Framework for Financial Reporting

(b)New standards not yet effective

Furthermore, certain new and amended standards and interpretations have been published that are not mandatory for December 31, 2020 reporting periods and have not been early adopted by the Group. The Group intends to adopt these new and amended standards and interpretations, if applicable, when they become effective. There are no new or amended standards or interpretations that are issued and become effective for the 2021 annual reporting period, that are expected to have a material impact on the Group.

Basis of consolidation	12 Months Ended
Basis of consolidation	Dec. 31, 2020
Basis of consolidation
Basis of consolidation	4 Basis of consolidation The basis of consolidation includes the entities over which Centogene N.V. has control within the meaning of IFRS 10 Consolidated Financial Statements. According to IFRS 10, Centogene N.V. has control of an investee when it has direct or indirect power over the investee, exposure, or rights to variable returns from its involvement with the investee and the ability to use its power over the investee to affect those returns. Control is established when it is possible to influence operating and financial policies of the investee, typically with a share in the voting rights or shareholding of more than 50% in the investee. An entity is included in the Group’s basis of consolidation from the point in time when the Group obtains control of the entity and ceases when the Group loses control of the subsidiary. Assets, liabilities, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated financial statements from the date the Group gains control until the date the Group ceases to control the subsidiary. Profit or loss and each component of other comprehensive income are attributed to the equity holders of the parent of the Group and to the non-controlling interests, even if this results in the non-controlling interests having a deficit balance. All intra-group assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full upon consolidation. If the Group loses control over a subsidiary, it derecognizes the related assets, liabilities, non-controlling interest and other components of equity, while any resultant gain or loss is recognized in profit or loss. In the third quarter of 2020, the Company entered into a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock (hereafter ‘Bauer GmbH’). Bauer GmbH supports Centogene in certain areas of its COVID-19 testing business by providing the medical laboratory services to facilitate Centogene to perform its COVID-19 testing business activities. Bauer GmbH is wholly owned by a long-time employee of Centogene, who from a medical perspective and by observing the Medical Association's professional code of conduct continues to operate as an independent medical physician. As per the criteria in IFRS 10, Centogene assessed the control it has over Bauer GmbH and concluded to consolidate the activities of Bauer GmbH in the Group from the third quarter of 2020. Centogene does not own any shares in Bauer GmbH. However, based on the analysis of all facts and circumstances surrounding the close collaboration with Bauer GmbH and the employment relationship with the sole shareholder of Bauer GmbH, this shareholder is considered as a de facto agent. Centogene meets the criteria of the control model under IFRS 10 as it has exposure to variable returns and the ability to use power to affect returns. Bauer GmbH has a share in the net result of the respective COVID-19 testing business which has been accounted for under non-controlling interest (see note 23).

Significant accounting policies

12 Months Ended

Dec. 31, 2020

Significant accounting policies

Significant accounting policies

5 Significant accounting policies

The Group applied the following accounting policies consistently for all of the periods presented in these consolidated financial statements.

(a)Foreign currency and currency translation

The Group’s consolidated financial statements are presented based on the parent company’s functional currency. For each entity, the Group determines the functional currency and items included in the financial statements of each entity are measured using that functional currency. The Group uses the direct method of consolidation and on disposal of a foreign operation, the gain or loss that is reclassified to profit or loss reflects the amount that arises from using this method.

Transactions in foreign currency are translated into the respective entity’s functional currency at the spot rate prevailing on the date of the transaction.

The functional currency of each entity is the respective local currency, since the entities carry out their business activities independently from a financial, economic and organizational perspective.

Monetary assets and liabilities denominated in foreign currency are translated to the functional currency using the closing rate at the reporting date. Currency translation differences are recognized immediately through profit or loss. Non-monetary items denominated in a foreign currency that are measured at historical cost are not translated at the reporting date.

On consolidation, the assets and liabilities of foreign operations are translated into euros using the closing rate on the reporting date. Income and expenses of foreign operations are translated using the exchange rate prevailing on the date of the transaction or the annual average exchange rate. Equity is translated using historical rates until the entity is removed from the Group’s basis of consolidation. Any resulting currency translation differences are recorded in other comprehensive income and recognized under the currency translation reserve in equity if the exchange difference is not allocable to the non-controlling interests.

The exchange rates used are presented in the following table:


	Average rate			Closing rate
				Dec 31,	Dec 31,	Dec 31,
	2018	2019	2020	2018	2019	2020
USD (EUR 1)	1.1779	1.1191	1.1412	1.1419	1.1234	1.2271
AED (EUR 1)	4.2713	4.0985	4.2091	4.1396	4.0795	4.5045
INR (EUR 1)	79.3177	78.7980	84.5737	78.5156	80.1870	89.6605

(b)Revenues from contracts with customers

The Group provides pharmaceutical solutions and diagnostic tests, as well as COVID-19 tests, enabled by its knowledge and interpretation-based platform. Revenue from contracts with customers is recognized when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the Group expects to be entitled in exchange for those goods or services, usually on delivery of the goods.

(i)Pharmaceutical segment

The Group's contracts with customers relate to a variety of solutions provided to the Group's pharmaceutical partners in order to accelerate their development of treatments for rare diseases, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The collaboration agreements are structured on a fee per sample basis, milestone basis, fixed fee basis, royalty basis or a combination of these. In addition, some of the Group's contracts with its pharmaceutical partners also include sales of CentoCards for the collection of biological samples from patients.

The performance obligations in Pharmaceutical segment can either be satisfied over time or at a point in time depending on the structure of the collaborations, which are determined based on nature of the service provided, as detailed below.

-Revenue from early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring is based on fee per sample, milestone fees and fixed fees. The revenues from these solutions are recognized over time using an input method based on the work rendered in order to measure progress towards complete satisfaction of the services.

-Revenue from the licensing of intellectual property for an unlimited period, usually in the structure of an upfront fee, is recognized at a point in time, when the right (or license) to use intellectual property is conveyed.

-Revenues from the licensing of intellectual property for a certain period, being a right to access such intellectual property as defined in IFRS 15, is recognized over time over the licensing period.

-Revenue from the sale of CentoCards is recognized at a point in time when the control of the CentoCards has transferred to the customer, which typically occurs on delivery.

(ii)Diagnostics segment

Revenues from the Group's diagnostics segment are typically generated from genetic sequencing and diagnostics services that the Group provides to clients, who are typically physicians, laboratories or hospitals, either directly or through distributors. Revenues are based on a negotiated price per test or on the basis of agreements to provide certain testing volumes over defined periods. The Group has concluded that the services rendered in the diagnostics segment comprise one performance obligation.

The performance obligation in the Diagnostics segment is recognized over time, using an input method to measure progress towards complete satisfaction of the service. In order to measure progress, the Group uses a standardized process which measures progress to completion by stages, consisting of (i) a preparation stage, (ii) a clarification stage, (iii) a sequencing stage, and (iv) an output stage. The percentages attributed to those stages are indicative of the cost incurred in performing the respective stage in relation to total cost.

(iii)COVID-19 segment

COVID-19 revenues are based on a negotiated price per test or on the basis of agreements covering tests to be performed over defined periods. Given the short turnaround time for the COVID-19 tests, revenues from COVID-19 tests that are on a price per test basis are recognized at a point in time. Revenues from COVID-19 tests that are on the basis of agreements covering tests to be performed over defined periods are recognized over time over the agreement period.

The Group has disaggregated revenue recognized from contracts with customers into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The Group has also disclosed information about the relationship between the disclosure of disaggregated revenue and the revenue information disclosed for each reportable segment. See note 7 for the disclosure on disaggregated revenue.

Contract balances

(i) Contract assets

A contract asset is the right to consideration in exchange for goods or services transferred to the customer. If the Group satisfies a performance obligation by transferring goods or services to a customer before the customer pays consideration or before payment is due, a contract asset is recognized for the earned consideration that is conditional. Contract assets are subject to impairment assessment, refer to accounting policies of impairment of financial assets in note 5(n) “Financial instruments”.

(ii) Trade receivables

A receivable represents the Group’s right to an amount of consideration that is unconditional (i.e., only the passage of time is required before payment of the consideration is due). Refer to accounting policies of impairment of financial assets in note 5(n) “Financial instruments”.

(iii) Contract liabilities

A contract liability is the obligation to transfer goods or services to a customer for which the Group has received consideration or an amount of consideration is due from the customer (whichever is earlier). If a customer pays consideration before the Group transfers goods or services to the customer, a contract liability is recognized when the payment is made or the payment is due (whichever is earlier). Contract liabilities are recognized as revenue when the Group performs under the contract.

(c)Finance income and finance costs

Interest income and expenses are recognized in the period which they relate to through profit or loss using the effective interest rate method.

(d)Current versus non-current classification

The Group presents assets and liabilities in the statement of financial position based on current/non-current classification. An asset is current when it is:

-Expected to be realized or intended to be sold or consumed in the normal operating cycle

-Held primarily for the purpose of trading

-Expected to be realized within twelve months after the reporting period; or

-Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

-It is expected to be settled in the normal operating cycle

-It is held primarily for the purpose of trading

-It is due to be settled within twelve months after the reporting period; or

-There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

The Group classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities

(e)Intangible assets

Research and development

Expenses for research activities are recognized through profit or loss in the period in which they are incurred.

Development expenditures on an individual project are recognized as an intangible asset from the date the Group can demonstrate:

-the product or process is technically and commercially feasible so that the asset will be available for use or sale

-the Group has the intention and its ability and intention to use or sell the asset

-a future economic benefit is probable

-the Group has sufficient resources to complete the development and

-the development costs can be measured reliably.

The Group’s research and development activities mainly relate to development of biomarkers and IT driven solutions. With respect to biomarkers, the development stage is usually considered to be achieved when the target validation process is completed and commercialization is probable. With respect to IT driven solutions, the development stage is considered to be achieved upon the completion of the Group’s internal validation test. Before such dates, any development costs are recognized in profit or loss and may not be subsequently capitalized.

Capitalized development costs are recognized at cost less accumulated amortization and any accumulated impairment losses. They are only amortized as from the date the asset is ready for its intended use, which in the case of biomarkers is normally at the time the patent application for such biomarker is made. Amortization expense commences when the assets are ready to be put in use, and is recorded in cost of sales and research and development expenses.

Capitalized development costs which are still under development are tested for impairment annually and when circumstances indicate that the carrying value may be impaired.

Other intangible assets

Other intangible assets purchased by the Group with finite useful lives are recognized at cost less accumulated amortization and any accumulated impairment losses. Subsequent expenditure is only capitalized if it increases the future economic benefits of the respective asset.

Intangible assets are amortized over their estimated useful life using the straight-line method and assessed for impairment whenever there is an indication that the intangible asset may be impaired.

The estimated useful lives are as follows:

Software, patents and trademarks: 3‑7 years

Corona Test Portal: 2 years

Capitalized development costs: 7 years

The useful lives and depreciation methods are reviewed annually to ensure that the methods and periods of depreciation are consistent with the expected economic benefit from the asset.

(f)Property, plant and equipment

Property, plant and equipment are carried at cost less any accumulated depreciation and any accumulated impairment losses.

The cost of property, plant and equipment comprises its purchase price including customs duties and non-refundable acquisition taxes, and proportionate VAT not deductible from input tax as well as any directly attributable costs of bringing the asset to its working condition and location for its intended use.

Subsequent expenditure is only capitalized if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

Depreciation is calculated over the estimated useful life using the straight-line method. The Group has assessed that none of its property, plant and equipment has a residual value. The estimated useful lives of significant property, plant and equipment are as follows:

Freehold land is not depreciated

Buildings: 33 years and

Plant and other equipment, furniture and fixtures: 2‑15 years

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the statement of comprehensive loss when the asset is derecognized.

The depreciation methods, useful lives and residual values are reviewed, and adjusted prospectively if appropriate, as of each reporting date.

Assets under construction are reported at cost and are allocated to property, plant and equipment until they are completed and put into operational use, from which point onwards they are depreciated.

(g)Leases

Before January 1, 2019 prior to adoption of IFRS 16, the accounting treatment of leases depended on if key risk and rewards of ownerships of the assets under leases were transferred. Assets that are held by the Group under a lease that transfers the key risks and rewards of ownership to the Group are classified as finance leases. The leased asset is initially measured at the lower of fair value and the present value of the minimum lease payments. After initial recognition, the asset is carried in accordance with applicable accounting policy for the asset.

Finance lease payments are apportioned between finance costs and the reduction of the outstanding liability. The finance costs are allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Assets from other leases are classified as operating leases and the respective lease expenses are recognised in profit or loss on a straight-line basis over the lease term.

Since January 1, 2019, the Group adopted IFRS 16 and assesses at contract inception whether a contract is, or contains, a lease. That is, if the contract conveys the right to control the use of an identified asset for a period of time in exchange for a consideration.

Group as a lessee

The Group applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Group recognizes lease liabilities to make lease payments and right-of-use assets representing the right to use the underlying assets.

(i)Right-of-use assets

The Group recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. Unless the Group is reasonably certain to obtain ownership of the leased asset at the end of the lease term, the recognized right-of-use assets are depreciated on a straight-line basis over the shorter of its lease term and the estimated useful lives, as follows:

-Buildings: 33 years

-Offices: 4 – 12 years and

-Plant and other equipment, furniture and fixtures: 2-15 years

If ownership of the leased asset transfers to the Group at the end of the lease term or the cost reflects the exercise of a purchase option, depreciation is calculated using the estimated useful life of the asset.

The right-of-use assets are also subject to impairment. Refer to accounting policies of impairment of financial assets in note 5(n) “Financial instruments”.

(ii)Lease liabilities

At the commencement date of the lease, the Group recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Group and payments of penalties for leases reasonably certain to be terminated. The variable lease payments that do not depend on an index or a rate are recognized as expenses in the period during which the event or condition that triggers the payment occurs.

In calculating the present value of lease payments, the Group uses the incremental borrowing rate at the lease commencement date if the interest rate implicit in the lease is not readily determinable. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is remeasured if there is a modification, a change in the lease term, a change in the in-substance fixed lease payments or a change in the assessment to purchase the underlying asset.

(iii)Short-term leases and leases of low-value assets

The Group applies the short-term lease recognition exemption to its short-term leases of machinery and equipment (i.e., those leases that have a lease term of 12 months or less from the commencement date and do not contain a purchase option). It also applies the lease of low-value assets recognition exemption to leases of office equipment that are considered of low value (i.e., below EUR 5k). Lease payments on short-term leases and leases of low-value assets are recognized as expenses on a straight-line basis over the lease term.

(iv)Sale and leaseback transactions

The Group applies IFRS 15 for determining if the transfer of an asset to the buyer (lessor) is to be accounted for as a sale of assets. After the sale of assets is concluded, the Group measures the right-of-use assets arising from the leaseback at the proportion of the previous carrying value of the asset that relates to the right of use retained by the Group. Accordingly, the Group recognizes only the amount of any gain or loss that relates to the rights transferred to the buyer (lessor).

If the fair value of the consideration for the sale of an asset does not equal the fair value of the asset, or if the payments for the leases are not at market rates, the Group makes the following adjustments to measure the sale proceeds at fair value:

•any below-market terms shall be accounted for as a prepayment of lease payments

•any above-market terms shall be accounted for as additional financing provided by the buyer-lessor to the seller-lessee

(h)Impairment of non-financial assets

Property, plant and equipment and intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Whenever the carrying amount of an asset exceeds its recoverable amount, an impairment loss is recognized in profit or loss. The recoverable amount is measured as the higher of fair value less costs to sell and value in use. Recoverable amounts are estimated either for individual assets or, if an individual asset does not generate cash flows independently of other assets, for the whole cash-generating unit.

(i)Inventories

Inventories are measured at the lower of cost and net realizable value. Inventories are recognized at cost based on the first in first out (FIFO) method.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

(j)Government grants

Government grants are recognized where there is reasonable assurance that the grant will be received and all attached conditions will be complied with. Grants that are intended to compensate the Group for expenses incurred are recognized through profit or loss on a systematic basis over the periods in which expenses are recognized.

Government grants which relate to an asset are initially recognized as deferred income at nominal amounts. They are subsequently released to profit or loss on a systematic basis over the expected useful life of the related asset.

The release of deferred income related to either type of grant is presented as other operating income (see note 8).

(k)Share-based payments

Plan recipients (including senior executives and certain member of Supervisory Board) of the Group receive remuneration in the form of share-based payments, whereby the recipients render services as consideration for equity instruments (equity-settled transactions) or settled in cash (cash-settled transactions).

Equity settled transactions

The cost of equity-settled transactions is determined by the fair value of the granted options when the grant is made, using a Black-Scholes or Monte Carlo simulation model, with further details given in note 20.

The cost is recognized in employee benefits expense (see note 8.4) or other relevant expenses, together with a corresponding increase in equity (capital reserves), over the period in which the service conditions are fulfilled (the vesting period). The cumulative expense recognized for equity-settled transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Group’s best estimate of the number of equity instruments that will ultimately vest. The expense or credit in profit or loss for a period represents the movement in cumulative expense recognized as at the beginning and end of that period.

Cash-settled transactions

A liability is recognized for the fair value of cash-settled transactions. The fair value is measured initially and at each reporting date up to and including the settlement date, with changes in fair value recognized in employee benefits expense (see note 8.4). The fair value per option is determined using the Black-Scholes model, further details of which are given in note 20. The fair value per option is then multiplied by the Group’s best estimate of the number of awards expected to vest and the portion of the expired vesting period (period in which the service conditions are fulfilled). The cumulative amount of expense recognized will be equal to the cash that is paid on settlement.

Service and non-market performance conditions are not taken into account when determining the grant date fair value of awards, but the likelihood of the conditions being met is assessed as part of the Group’s best estimate of the number of equity instruments that will ultimately vest. Market performance conditions are reflected within the grant date fair value. Any other conditions attached to an award, but without an associated service requirement, are considered to be non-vesting conditions. Non-vesting conditions are reflected in the fair value of an award and lead to an immediate expensing of an award unless there are also service and/or performance conditions.

No expense is recognized for awards that do not ultimately vest because non-market performance and/or service conditions have not been met. Where awards include a market or non-vesting condition, the transactions are treated as vested irrespective of whether the market or non-vesting condition is satisfied, provided that all other performance and/or service conditions are satisfied.

If the terms and conditions of a cash-settled share-based payment transaction are modified with the result that it becomes an equity-settled share-based payment transaction, the transaction is accounted for as such from the date of the modification. Specifically, the equity-settled share-based payment transaction is measured by reference to the fair value of the equity instruments granted at the modification date and recognized in equity. The liability for the cash-settled share-based payment transaction as at the modification date is derecognized on that date. Any difference between the carrying amount of the liability derecognized and the amount of equity recognised on the modification date is recognised immediately in profit or loss.

(l)Provisions

A provision is recognized when the Group has a present obligation (legal, contractual or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Group expects some or all of a provision to be reimbursed, for example, under an insurance contract, the reimbursement misrecognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the profit or loss net of any reimbursement. Provisions are reviewed at each reporting date and adjusted to reflect the current best estimate.

If the requirements for recognizing a provision are not satisfied, the corresponding obligations are recorded as contingent liabilities unless the possibility of an outflow of resources embodying economic benefits is remote.

(m)Income taxes

Tax expense comprises current and deferred taxes. Current taxes and deferred taxes are recognized through profit or loss apart from deferred taxes related to items recognized outside profit or loss, in which case it is recognized in correlation to the underlying transaction either directly in equity or in other comprehensive income.

Current income tax assets and liabilities are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted at the reporting date in the countries where the Group operates and generates taxable income.

Deferred taxes are set up for temporary differences between the carrying amounts of assets and liabilities for group financial reporting purposes at the reporting date and the amounts used for tax purposes. Deferred tax liabilities are recognized for all taxable temporary differences, except:

-temporary differences arising from the initial recognition of assets or liabilities in the course of a business transaction that is not a business combination and does not affect either the accounting profit or the taxable profit or loss

-temporary differences associated with investments in subsidiaries if the Group controls the timing of the reversal of the temporary differences, and it is probable that the differences will not reverse in the foreseeable future.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates that have been enacted or substantively enacted at the reporting date.

Deferred tax assets and deferred tax liabilities are offset against each other if certain conditions are met.

(n)Financial instruments

(i) Financial assets

The Group’s financial assets principally consist of those accounted for as receivables and contract assets.

Receivables and contract assets

Receivables, including contract assets, are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. Contract assets and trade receivables that do not contain a significant financing component or for which the Group has applied the practical expedient are measured at the transaction price determined under IFRS 15. Refer to the accounting policies in note 5(b) “Revenues from contracts with customers”.

After initial recognition, Receivables and contract assets are subsequently carried at amortized cost using the effective interest rate method less any impairment losses. Gains and losses are recognized in the profit or loss for the period when the assets are derecognized or impaired.

Derecognition

A financial asset or a part of a financial asset is derecognized when the Group no longer has the contractual rights to the asset or the right to receive cash flows from the asset have expired.

Impairment

The Group recognizes an allowance for expected credit losses (ECLs). ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate.

The Group applies a simplified approach in calculating ECLs. Therefore, the Group does not track changes in credit risk, but instead recognizes a loss allowance based on lifetime ECLs at each reporting date. The Group has established a provision matrix that is based on its historical credit loss experience, adjusted for forward-looking factors specific to the debtors and the economic environment.

The Group considers a financial asset in default when contractual payments are 360 days past due. However, in certain cases, the Group may also consider a financial asset to be in default when internal or external information indicates that the Group is unlikely to receive the outstanding contractual amounts in full before taking into account any credit enhancements held by the Group. A financial asset is written off when there is no reasonable expectation of recovering the contractual cash flows.

Further disclosures relating to impairment of trade receivables, including contract assets, are in note 21.

(ii) Financial liabilities

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group’s financial liabilities include trade and other payables (include contract liabilities), as well as loans and borrowings including bank overdrafts.

Loans and borrowings

Loans and borrowings are initially recognized at fair value and subsequently measured at amortized cost using the effective interest rate method, taking into account any principal repayments and any discount or premium on acquisition and including transaction costs and fees that are an integral part of the effective interest rate.

Gains or losses are recognized through profit or loss at the time the liabilities are derecognized or disposed of.

Derecognition

A financial liability is derecognized when the obligation underlying the liability is discharged, canceled or expires.

When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized through profit or loss.

(o) Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and bank balances, including short-term, highly liquid investments that can be quickly converted into cash amounts. These have original maturities of three months or less and are subject to a low risk of fluctuation in value.

Accounting judgments and estimates	12 Months Ended
Accounting judgments and estimates	Dec. 31, 2020
Accounting judgments and estimates
Accounting judgments and estimates	6 Accounting judgments and estimates The preparation of the consolidated financial statements requires the management board to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures. Actual results could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis and revisions of estimates are recorded prospectively. 6.1Judgments Development costs Development costs are recognized in accordance with the accounting policy for certain internally generated assets. The Group’s research and development activities mainly relate to development of biomarkers and IT driven solutions. With respect to biomarkers, the development stage is usually considered to be achieved when the target validation process is completed and commercialization is probable. With respect to IT driven solutions, the development stage is considered to be achieved upon the completion of the Group’s internal validation test. Before such date, any development costs are recognized in profit or loss and may not be subsequently capitalized. As of December 31, 2020, the carrying amount of capitalized development costs was EUR 9,680k (2019: EUR 12,923k). This amount includes investments in the development of biomarkers and IT driven solutions (e.g., the Group’s CentoMD database, CentoMetabolome and CentoPortal online platform). Provision for expected credit losses of trade receivables and contract assets The Group uses a provision matrix to calculate ECLs for trade receivables and contract assets. The provision rates are based on days past due for groupings of various customer segments that have similar loss patterns (e.g. by segment, geography, customer type and rating). The provision matrix is initially based on the Group's historical observed default rates. The Group will calibrate the matrix to adjust the historical credit loss experience with forward-looking information. For instance, if forecasted economic conditions (i.e., gross domestic product) are expected to deteriorate over the next year which can lead to an increased number of defaults in the manufacturing sector, the historical default rates are adjusted. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analyzed. The assessment of the correlation between historical observed default rates, forecasted economic conditions and ECLs is a significant estimate. The amount of ECLs is sensitive to changes in circumstances and of forecasted economic conditions. The Group's historical credit loss experience and forecast of economic conditions may also not be representative of customer's actual default in the future. The information about the ECLs on the Group's trade receivables and contract assets is disclosed in note 21. Deferred tax asset on loss carryforwards The tax losses carried forward do not expire. In the light of the Company’s loss history, the recognition of deferred taxes for tax losses carried forward and deductible temporary differences is limited to the future reversal of existing taxable temporary differences. 6.2 Assumptions and estimation uncertainties Information concerning assumptions and estimation uncertainty that have a significant risk of causing a material adjustment to the fiscal year ended on December 31, 2020 are presented in the following disclosures. The Group based its assumptions and estimates on parameters available when the consolidated financial statements were prepared. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Group. Such changes are reflected in the assumptions when they occur. Share‑based payments Estimating fair value for share-based payment transactions requires a determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. For the measurement of the fair value of equity-settled transactions at the grant date (including those issued to replace the cash-settled transactions), the Group uses the Monte Carlo simulation model (previously the Black-Scholes model). The fair value at grant date of equity-settled transactions is not updated at the end of each reporting period. Valuation of Share Options The Black-Scholes option pricing model requires the input of subjective assumptions, including assumptions about the expected life of share-based awards and share price volatility. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. As a company listed on the NASDAQ stock exchange in 2019, the Group’s share price only has limited sufficient historical information to be used as a reference, and therefore subjective inputs were included when estimating the fair value of our common shares to be used in both option pricing model. In addition, our management used different key assumptions in the models to calculate the fair value. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in note 20. The Group intends to continue to consistently apply this methodology using the same comparable companies until a sufficient amount of historical information regarding the volatility of our own share price as a public company becomes available.

Segment information and revenue from contracts with customers

12 Months Ended

Dec. 31, 2020

Segment information and revenue from contracts with customers

Segment information and revenue from contracts with customers

7 Segment information and revenue from contracts with customers

7.1 Segment information

For management purposes, the Group is organized into business units based on its products and services. In line with the management approach, the operating segments were identified on the basis of the Group’s internal reporting and how the chief operating decision maker (“CODM”) assesses the performance of the business. On this basis, the Group has the following three operating segments, which also represent the Group’s reportable segments:

Pharmaceutical segment: This segment provides a variety of solutions to our pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring, in order to accelerate their development of treatments for rare diseases; and

Diagnostics segment: This segment provides genetic sequencing and diagnostics services to our clients, who are typically physicians, laboratories or hospitals, either directly or through distributors; and

COVID-19 segment: This segment provides COVID-19 testing services to our clients. Our original COVID-19 test is a molecular diagnostic test performed for the in vitro qualitative detection of RNA from the SAR-CoV-2 in oropharyngeal samples from presymptomatic probands according to the recommended testing by public health authority guidelines. In addition, we also offer COVID-19 antigen testing.

The management board is the Chief Operating Decision Maker and monitors the operating results of the segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on segment results and is measured with reference to the Adjusted EBITDA. Adjusted EBITDA is a financial measure which is not prescribed by IFRS, which the Group defines as income/loss before finance costs (net), taxes, and depreciation and amortization (including impairments), adjusted to exclude corporate expenses as well as share-based payment expenses.

Corporate expenses, interest and similar income and expenses, as well as share-based payment expenses are not allocated to individual segments as the underlying instruments are managed on a group basis. Assets and liabilities are managed on a Group basis and are not allocated to the different segments for internal reporting purposes. Therefore, our CODM does not regularly review this information by segment and accordingly we do not report this information by segment.


	2018
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	17,307	23,171	—	40,478

Adjusted EBITDA	13,641	2,285	(15,836)	90

Capital Expenditures
Additions to property, plant and equipment	1,225	1,917	5,568	8,710
Additions to intangible assets	1,948	—	1,111	3,059

Other segment information
Depreciation and amortization	1,222	1,838	2,115	5,175
Research and development expenses	334	—	5,966	6,300


	2019
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	21,522	27,258	—	48,780

Adjusted EBITDA	14,956	2,306	(22,949)	(5,687)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	1,362	1,998	17,908	21,268
Additions to intangible assets	3,603	—	3,677	7,280

Other segment information
Depreciation and amortization	1,308	2,032	3,239	6,579
Research and development expenses	—	—	9,590	9,590


	2020
in EUR k	Pharmaceutical	Diagnostics	COVID-19(1)	Corporate	Total
Total Revenues from contracts with external customers	16,951	22,108	89,322	—	128,381

Adjusted EBITDA	6,194	(2,408)	37,215	(39,918)	1,083

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	333	602	9,113	2,682	12,730
Additions to intangible assets	3,183	—	1,672	1,802	6,657

Other segment information
Depreciation and amortization (including impairments)	6,769	2,289	1,400	4,670	15,128
Research and development expenses	—	—	—	14,935	14,935

(1)

As discussed in note 2, in March 2020 the Group commenced testing for COVID-19 in response to the COVID-19 pandemic and in the third quarter started managing and reporting the COVID-19 business as a separate segment. As such, the Group did not have any activities related to the COVID-19 business prior to 2020 and retrospective presentation in prior year segment reporting is not applicable.

Adjustments

Adjustments include non-cash charges in relation to depreciation, amortization (including impairments), and share-based payments as well as net financial costs, and income taxes. Certain costs, and related income, are not allocated to our reporting segment results and represent the residual operating activities of the Group reported as ‘Corporate’. These include corporate overheads, which are responsible for centralized functions such as communications, information technology, facilities, legal, finance and accounting, insurance (D&O), human resources, business development and strategic initiatives, certain professional and consulting services, procurement, research and development and other supporting activities.

Corporate expenses for the year ended December 31, 2020 also included expenses incurred in relation to the July 2020 Offering as described in note 1 of EUR 278k (2019 IPO: EUR 1,092k ;2018: EUR nil) (see note 8.2). The corporate expenses for the year ended December 31, 2019 includes a real estate transfer tax of EUR 1,200k (2018: EUR nil) related to an intercompany sale of land and building (see note 13.1).

Reconciliation of segment Adjusted EBITDA to Group loss for the period


in EUR k	2018	2019	2020
Reportable segment Adjusted EBITDA	15,926	17,262	41,001
Corporate expenses	(15,836)	(22,949)	(39,918)
	90	(5,687)	1,083
Share‑based payment expenses (Note 20)	(5,521)	(6,418)	(5,658)
Depreciation and amortization (including impairments)	(5,175)	(6,579)	(15,128)
Operating loss	(10,606)	(18,684)	(19,703)
Financial costs, net	(1,042)	(2,013)	(1,394)
Income taxes	310	(158)	(281)
Loss for the year	(11,338)	(20,855)	(21,378)

Non-current asset locations

Non‑current assets of the Group consist of right-of-use assets (under IFRS 16), property, plant and equipment, as well as intangible assets. All of such assets are located in Germany, which is the country of the business address of the Centogene GmbH, except for property, plant and equipment of EUR 516k (2019: EUR 286k; 2018: EUR 718k) and right-of-use assets of EUR 709k (2019: 1,042k; 2018: EUR nil), which are located in the United States.

7.2 Revenue from contracts with customers


in EUR k	2018
	Pharmaceutical	Diagnostics	Total
Rendering of services	16,077	23,171	39,248
Sales of goods	1,230	—	1,230
Total Revenues from contracts with external customers	17,307	23,171	40,478

Recognized over time	12,077	23,171	35,248
Recognized at a point in time	5,230	—	5,230
Total Revenues from contracts with external customers	17,307	23,171	40,478

Geographical information
Europe	654	6,196	6,850
—Germany*	654	407	1,061
Middle East	—	12,401	12,401
—Saudi Arabia#	—	5,475	5,475
North America	16,653	1,460	18,113
—United States#	16,653	643	17,296
Latin America	—	2,185	2,185
Asia Pacific	—	929	929
Total	17,307	23,171	40,478


in EUR k	2019
	Pharmaceutical	Diagnostics	Total
Rendering of services	19,089	27,258	46,347
Sales of goods	2,433	—	2,433
Total Revenues from contracts with external customers	21,522	27,258	48,780

Recognized over time	17,159	27,258	44,417
Recognized at a point in time	4,363	—	4,363
Total Revenues from contracts with external customers	21,522	27,258	48,780

Geographical information
Europe	381	7,066	7,447
—Germany*	233	275	508
—Netherlands**	—	25	25
Middle East	122	13,977	14,099
—Saudi Arabia#	—	7,417	7,417
North America	20,896	2,380	23,276
—United States#	20,896	1,882	22,778
Latin America	123	2,864	2,987
Asia Pacific	—	971	971
Total	21,522	27,258	48,780


in EUR k	2020
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	15,947	22,108	88,587	126,642
Sales of goods	1,004	—	735	1,739
Total Revenues from contracts with external customers	16,951	22,108	89,322	128,381

Recognized over time	15,947	22,108	24,684	62,739
Recognized at a point in time	1,004	—	64,638	65,642
Total Revenues from contracts with external customers	16,951	22,108	89,322	128,381

Geographical information
Europe	149	5,605	88,314	94,068
—Germany*#	—	186	80,879	81,065
—Netherlands**	—	3	6,572	6,575
Middle East	56	12,568	—	12,624
North America	16,711	1,576	978	19,265
—United States#	16,711	1,370	978	19,059
Latin America	35	1,851	2	1,888
Asia Pacific	—	508	28	536
Total	16,951	22,108	89,322	128,381

* country of the incorporation of Centogene GmbH

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group's total consolidated revenues for the respective year ended December 31, 2018, 2019 and 2020

The Group collaborated with the majority of our pharmaceutical partners on a worldwide basis in 2018, 2019 and 2020. In addition, in cases where our pharmaceutical partners are developing a new rare disease treatment, it is generally anticipated that the final approved treatment will be made available globally. As a result, we allocate the revenues of our pharmaceutical segment by geographical region by reference to the location where each pharmaceutical partner mainly operates, which is based on the region from which most of their revenues are generated. The allocation of revenues in our diagnostics and COVID-19 segments are based on the location of each customer.

Pharmaceutical segment

During the year ended December 31, 2020, revenues from one pharmaceutical partner represented 8.6% of the Group’s total revenues (2019: 24.3%; 2018: 27.3%).

During the year ended December 31, 2019, Centogene entered into several collaborations with pharmaceutical partners, of which upfront fees totaling EUR 1,930k were received. Such upfront payments were recognized as revenues during the year as they represented the transaction price allocated to the one-off transfer of the Group’s intellectual property—provision of epidemiological insights of relevant rare diseases and relevant data. For the year ended December 31, 2018, upfront payments totaling EUR 4,000k were received and recognized as revenues during the period as they represented the transaction price to be allocated to the grant of licences which are distinct and qualify as a licence to use such intellectual property for an unlimited period or for the time specified in the agreements. No such payments received or revenues were recognized for the year ended December 31, 2020.

COVID-19 segment

During the year ended December 31, 2020, revenues from two COVID-19 partners represented 14.6% and 13.5%, respectively, of the Group’s total revenues.

To support the expansion of test offerings, the Company acquired laboratory facilities and equipment, developed a Corona Test Portal and leased laboratory space at several locations in Germany. Additionally, COVID-19 testing capacity is provided through our custom-built CentoTruck, a mobile laboratory in a container designed to carry out COVID-19 analysis. Total capitalized investments in COVID-19 testing as of December 31, 2020 amounted to approximately € 10.8 million, of which approximately € 7.7 million and € 1.4 million, respectively, are included in property, plant and equipment and right-of-use assets. An amount of € 1.7 million is included in intangible assets and relates to the development of the Corona Test Portal.

Contract balances


in EUR k	Dec 31, 2019	Dec 31, 2020
Trade receivables (note 15)	12,709	25,656
Contract assets (note 15)	3,884	3,543
Contract liabilities (note 19.2)	3,748	4,479

The contract assets primarily relate to the Group’s rights to consideration for work completed but not billed at the reporting date on the tests for the diagnostics segment, with the satisfaction of the respective performance obligation measured by reference to stages in a standardized process. The contract assets also include work performed for pharmaceutical partners which are based on milestone fees. In 2020, EUR 356k (2019: EUR 8k) was recognised as provision for expected credit losses on contract assets (see note 21). The contract assets are transferred to receivables when the rights become unconditional. This usually occurs when the Group issues an invoice to the customer.

The contract liabilities include EUR 2,516k (2019: EUR 3,748k) which relate to the advance consideration, including various contracts with performance obligations, received from pharmaceutical partners for which revenue is recognized over time, and consideration from sales of CentoCards which have not yet been delivered. In addition, EUR 1,963k relates to COVID-19 performance obligations that have not been met as of December 31, 2020 (2019: EUR nil).

Other income and expenses

12 Months Ended

Dec. 31, 2020

Other income and expenses

Other income and expenses

8 Other income and expenses

8.1Other operating income


in EUR k	2018	2019	2020
Government grants	1,611	2,641	2,152
Gain on disposal of property, plant and equipment	—	532	2
Exchange rate gains	147	314	—
Income from the reversal of provisions	309	89	—
Others	239	205	240
Total other operating income	2,306	3,781	2,394

Government grants contain performance-based grants to subsidize research, development and innovation in the state of Mecklenburg-Western Pomerania from funds granted by the European Regional Development Fund. Furthermore, government grants contain the release of deferred income from investment related grants.

In July 2019, the Group entered into a sale and leaseback transaction. According to which, the Group sold the Rostock headquarters building to a third party and then leased the building from the third party for a period of 12 years at a fixed rate per month with the option to extend. The sale of the Rostock headquarters in 2019 resulted in a gain of EUR 532k and was recognized in the period of sale (See note 13.1).

8.2Other operating expenses


in EUR k	2018	2019	2020
Currency losses	250	192	10
Other	23	1,092	172
Total other operating expenses	273	1,284	182

Other operating expenses for the year ended December 31, 2019 included costs incurred related to the IPO charged to profit and loss of EUR 1,092k (2018: EUR nil).

During the year ended December 31, 2020, the Group disposed of its entire 51% interest in LPC GmbH (“LPC”) to the minority shareholders for a consideration of EUR 213k, of which EUR 200k is to be paid over a period of four years and EUR 150k is outstanding as of December 31, 2020 (included in other assets, see note 15). The related non-controlling interest of EUR 268k (accumulated share of loss) was debited to profit or loss, and the sale resulted in a loss of EUR 101k.

8.3Financial costs, net


in EUR k	2018	2019	2020
Interest expenses from loans	(922)	(1,690)	(173)
Currency losses	—	—	(362)
Unwinding of the discount on lease liabilities	(153)	(339)	(865)
Interest income from loans and receivables	33	16	6
Total	(1,042)	(2,013)	(1,394)

8.4Employee benefits expense


in EUR k	2018	2019	2020
Wages and salaries	17,965	23,854	31,121
Social security contributions	2,492	3,212	4,095
Share‑based payments	5,521	5,714	3,486
Termination benefits	56	63	569
Total	26,034	32,843	39,271

Social security contributions include contributions to state pension scheme of EUR 1,851k (2019: EUR 1,136k; 2018: EUR 1,046k) as defined contribution plan expenses. Additionally, the Company recognized compensation expense of EUR 2,775k (2019: EUR 1,203k; 2018: EUR 341k) for remuneration of supervisory board members, including share-based payments (see note 25).

Income taxes

12 Months Ended

Dec. 31, 2020

Income taxes

Income taxes

9 Income taxes

Taxes recognized through profit or loss:


in EUR k	2018	2019	2020
Current tax expenses	(87)	(158)	(74)
Current year	(87)	(1)	(58)
Adjustments for prior periods	—	(157)	(16)
Deferred tax (expense)/income	397	—	(207)
Temporary differences	527	(514)	(182)
Tax losses	(130)	514	(25)
Total income tax (expenses)/benefit	310	(158)	(281)

No income taxes were recognized directly in other comprehensive income for the years ended December 31, 2018, 2019 and 2020.

A reconciliation of the effective tax rate to the Group’s statutory rate of 31.1% for each of the years ended December 31, 2018, 2019 and 2020 is presented in the table below.


in EUR k	2018	2019	2020
Loss before tax	(11,648)	(20,697)	(21,097)
Taxes on the basis of the Company’s domestic tax rate	3,623	6,445	6,570
Tax rate effect of foreign tax jurisdictions	406	412	65
Non‑deductible expenses	(105)	(441)	(903)
Current year losses for which no deferred tax assets were recognized	(3,528)	(6,416)	(5,792)
Tax income related to prior years	—	(157)	(137)
Other effects	(86)	(1)	(84)
Income tax (expenses)/ benefit	310	(158)	(281)

The domestic tax rate of 31.1% is composed of the corporate income tax rate of 15%, the solidarity surcharge of 5.5% of this corporate income tax, as well as trade tax of 15.3%. The tax rate effects from foreign tax jurisdictions are primarily attributable to the tax‑exempt profit of a Group subsidiary located in Dubai.

Tax losses carryforwards for which no deferred tax assets were recognized amount to EUR 64,464k in Germany (2019: EUR 41,570k; 2018: EUR 21,728k) and to EUR 1,002k in other countries (2019: EUR 505k; 2018: EUR 788k). Deductable temporary differences, for which no deferred tax asset is recognized, amount to EUR 3,381k.

Tax losses carried forward in Germany do not expire. Foreign tax losses carried forward may be restricted. In the light of the Group’s loss history, the recognition of deferred taxes for tax losses carried forward and deductible temporary differences was limited to the future reversal of existing taxable temporary differences.

For temporary differences associated with investments in the amount of EUR 4,313k (2019: EUR 4,360k; 2018: EUR 3,049k), no deferred tax liability has been recognized because the Company is able to control the timing of the reversal and it is probable that the difference will not reverse in the foreseeable future.

The below table shows a breakdown of deferred taxes in the Group’s statement of financial position.


	December 31, 2019		December 31, 2020
	Deferred	Deferred	Deferred	Deferred
in EUR k	tax assets	tax liabilities	tax assets	tax liabilities
Intangible assets	—	(3,013)	—	(2,934)
Property, plant and equipment	—	(156)	—	(133)
Right-of-use assets	—	—	—	(5,029)
Measurement of service contracts	—	(173)	—	(145)
Leasing liabilities	—	—	4,865	—
Government grants	2,051	—	1,903	—
Unused tax losses	1,291	—	1,266	—
Sum	3,342	(3,342)	8,034	(8,241)
Offset	(3,342)	3,342	(8,034)	8,034
Deferred Taxes	—	—	—	(207)

Loss Per Share	12 Months Ended
Loss Per Share	Dec. 31, 2020
Loss Per Share
Loss Per Share	10 Loss Per Share Basic loss per share is calculated by dividing loss for the period attributable to equity holders of the Group by the weighted average number of shares outstanding during the same period, adjusted for the effect of the corporate reorganization as discussed in Note 1 and applied retrospectively to all prior periods presented. The weighted average number of outstanding shares for the year ended December 31, 2020 was 20,909,673 (2019: 16,409,285; 2018: 14,112,841, adjusted for the effect of the 2019 corporate reorganization). For the periods included in these financial statements, the share options are not included in the diluted loss per share calculation as the Company was loss-making in all these periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted loss per share is equal.

Intangible assets

12 Months Ended

Dec. 31, 2020

Intangible assets

Intangible assets

Assets

11 Intangible assets

Reconciliation of carrying amounts


	Internally
	generated	Internally	Purchased rights,
	/acquired	developed	licenses,
in EUR k	biomarkers	databases	software	Total
Cost
As of Jan 1, 2019	7,133	3,365	3,370	13,868
Reclass from property, plant and equipment (Note 12)	386	—	—	386
Reclass*	900	758	(1,658)	—
Additions	3,603	2,379	1,298	7,280
As of Dec 31, 2019	12,022	6,502	3,010	21,534
Additions	1,900	2,717	2,040	6,657
Deconsolidation	—	—	(151)	(151)
As of Dec 31, 2020	13,922	9,219	4,899	28,040

Accumulated amortization and impairment
As of Jan 1, 2019	2,660	1,047	1,366	5,073
Amortization	1,171	723	422	2,316
As of Dec 31, 2019	3,831	1,770	1,788	7,389
Amortization and impairment	6,917	943	508	8,368
Deconsolidation	—	—	(124)	(124)
As of Dec 31, 2020	10,748	2,713	2,172	15,633

Carrying amounts
As of Dec 31, 2019	8,191	4,732	1,222	14,145
As of Dec 31, 2020	3,174	6,506	2,727	12,407

* The reclassification of EUR 1,658k from purchased rights, licenses, software represented purchased rights related to certain biomarkers in prior years, as well as expenses incurred for certain licenses and software, which were used in the process of developing internal IT driven solutions. Reclassification is made to allow more transparent presentation considering this is more in line with each sub-group of intangible assets.

Development costs and amortization

Internally generated intangible assets include capitalized development costs for biomarkers and IT driven solutions such as CentoPortal, CentoMetabolome and the CentoMD mutation database (see notes 5 and 6 regarding measurement).

The amortization of patents, trademarks and development costs is expensed and recorded under “cost of sales” to the extent the related intangible is used in generating revenue and recorded in research and development expenses to the extent the related intangibles are used for R&D purposes.

As of December 31, 2020, certain identified biomarkers amounting to EUR 4.7 million were impaired as part of the Company’s strategy reassessment which began in Q4 2020. The impairment is expensed under cost of sales and included in amortization and impairment expense in the Pharma segment.

Property, plant and equipment

12 Months Ended

Dec. 31, 2020

Property, plant and equipment

Property, plant and equipment

12 Property, plant and equipment

Please refer to the following table for the development from January 1, 2019 to December 31, 2020:


				Other
				equipment,
				furniture
in EUR k	Land	Buildings	Plant	and fixtures	Total
Cost
As of Jan 1, 2019	2,149	24,891	16,011	4,856	47,907
Reclass to right-of-use assets*	—	—	(6,303)	(32)	(6,335)
Reclass to intangible assets (note 11)	—	—	—	(386)	(386)
Additions	—	—	22	274	296
Disposal (note 13.1)	(2,149)	(21,637)	—	—	(23,786)
As of Dec 31, 2019	—	3,254	9,730	4,712	17,696
Additions	—	105	1,295	8,490	9,890
Disposal***	—	—	—	(612)	(612)
Reclass from right-of-use assets**	—	—	3,099	—	3,099
As of Dec 31, 2020	—	3,359	14,124	12,590	30,073

Accumulated depreciation and impairment
As of Jan 1, 2019	—	612	6,178	2,002	8,792
Reclass to right-of-use assets*	—	—	(963)	(8)	(971)
Depreciation	—	737	940	779	2,456
Disposal (note 13.1)	—	(957)	—	—	(957)
As of Dec 31, 2019	—	392	6,155	2,773	9,320
Depreciation	—	194	993	1,913	3,100
Disposal***	—	—	—	(44)	(44)
Reclass from right-of-use assets**	—	—	1,107	—	1,107
As of Dec 31, 2020	—	586	8,255	4,642	13,483

Carrying amounts
As of Dec 31, 2019	—	2,862	3,575	1,939	8,376
As of Dec 31, 2020	—	2,773	5,869	7,948	16,590

* The reclass to right-of-use assets of EUR 5,364k represented the carrying amount of assets previously classified as finance leases under IAS 17 and recognized as right-of-use assets upon the adoption of IFRS 16. As disclosed in note 3(a), the Group has applied a modified retrospective method of adoption and did not change the initial carrying amounts of recognized assets and liabilities at the date of initial application for leases previously classified as finance leases.** The reclass from right-of-use assets of EUR 1,992k represents assets purchased at the end of the lease term.*** The disposal relates to the sale of a CentoTruck as part of a contract with a COVID-19 customer.

Right-of-use assets

12 Months Ended

Dec. 31, 2020

Right-of-use assets

Right-of-use assets

The Group has lease contracts for land and buildings and offices in Germany and the United States, as well as various items of plant, machinery, motor vehicles and other equipment used in its operations. Leases for land and buildings is related to the sale and leaseback transaction of the Rostock headquarters building (see note 13.1) with a lease term of 12 years, while the lease terms of offices in Berlin and Boston, Massachusetts are 12 years and 4 years respectively. Leases of plant and machinery and other equipment generally have lease terms between 2 and 4 years, while motor vehicles generally have lease terms of 3 years. The Group’s obligations under its leases are secured by the lessor’s title to the leased assets. Generally, the Group is restricted from subleasing the leased assets. In addition, a bank guarantee of EUR 3,256k (which is secured by cash deposit of EUR 1,628k) is required to be maintained for the leases of Rostock headquarters building and Berlin offices until the expiry or termination of the leases. Leases of certain plant and machineries were also secured with rental deposits of EUR 115k.

The lease contract of Rostock headquarters building includes extension options. These options are negotiated by management to provide flexibility in managing the leased-asset portfolio and align with the Group’s business needs. The lease of Rostock headquarters building allows the Group to extend the rental contract twice, each for a period of 6 years, after the expiration of agreement in September 2031 with rental payments of EUR 1,400k per annum. Such extension option was not included in the right-of-use assets and lease liabilities, as it is not reasonably certain that such extension option will be exercised. None of the other lease contracts contain termination options.

The Group also has certain leases of motor vehicles and premises with lease terms of 12 months or less and leases of office equipment with low value. The Group applies the ‘short-term lease’ and ‘lease of low-value assets’ recognition exemptions for these leases.

Set out below are the carrying amounts of right-of-use assets and movements during the period:


			Plant and	Other	Motor
In EUR k	Buildings*	Offices	equipment	equipment	Vehicles	Total

As of January 1, 2019	—	391	5,340	24	12	5,767
Additions	13,456	4,288	2,824	386	18	20,972
Depreciation expenses	(330)	(272)	(1,175)	(20)	(10)	(1,807)
As of December 31, 2019	13,126	4,407	6,989	390	20	24,932
Additions	—	426	1,265	1,112	37	2,840
Reclass to property, plant & equipment**	—	—	(1,992)	—	—	(1,992)
Depreciation expenses	(1,121)	(657)	(1,675)	(187)	(20)	(3,660)
As of December 31, 2020	12,005	4,176	4,587	1,315	37	22,120

* As the lease of land and buildings are made through one contract, all the related right-of-use assets are allocated to Buildings.

** Reclass of leased assets to PP&E (note 12) represents purchased assets at the end of lease term.

Set out below are the carrying amounts of lease liabilities and the movements during the period:


in EUR k	2019	2020

As of January 1	3,465	21,704
Additions	20,946	3,654
Interest expenses	339	865
Payments	(3,046)	(5,018)
As of December 31	21,704	21,205

Current	3,635	3,528
Non-current	18,069	17,677

The maturity analysis of lease liabilities is disclosed in note 21.

The following are the amounts recognised in profit or loss:


in EUR k	2019	2020
Depreciation expense of right-of-use assets	1,807	3,660
Interest expenses on lease liabilities	339	865
Rent expenses—short-term leases	185	1,695
Rent expense—leases of low-value assets	25	33
Total amounts recognized in profit or loss	2,356	6,253

The Group had total cash outflows for leases of EUR 6,746k in 2020 (2019: EUR 3,256k). All additions to right-of-use assets and lease liabilities in 2019 were non-cash in nature. The increase in the short-term lease expenses is due to several short-term lease contracts for the COVID-19 test centers. The future cash outflows relating to non-cancellable short-term leases and leases of low-value assets, are disclosed in note 24.

13.1Sale and Leaseback transaction

In June 2019, in preparation for a sale and leaseback transaction, Centogene AG sold its land and building (the Rostock headquarters building) with a carrying value of EUR 22,829k to a subsidiary of the Group. Such intercompany transaction resulted in a real estate transfer tax expense of EUR 1,200k and was recognized in the year ended December 31, 2019.

In July 2019, the Group concluded the sale and leaseback transaction, according to which, the Company sold the Rostock headquarters building to a third party for EUR 24,000k, representing the fair value of the building as of June 30, 2019. The Group then leased the building from the third party for a period of 12 years at a fixed rate per month with the option to extend.

The consideration received was used to repay the loans related to the construction of the building of EUR 10,776k (see note 19), plus additional interest of EUR 1,159k. In addition, part of the consideration was used to pay for the rental deposits of the lease of EUR 3,000k. In November 2019, the Group has arranged a bank guarantee to replace the rental deposits to the lessor, while a cash deposit of EUR 1,500k was used to secure the bank guarantee. In addition, government grants received which related to the purchase of land amounting to EUR 358k were refunded to the relevant authority subsequent to the transaction (note 19.2).

The transaction was recorded according to IFRS 16, resulting in a gain on disposal of fixed assets of EUR 532k (see note 8.1), a decrease in property, plant and equipment of EUR 22,829k, an increase of right-of-use assets of EUR 13,456k (see note 13) and an increase in lease liabilities of EUR 14,091k (see note 19).

Inventories

12 Months Ended

Dec. 31, 2020

Inventories

Inventories

14 Inventories


in EUR k	Dec 31, 2019	Dec 31, 2020
Raw materials, consumables and supplies	1,644	11,167
Finished goods and merchandise	165	238
Inventories	1,809	11,405

In the year ended December 31, 2020, raw materials, consumables and changes in inventories of finished goods recorded as expenses under “cost of sales” came to EUR 41,594k (2019: EUR 11,285k; 2018: EUR 9,473k).

Trade and other receivables and other assets

12 Months Ended

Dec. 31, 2020

Trade and other receivables and other assets

Trade and other receivables and other assets

15 Trade and other receivables and other assets


in EUR k	Dec 31, 2019	Dec 31, 2020
Non‑current
Other assets—Rental deposits	1,948	1,867
Other assets—Others	—	100
	1,948	1,967
Current
Trade receivables	12,709	25,656
Contract assets	3,884	3,543
Receivables due from shareholders	2,766	—
Other assets	5,846	8,286
	25,205	37,485
Total non-current and current trade and other receivables and other assets	27,153	39,452

Other non-current assets

The non-current portion of other assets mainly include cash deposit of EUR 1,500k, used to secure a bank guarantee of EUR 3,000k, relating to the leases of Rostock headquarters building, cash deposits of EUR 128k, used to secure a bank guarantee of EUR 257k, relating to the leases of Berlin office and EUR 190k for the leases of certain plant and machineries. It also includes the non-current part of the consideration receivable for the sale of LPC of EUR 100k (see note 8.2).

Trade receivables

Trade receivables are non‑interest bearing and are generally due in 30 to 90 days. In general, portfolio‑based expected credit loss allowances are recognized on trade receivables and contract assets (see note 21.2).

Receivables due from shareholders

In 2016, the Group established a virtual share option program (“2016 VSOP”) under Centogene GmbH that entitled the management board to grant virtual share options to individuals, in regard to services they provide and their continuous commitment to the Group. Upon completion of the IPO in November 2019, all options granted under the 2016 VSOP were vested immediately in full, and the holders of vested options were entitled to receive a direct cash payment from the Company according to the calculation as stipulated in the 2016 VSOP, which is determined based on the IPO price of the shares of Centogene N.V. and the exercise prices of the vested options.

The payables by the Group to the holders of vested options were recorded as a liability with a carrying amount of EUR 2,769k by the end of December 31, 2019 (see note 19.2). As the payments to the option holders would be reimbursed by certain original shareholders to the Company, corresponding receivables against shareholders were recorded. Such receivables were considered as additional capital from shareholders and recorded against equity (capital reserve). Upon the completion of the July 2020 Offering, the relevant payables to the holders of vested options were settled mainly by the proceeds received from such original shareholders from the sale of their shares.

Other current assets

Other current assets include VAT receivables of EUR 226k (2019: EUR 1,311k), prepaid expenses of EUR 4,431k (2019: EUR 3,481k), receivables related to exercised share-based payment grants of EUR 1,253k (2019: nil), receivables related to COVID-19 bank or credit card transactions of EUR 1,076k (2019: nil), as well as receivables from grants of EUR 442k (2019: EUR 409k).

Cash and short-term deposits	12 Months Ended
Cash and short-term deposits	Dec. 31, 2020
Cash and short-term deposits
Cash and short-term deposits	16 Cash and short‑term deposits As of December 31, 2020, the Group has pledged its short-term deposits with carrying amount of EUR 1,500k (December 31, 2019: EUR 1,500k) and EUR 2,500k (December 31, 2019: EUR 2,500k) respectively, to fulfil collateral requirements in respect of existing secured bank loan and overdraft facility up to EUR 2,500k. In addition, the Group has pledged its short-term deposits of EUR 1,000k (December 31, 2019: EUR nil) related to two other overdraft facilities worth EUR 500k each. The restriction applying to the collateral may be terminated at any time subject to the full amount of the relevant bank loans and the overdrafts being repaid.

Equity

12 Months Ended

Dec. 31, 2020

Equity.

Equity

Equity and liabilities

17 Equity

On October 29, 2019, the general meeting of shareholders of the Company resolved to approve the corporate reorganization and to execute the Deed of Conversion. The reorganization was effected by the following procedures:

1.Existing shareholders of common shares and preferred shares of Centogene AG subscribed for new common shares in Centogene B.V., and in return transferred their respective shares (both common and preferred) in Centogene AG to Centogene B.V. as a contribution in kind. The exchange ratios for the common and preferred shares of Centogene AG to common shares of Centogene B.V. were as follows:

-Preferred shares of Centogene AG were exchanged for common shares of Centogene B.V. (share split) on a 1.00 to 89.6125 basis

-Common shares of Centogene AG were exchanged for common shares of Centogene B.V. (share split) on a 1.00 to 33.2238 basis

2.the legal form of Centogene B.V. were converted from a Dutch private company with limited liability to a Dutch public company, Centogene N.V. and the articles of association of Centogene N.V. became effective. The conversion took place by means of the execution of a notarial deed of conversion and amendment, and resulted in a name change from Centogene B.V. to Centogene N.V.

The corporate reorganization was fully completed on November 12, 2019. All share, per-share and related information presented in the financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share split resulting from the reorganization.

Issued capital and capital reserve


in thousands of shares	2019	2020
Common shares as of Jan 1, fully paid(1)	15,861	19,861
Issued shares	4,000	2,000
Exercise of options	—	256
Common shares issued as of Dec 31, fully paid	19,861	22,118

(1)

Common shares as of January 1, 2019, issued as a result of corporate reorganization


	as of	as of
in thousands of shares	Dec 31, 2019	Dec 31, 2020
Authorized common shares of EUR 0.12 each	79,000	79,000

Common Shares

As of December 31, 2018, 15,861,340 common shares of Centogene N.V. with a nominal value of EUR 0.12 (converted from 230,445 Centogene AG common shares with a conversion ratio of 33.2238 and 91,562 Centogene AG preferred shares with a conversion ratio of 89.6125, both with a nominal value of EUR 1.00), were issued and fully paid up.

The preferred shares were issued to certain investors to fund the Company’s development activities. The preferred shares each had one voting right per share and did not contain a redemption feature or a contractual right to fixed dividends. The preferred shareholders were entitled to a disproportionate share of the net assets of the Company in case of certain exit events , including IPO, which was reflected by the different conversion ratios (share split) for common and preferred shares of Centogene AG to Centogene B.V. As a result of the IPO, all issued and paid-in preferred shares were converted to common shares, based on the conversion ratio above which reflected the return to investors as agreed in the relevant investment agreements.

On November 7, 2019, the Company offered and sold a total of 4,000,000 of our common shares, €0.12 nominal value per share, at a public offering price of USD 14.00 (EUR 12.58) per share, raising aggregate net offering proceeds of €42 million, after deduction of underwriting discounts and commissions as well as transaction costs.

In July 2020, the Company completed a follow-on public offering of 3,500,000 common shares of the Company, consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of USD 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts, commissions and transaction costs, were EUR 22 million to the Company.

As of December 31 2020, 22,117,643 common shares of Centogene N.V. with a nominal value of EUR 0.12 were issued and fully paid up (December 31, 2019 19,861,340). As of December 31, 2020, the authorized but unissued common share capital amounted to EUR 6,826k (December 31, 2019: EUR 7,097k).

The holders of common shares are entitled to the Company's approved dividends and other distributions as may be declared from time to time by the Company, and is entitled to vote per share on all matters to be voted at the Company's annual general meetings.

Capital reserve

As of December 31, 2020, capital reserve included a share premium of EUR 107,498k (December 31, 2019 EUR 90,297k), being amounts paid in by shareholders at the issuance of shares in excess of the par value of the shares issued, net of any transaction costs incurred for the share issuance.

The capital reserve consists of the share premium account and amounts recorded in respect of share‑based payments. For additional information on the share‑based payments, please refer to note 20.

Capital management	12 Months Ended
Capital management	Dec. 31, 2020
Capital management
Capital management	18 Capital management The Group's objective when managing capital are to safeguard the Company's ability to continue as a going concern and finance all necessary sustainable developments, so that it can continue to provide returns for shareholders and benefits for other stakeholders. In particular, care is taken and an optimal capital structure is tried to achieve to reduce the cost of capital. With the IPO in November 2019 and follow-on public offering of July 2020, the Group also put more attention on achieving a healthy capital base to increase the confidence of investors and the capital market. The Group manages its capital structure and makes adjustments in light of changes in economic conditions and the risk characteristics of its activities. To maintain or adjust the capital structure, the Group may adjust the return to shareholders, issue new shares, or pay additional interests to reduce debt.

Financial liabilities

12 Months Ended

Dec. 31, 2020

Financial liabilities

Financial liabilities

19 Financial liabilities

19.1Interest‑bearing loans


in EUR k	Dec 31, 2019	Dec 31, 2020
Non‑current liabilities
Non‑current portion of secured bank loans	968	401
Municipal loans	610	—
Total non‑current loans	1,578	401
Lease liabilities	18,069	17,677
Total non‑current liabilities	19,647	18,078

Current liabilities
Current portion of secured bank loans	802	567
Other bank loans	—	387
Bank overdrafts	2,636	1,538
Municipal loans	250	—
Total current loans	3,688	2,492
Current portion of lease liabilities	3,635	3,528
Total current liabilities	7,323	6,020

Total non‑current and current liabilities	26,970	24,098

As of December 2020, short-term cash deposits of EUR 1,500k (December 31, 2019: EUR 1,500k) were used to secure the remaining bank loan outstanding (see note 16).

Other bank loans outstanding as of December 31, 2020 represented bank loans granted under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Subject to certain reporting and review requirements, the Company applied for forgiveness of the amount in December 2020 after the 24-week covered period beginning on the date of disbursement of the loan. The Company anticipates that the result of the forgiveness will be available in the first half of 2021. The amount which is forgiven will be considered as government grant income, while any remaining amount not forgiven will be repaid by the Company. Accordingly, the entire amount was classified as current.

The following table is based on the original terms and conditions:

Conditions and statement of liabilities

The outstanding interest-bearing loans as of December 31, 2020 and 2019 have the following conditions:


				Dec 31, 2019		Dec 31, 2020
		Nominal		Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	interest rate	Maturity	amount	amount	amount	amount
Secured bank loan	EUR	2.95%	2017‑22	1,770	1,770	968	968
Other bank loan	USD	1%	2020-22	—	—	387	387
Municipal loan	EUR	8.25%; plus 1.5% profit-related; 0.75% on losses	2018-23	500	500	—	—
Municipal loan	EUR	8%; plus 1.5% profit-related; 0.75% on losses	2021	360	360	—	—
Bank overdrafts	EUR	4.75%	Rollover	476	476	498	498
Bank overdrafts	EUR	3.75%	Rollover	2,160	2,160	628	628
Bank overdrafts	EUR	4.50%	Rollover	—	—	412	412
Lease liabilities	EUR	2.1%-3.5%*, 5.4%-9.1%	2017-31	21,704	21,704	21,205	21,205
Total interest‑bearing financial liabilities				26,970	26,970	24,098	24,098

* represents the incremental borrowing rate of the Group at the commencement of the leases

The bank overdrafts of EUR 628k as of December 31, 2020 (2019: EUR 2,160k) were secured by short-term deposits with a carrying amount of EUR 2,500k (2019: EUR 2,500k) (see note 16). The other bank overdrafts of EUR 910k (2019: EUR 476k) were secured by guarantees provided by certain of the Group’s shareholders as of December 31, 2019, and these guarantees were released by providing security over two short-term deposits with a carrying amount of EUR 500k each subsequent to the year ended December 31, 2019 (see note 16).

The municipal loan due to MBMV (Mittelständische Bürgschaftsbank Mecklenburg-Vorpommern) of EUR 860k outstanding as of December 31, 2019 was secured by guarantees provided by the Group's shareholders, and were released upon full repayment in February 2020.

19.2Trade payables and other liabilities


in EUR k	Dec 31, 2019	Dec 31, 2020
Trade payables	8,554	31,736
Government grants (deferred income)	11,289	10,292
Liability for Virtual Stock Option Program	2,769	—
Contract liabilities	3,748	4,479
Others	5,258	13,483
Trade payables and other liabilities	31,618	59,990
Non‑current	9,941	8,950
Current	21,677	51,040

Government grants mainly include investment-related government grants. These were received for the purchase of certain items of property, plant and equipment for the research and development facilities in Mecklenburg-Western Pomerania, including the Rostock facility. The grants were issued in the form of investment subsidies as part of the joint federal and state program, “Verbesserung der regionalen Wirtschaftsstruktur” (improvement of the regional economic structure) in connection with funds from the European Regional Development Fund. Additional grants received during the year ended December 31, 2020 amounted to EUR 390k (2019: EUR 793k). Subsequent to the sale and leaseback transaction in 2019, investment-related government grant received in prior years of EUR 358k relating to purchase of land was refunded to the authority (note 13.1).

In addition, other liabilities include a provision for outstanding invoices of EUR 1,245k (2019: EUR 1,210k), personnel-related liabilities for vacation and bonuses totaling EUR 4,032k (2019: EUR 2,264k), a VAT payable of EUR 4,578k (December 31, 2019: EUR 1,311k receivable), as well as liabilities for wage and church tax of EUR 1,988k (December 31, 2019: EUR 376k). Other liabilities as of December 31, 2020 do not include costs related to the July 2020 Offering, while other liabilities as of December 31, 2019 included costs relating to the IPO of EUR 565k.

Share-based payments

12 Months Ended

Dec. 31, 2020

Share-based payments

Share-based payments

20 Share‑based payments

As of December 31, 2020 and 2019, the Group had the following share‑based payment arrangements.

(i) Virtual share option program 2016 (Cash‑settled)

On July 1, 2016, the Group established a virtual share option program (the “2016 VSOP”) under Centogene AG that entitles the management board to grant virtual share options to individuals, in regard to services they provide and their continuous commitment to the Group. The 2016 VSOP allowed the management board to grant up to 1,000,000 virtual options, representing 5% of the original 205,000 shares of Centogene AG which are issued and owned by the original shareholders. The share options are subject to service conditions.

The completion of IPO in November 2019 was defined as one of the “exit events” in the 2016 VSOP program. Accordingly, all options granted under the 2016 VSOP vested immediately in full upon the completion of the IPO. In addition, holders of vested options are entitled to receive a direct cash payment from the Company according to the calculation as stipulated in the program, which is determined based on the IPO price of the shares of Centogene N.V. and the exercise prices of the vested options. As of December 31, 2019, all options under the 2016 VSOP were considered vested and exercised and a liability with an carrying amount of EUR 2,768k (2018: EUR 2,170k) was recorded.

The payment to the option holders will be reimbursed by the original shareholders of the Company at the same time as the obligation to pay the options holders arises. A respective receivable against the shareholders was recorded (see note 15). As this is a shareholder transaction, the respective receivable against the shareholders was recorded against equity (capital reserve). Upon the completion of the July 2020 Offering, the relevant payments to the holders of vested options were settled by the proceeds received from such original shareholders from the sale of their shares.


	2019
	Number	WAEP
Outstanding as of January 1	802,283	3.22
Exercised during the year	(802,283)	3.45
Outstanding as of December 31	—	—
Vested as of December 31	—	—
Exercisable as of December 31	—	—

(ii) Virtual share option program 2017 (Cash‑settled)

In 2017, the Group established an additional virtual share option program (the “2017 VSOP”) that entitled the management board to grant virtual share options to individuals, in regard to services they provide and their continuous commitment to the Group. The 2017 VSOP allowed the management board to grant up to 29,560 virtual options, representing approximately 10% of the total shares of Centogene AG which were then issued and anticipated to be issued after additional investment by the investors. Under this program, holders of vested options were entitled to receive a direct cash payment from the Company, which is determined based on the exit price of the Company’s shares, upon the occurrence of any of the “exit events” as defined in the 2017 VSOP. The vesting period was three years commencing on the day of grant, during which one-third of the granted options would vest at the end of each year of grant. Upon an exit event, the vesting of any unvested awards will be accelerated.

As part of the corporate reorganization, in connection with the IPO (see note 1), a transfer agreement was entered into between the holders of options granted under the 2017 VSOP, Centogene AG and the Company in November 2019, according to which, the 2017 VSOP was terminated, and the option holders were instead granted new share options of the Centogene N.V. under the 2019 Plan (as defined and discussed below), determined based on the IPO price of the shares of Centogene N.V. and the number of options granted under the 2017 VSOP (see note 20(iii)).


	2019
	Number	WAEP
Outstanding as of January 1	10,496	1.0
Granted during the year	5,878	1.0
Cancelled during the year	(16,374)	1.0
Replacement awards granted during the year (note 20(iii))	805,308	0.12
Outstanding as of December 31	805,308	0.12
Vested as of December 31	805,308	0.12
Exercisable as of December 31	—	—

Upon the completion of the IPO, the liability under 2017 VSOP was calculated based on cash payment entitled to by the holders of options from the Company as stipulated in the program.

The termination of the 2017 VSOP and the grant of new share options of Centogene N.V. under the 2019 Plan was accounted for as a modification under IFRS 2. The total accumulated liability prior to the modification date of EUR 10,038k was reclassified to the capital reserve in 2019, since the new share options of Centogene N.V. are classified as an equity-settled share-based payment (see note 20(iii) below).

(iii) 2019 Equity Incentive Plan (2019 Plan)

In conjunction with the consummation of the IPO, the Company established a new long‑term incentive plan (the “2019 Plan”) with the purpose of advancing the interests of our shareholders and other stakeholders by enhancing our ability to attract, retain and motivate individuals who are expected to make important contributions to us. The 2019 Plan governs issuances of equity and equity‑based incentive awards from and after the consummation of the IPO. Awards under the 2019 Plan may be granted to our employees, the members of our management board and supervisory board, consultants or other advisors. As of January 1, 2021 the maximum number of common shares underlying awards that may be granted pursuant to the 2019 Plan (other than replacement awards) will not exceed 19% of the Company’s issued share capital. Such maximum number will be increased on January 1 of each calendar year, by an additional number of common shares equal to 3% of the Company’s issued share capital on such date (or a lower number of common shares as determined by the management board or supervisory board, where appropriate on the basis of a recommendation of the compensation committee (as the case may be, as prescribed by the 2019 Plan and, collectively, the “Committee”)).

In the event of a good leaver’s (as defined in the 2019 Plan) termination of employment or service, all vested awards will be exercised or settled in accordance with their terms within a period specified by the Committee and all unvested awards will be cancelled automatically unless decided otherwise by the Committee. In the event of a bad leaver’s (as defined in the 2019 Plan) termination of employment or service, all vested and unvested awards will be cancelled automatically without compensation. Pursuant to an amendment to the 2019 Plan applicable to awards granted in the period between September 11, 2020 and November 25, 2020, unless otherwise determined by the Committee, in the event of a good leaver’s termination of employment or service, all unvested awards will vest in full and all vested awards that have not yet been exercised or settled must be exercised or settled in accordance with their terms within a period specified by the Committee. If those awards are not exercised or settled within such period, they will be cancelled automatically without compensation. This arrangement is applicable to awards granted in the above-mentioned period only (see note 20(vi)).

In the event of a change in control of the Company (as defined in the 2019 Plan), outstanding awards that will be substituted or exchanged for equivalent replacement awards, in connection with the change in control will be cancelled. Outstanding rewards that are not substituted or exchanged for equivalent replacement awards, in connection with the change in control will immediately vest and settle in full, unless otherwise decided by the Committee.

The grants disclosed in the following paragraphs were granted under the 2019 Plan.

(iv) Equity share option - Replacement (ESOP 2017)

As discussed in note 20(ii), share options of Centogene N.V. were issued to the holders of options originally granted under 2017 VSOP as part of the corporate reorganization to replace the cash-settled share-based program.

The number of options granted to each holder was based on the number of options granted to them under 2017 VSOP and the IPO price of Centogene N.V. Accordingly, during 2019, 805,308 new share options were granted pursuant to the Centogene N.V. 2019 Plan, with each option representing the right to acquire one common share of Centogene N.V., with an exercise price equal to the nominal value of a share of Centogene N.V., which is EUR 0.12. The options were considered vested upon the completion of the IPO, but were not exercisable in the first 180 days after the IPO (lock-up period). As of December 31, 2019 all granted options were outstanding.


	2020
	Number	WAEP
Outstanding as of January 1	805,308	0.12
Granted during the year	—	0.12
Cancelled during the year	—	0.12
Exercised during the year	(256,303)	0.12
Outstanding as of December 31	549,005	0.12
Vested as of December 31	549,005	0.12
Exercisable as of December 31	549,005	0.12

During 2020, 256,303 options were exercised. The weighted average share price at the date of exercise was USD 12.13.

The contractual term of the share options as of December 31, 2020 is nine years.

The share options issued under ESOP 2017 are equity-settled and the fair value of the options were recognized in equity under capital reserve on the date of grant.

(v)Equity share option 2019 (ESOP 2019) to Flemming Ornskov

In 2019, an agreement was entered into between the Company and Flemming Ornskov. According to this agreement, a total of 396,522 options, each option representing the right to acquire one common share, were granted pursuant to the 2019 Plan for his services as chairman of the supervisory board, with an exercise price equaling the IPO price, which is EUR 12.58 per share, on the date of the IPO of the Company. The vesting period was three years commencing on the day of grant, during which one-third of the granted options would vest at the end of each year of grant, with the first year ending on March 31, 2020.

The contractual term of the share options as of December 31, 2019 was ten years and the weighted average fair value of options outstanding was EUR 9.08. The share options issued under “ESOP 2019” will be equity-settled and the fair value of the options were recognized in equity under capital reserve, based on the fair value on the date of grant, and will be charged to profit or loss over the vesting period using the graded approach.

On December 18, 2020, in an extraordinary general meeting of shareholders of Centogene N.V., the shareholders approved the grant of 300,000 restricted stock units (“RSUs”) to Flemming Ornskov under the 2019 Plan, which replaced the ESOP 2019 and pursuant to which Flemming Ornskov will forfeit the options awarded to him thereunder in exchange for the RSUs granted to him. The RSUs will expire after ten years, will not be subject to any other performance criteria, will have no exercise price and will be settled in shares. With respect to the RSUs granted:

33% will vest immediately;

the remaining 67% will vest in two equal annual instalments on each relevant anniversary of October 1 following the date of grant; and

will vest in full upon the occurrence of a change in control (as defined in the 2019 Plan), provided that the holder of the awards is an eligible participant (as defined in the 2019 Plan) on the date of such change in control.


	2019		2020
	Number	WAEP (EUR)	Number	WAEP
Outstanding as of January 1	—	—	396,522	12.58
Cancelled during the year	—	—	(396,522)	12.58
Replacement awards granted during the year	—	—	300,000	—
Granted during the year	396,522	12.58	—	—
Exercised during the year	—	—	—	—
Outstanding as of December 31	396,522	12.58	300,000	—
Vested as of December 31	—	—	100,000	—
Exercisable as of December 31	—	—	100,000	—

The replacement of the ESOP 2019 and the grant of new RSUs of Centogene N.V. was accounted for as modification under IFRS 2. The incremental fair value of EUR 135k will be recorded in the statement of comprehensive income over the vesting period of the replacement grant.

(vi) 2020 grant to management board and employees

On September 11, 2020, the Supervisory Board granted members of the management board the following options and RSUs under the 2019 Plan:

a.to the Company’s former Chief Executive Officer: 36,175 Options and 72,350 RSUs;

b.to the Company’s Chief Financial Officer: 16,250 Options and 32,250 RSUs; and

c.to the Company’s Chief Information Officer: 15,000 Options and 30,000 RSUs.

On September 11, 2020, the management board granted 87,500 options and 75,000 RSUs to other key current and former executive officers under the 2019 Plan. On October 15, 2020, 251,500 RSUs were granted to employees, subject to the terms of the 2019 Plan, the applicable award agreement and the terms specified in the authorization from the Supervisory Board for this purpose.

Apart from one award that immediately vested in full on the grant date and another award that vests in three equal tranches on each anniversary of its date of first employment, all other awards referred to above will vest in three equal tranches from January 1 following the grant date, in accordance with the following vesting schedule:

i.one third of the award vests on January 1, 2021;

ii.one third of the award vests on January 1, 2022; and

iii.one third of the award vests on January 1, 2023.

All of the foregoing awards vest in full when the participant is considered to be a good leaver within the meaning of the 2019 Plan effective as of grant date, as discussed in note 20(iii). As a result, unrecognized costs related to any unvested part of the award of a good leaver will result in accelerated recognition of these unrecognized costs in the statement of comprehensive income in the period when the employment contract has been terminated. Furthermore, all of the foregoing awards vest upon the occurrence of a change of control as defined by the 2019 Plan, unless the holder is no longer eligible to participate in the 2019 Plan at that time.

The options referred to above vest only if the 20 trading day volume-weighted average stock price of the Company’s shares preceding the vesting date of each tranche exceeds the exercise price of USD 11.60. This hurdle is considered a market condition. Therefore, expenses would not be reversed, if the tranches do not ultimately vest. As the 20 trading day volume-weighted average stock price exceeded the exercise price as of January 1, 2021, the first tranche vested on January 1, 2021.

The RSUs referred to above have no performance-based vesting criteria. Each RSU represents a right to receive a payment in cash or shares equal to the value of the RSU at the exercise date. The Company has a choice to settle either in cash, in shares or a combination thereof. In line with this policy, both types of awards are to be settled in shares and expire on the 10th anniversary of the grant date.

(vii) 2020 grants to new CEO

In 2020, the Company and the new CEO entered into an award agreement under the 2019 Plan pursuant to which the CEO will receive certain awards in the form of RSUs. According to the agreement, a total of 324,000 RSUs were granted on December 1, 2020, subject to the purchase of ordinary shares of the Company in the amount of CHF 1,000k within a certain period after the grant date. Furthermore, on January 1, 2022, provided that the CEO is continuing in service with the Company, the CEO will be granted awards of RSUs in an amount equal to CHF 1,400k divided by the applicable 20-trading day volume-weighted average stock price of the Company prior to the grant date. These RSUs have a service commencement date of December 1, 2020, which corresponds to the CEO’s employment start date, as entitlement to the RSU grant is dependent on the CEO continuing his service with the Company through the grant date. However, the grant date criteria for these awards will be met on January 1, 2022 at such time when the terms of the award and number of RSU’s to be granted become fixed pursuant to the underlying award agreement. Additionally, on January 1, 2023 and on each anniversary thereafter during the term of the agreement, the supervisory board may issue to the CEO an additional annual RSU award in an amount and with terms and conditions to be determined by the supervisory board.

The RSUs referred to above have no performance-based vesting criteria. RSUs represent a right to receive a payment equal to the value of the RSU at the exercise date. All the RSUs will vest in four equal annual installments following the grant date, subject to the CEO’s continued service with the Company as of the vesting date and will be charged to profit or loss over the period by using the graded approach.

Additionally, a total of 500,000 performance-based vesting RSUs were granted to the new CEO on December 1, 2020, subject to the following conditions:

200,000 RSUs will vest if the applicable volume-weighted average stock price of the Company equals or exceeds USD 24 in any consecutive three month period prior to January 1, 2023 (for these RSUs, the “initial vesting date”). To the extent that this hurdle will not be met, these RSUs will be forfeited in their entirety.

300,000 RSUs will vest if the applicable volume-weighted average stock price of the Company equals or exceeds USD 33 in any consecutive three month period prior to January 1, 2024 (for these RSUs, the “initial vesting date”). To the extent that this hurdle will not be met, these RSUs will be forfeited in their entirety.

The hurdle to the performance-vesting RSUs is considered a market condition. Therefore, expenses would not be reversed, if the tranches do not ultimately vest. All the performance-vesting RSUs will vest in four equal annual installments following the relevant initial vesting date, if the applicable performance hurdles are met, and subject to the CEO’s continued service with the Company as of the vesting date and will be charged to profit or loss over the vesting period using the graded approach. If the CEO’s service with the Company terminates for any reason, any unvested RSUs will immediately be forfeited. The foregoing awards that have been granted vest in full upon the occurrence of a change in control as defined in the agreement, provided that the CEO is still eligible to participate in the 2019 Plan and in continuous service with the Company through the date of such change in control.

The contractual term of the RSUs is ten years from the respective grant dates. The RSUs issued are equity-settled.

(viii) 2020 supervisory board grants

In 2020, an agreement was entered into between the Company and Peer Schatz, as member of our supervisory board. According to this agreement, a total of 300,000 RSUs were granted pursuant to the 2019 Plan to Mr. Schatz. The RSUs will vest in four equal annual instalments on each relevant anniversary of November 25, 2020. The grant was approved in the Company’s extraordinary general meeting of shareholders on December 18, 2020. The contractual term of the RSUs is ten years from grant date. The RSUs are not subject to performance criteria and will be settled in shares.

In the same extraordinary general meeting of shareholders on December 18, 2020, shareholders also approved a new incentive compensation scheme for supervisory board members, under which certain members of the supervisory board will annually receive an award of options and RSUs for ordinary shares of the Company under the 2019 Plan with a target value of EUR 80,000 multiplied by the LTI factor. For each award, RSUs will constitute 75% of the value of the award while options will constitute the remaining 25% of the value of the award. The LTI factor will be 100% or less based on the volume-weighted average stock price of the shares over a 60 trading day period preceding December 31 of the relevant financial year. Furthermore, the chairman and vice-chairman of the supervisory board will each annually receive an additional award with a value of EUR 60,000 and EUR 40,000, respectively, multiplied by the LTI factor as of the financial year 2023; the chairman of the audit committee and the chairman of the compensation committee will each annually receive an additional award with a value of EUR 40,000 and EUR 8,000, respectively, multiplied by the LTI factor. The awards will be granted retrospectively for the preceding financial year following the audit of the Company’s annual accounts over such financial year, with the first annual awards to be granted in 2021 (in respect of the 2020 financial year). The awards will vest in four equal annual instalments on each relevant anniversary of the grant date, will expire on the ten-year anniversary of the grant date and are not subject to any performance criteria.

The options and RSU awards referred above have a service commencement date of December 18, 2020, based on when the understanding was reached between the Company and the holders regarding the required services to contribute to the achievement of the long-term incentive targets. However, the grant date criteria for these awards will be met at each future annual grant date, upon the approval of the audited annual accounts, at such time when the terms and value of the awards to be granted become fixed.

The foregoing awards are equity-settled and will vest in full upon the occurrence of a change in control as defined in the agreement, unless the holder is no longer eligible to participate in the plan at that time. The awards will be charged to profit or loss over the service period using the graded approach, pursuant to the equal annual vesting instalments.

Recapitulation of awards granted in 2020

The movement of the total awards granted in 2020 under the 2019 Plan, as disclosed under note 20(vi), 20(vii) and 20(viii), excluding the replacement of the ESOP 2019 as disclosed under note 20(v), can be specified as follows:


	2020
	Options		RSUs
	Number	WAEP (USD)	Number	WAEP
Outstanding as of January 1	—	—	—	—
Granted during the year(1)	154,925	11.60	1,585,100	—
Exercised during the year	—	—	—	—
Outstanding as of December 31	154,925	11.60	1,585,100	—
Vested as of December 31	36,175	11.60	124,850	—
Exercisable as of December 31	36,175	11.60	124,850	—

(1) The granted options and RSUs do not include the number of RSUs to be granted to the new CEO from 2022 (note 20(vii)) and the number of RSUs and options to be granted to be certain supervisory board members annually (note 20(viii)) based on the grant date criteria, as the number of grants to the new CEO depends on the volume-weighted average stock price of the Company and the number of grants to certain supervisory board members depends on the LTI factor determined at the respective grant dates.

Valuation of Options

Virtual share option program 2016 and 2017

The fair values of the 2016 VSOP upon its exercise and 2017 VSOP upon its cancellation in 2019 were based on the cash payments to which the holders of the virtual options are entitled, which were calculated according to the formulae as stipulated in the respective programs. The cash payment is with reference to the share price of Centogene N.V. at the date of IPO.

Equity share option 2017 and Equity share option 2019

The fair values of ESOP 2017 and ESOP 2019 were estimated at the date of grant using the Black-Scholes option pricing model, taking into account the terms and conditions under which the share options were granted. The model takes into account historical and expected dividends, and the share price volatility of other public companies in the relevant industries to predict the share performance. There are no cash settlement alternatives for either the option holders or the Company.

The key assumptions used to derive the option value are set out below:


	2019
	ESOP 2017	ESOP 2019
Exercise price (EUR)	0.12	12.58
Share price at grant date (EUR)	12.58	12.58
Volatility (%)	70	70
Risk‑free interest rate (%)	(0.7)	(0.7)
Dividend yield (%)	0	0
Option term (years)	10	10

Valuation of 2020 grants

The fair value of the replacement awards granted to Flemming Ornskov under the 2019 Plan and the awards granted to other participants under the 2019 Plan in 2020 were estimated at the grant date. The fair value of the standard RSUs (i.e., those without performance-based vesting criteria) is based on the observed value of the underlying shares. As no dividend payments are expected over the vesting period, no further adjustment is required. The weighted average fair value of standard RSUs granted under the 2019 Plan during the year ended December 31, 2020 was USD 11.62.

The fair value of the ESOP 2019 replacement was estimated at the date of grant using the Black-Scholes option pricing model, taking into account the terms and conditions on which the options were granted. The fair value of the options and performance-based RSUs as of the grant date was determined using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. The key assumptions used to derive the option and performance-based RSUs value and the weighted average fair value are set out below:


	2020 Fair Value assumptions
	ESOP 2019	Options	Performormance
	Replacement		Based RSUs
Exercise price (USD)	14.00	11.60	n/a
Share price at grant date (USD)	12.02	11.05	12.54
Volatility (%)	75	75	88
Risk‑free interest rate (%)	1.0	0.8	0.2-0.3
Dividend yield (%)	0	0	0
Expected contractual life (years)	8.9	10	12.08-13.08
Weighted average fair value (USD)	12.02	6.20	8.23

The expense recognized for the above share-based payment transactions during the year is shown in the following table:


in EUR k	2018	2019	2020
Expenses arising from cash-settled share-based payment transactions	5,521	5,714	—
- 2016 VSOP	1,442	596	—
- 2017 VSOP (2019: including modification gain)	4,079	5,118	—
Expenses arising from equity-settled share-based payment transactions	—	704	5,658
- ESOP 2019, including replacement by RSUs		704	2,105
- 2020 grants to management board and employees		—	3,217
- 2020 grants to new CEO		—	269
- 2020 supervisory board grant		—	67
Total expenses arising from share‑based payment transactions	5,521	6,418	5,658

Financial instruments—fair values and risk management

12 Months Ended

Dec. 31, 2020

Financial instruments—fair values and risk management

Financial instruments—fair values and risk management

Financial instruments

21 Financial instruments-fair values and risk management

21.1Classifications and fair values

The carrying values of the Group’s financial assets and financial liabilities approximate their fair value.

21.2Financial risk management

The Group is exposed to the following risks from the use of financial instruments:

Credit risk

Liquidity risk

Currency risk

Credit risk

Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Group is exposed to credit risk from its operating activities (primarily trade receivables) and from its financing activities, including deposits with banks and financial institutions and foreign exchange transactions.

The carrying amount of the financial assets corresponds to the maximum default risk.

Trade receivables and contract assets

The Group utilizes a receivables management system that closely manages open items of major customers. The Group’s customers in the pharmaceutical segment are mainly pharmaceutical companies which are usually listed companies, or strongly financed by private equity funds. The Group’s customers in the diagnostics segment are mainly hospitals, labs and physicians, of which a large part are generating revenues. To avoid default, the Company may request prepayment for new business.

In addition to the macroeconomic situation generally, the development of international healthcare markets is a key economic factor in assessing the default risk related to trade receivables and contract assets. These markets are closely monitored by the Group.

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on days past due for groupings of various customer segments with similar loss patterns (i.e. by customers from different segment; customers from different geographical region and customer type). The calculation reflects the probability weighted outcome, the time value of money and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. The maximum exposure to credit risk at the reporting date is the carrying value of each class of financial assets disclosed in note 15. The Group does not hold collateral as security and does not request letters of credit or other forms of credit insurance. The Group evaluates the concentration of risk with respect to trade receivables and contract assets and recorded credit losses reflecting the expected lifetime loss, based on different types of customers.

Considering the major exposure to the credit risk arising from the diagnostics segment, the Group focused its impairment analysis on the trade receivables due from customers in the diagnostic segment, in particular the MENA and Europe regions as they represent the majority of that segment’s revenue. In addition to applying the provision matrix, the Group performed an individual customer analysis on major debtors, with reference to the past history (such as sales and collection in the previous periods) and the assessment of their current financial condition and other relevant factors and evaluated if additional specific impairment losses would be necessary.

Set out below is the information regarding the credit risk exposure of the Group’s trade receivables and contract assets using a provision matrix.


As of December 31, 2019
									Past due by
	Total Gross				Past due 1 -		Past due 31‑ 90		more than 90
in EUR k	amount		Not past due		30 days		days		days
Middle East	10,470		3,956		721		1,411		4,382
Europe	3,311		2,476		268		222		345
Latin America	811		611		53		42		105
North America	4,156		3,908		53		24		171
Asia Pacific	180		151		18		9		2
Total	18,928		11,102		1,113		1,708		5,005
Expected credit loss rate	12.3	%	0.3	%	1.0	%	1.2	%	45.4	%
Expected credit loss	2,335		31		11		21		2,272


As of December 31, 2020
									Past due by
	Total Gross				Past due 1 -		Past due 31‑ 90		more than 90
in EUR k	amount		Not past due		30 days		days		days
Middle East	10,515		3,338		486		385		6,306
Europe	20,017		19,193		706		113		5
Latin America	387		313		24		13		37
North America	2,870		1,205		994		262		409
Asia Pacific	178		136		18		24		—
Total	33,967		24,185		2,228		797		6,757
Expected credit loss rate	14	%	1.6	%	3.1	%	7.7	%	63.0	%
Expected credit loss	4,768		382		70		61		4,255

Overdue trade receivables in the Middle East region mainly relate to major customers from the diagnostics segment. The trade receivables due from the top 10 diagnostics customers in the MENA region as of December 31, 2020 represent over 90% of overdue balances for the Middle East. These customers are mainly government hospitals administered by the Ministry of Health in the respective countries as well as distributors and, based on our past experience, they normally require a longer period to settle outstanding trade receivables. The average turnover period from these customers are 304 days. Therefore, a higher country specific loss rate has been used for the MENA region.

Set out below is the movement in the allowance for expected credit losses of trade receivables and contract assets:


in EUR k	2019	2020
As of January 1	1,633	2,355
Provision for expected credit losses	752	3,879
Write-off	(30)	(1,466)
As of December 31	2,355	4,768

The addition to the allowance for expected credit losses includes an amount of EUR 3,879k which was included in the impairment of financial assets in the profit and loss account. In 2020, trade receivables of EUR 1,466k were outstanding for more than 365 days and were derecognized.

Cash and cash equivalents

As of December 31, 2020, the Group held cash and cash equivalents of EUR 48,156k (2019: EUR 41,095k). This total, therefore, also represents the maximum default risk with regard to these assets. The cash and cash equivalents are deposited principally with financial institutions with investment grade credit ratings.

Liquidity risk

The liquidity risk is the risk of the Group possibly not being in a position to meet its financial liabilities as contractually agreed by providing cash or other financial assets.

The Group's objective is to maintain a balance between continuity of funding and flexibility through the use of bank overdrafts and lease contracts.

Managing liquidity within the Group is intended to ensure that - as far as possible - sufficient cash and cash equivalents are always available to meet payment obligations when these fall due, in both normal and challenging conditions, without incurring unacceptable losses or damaging the Group’s reputation.

The Group strives to maintain cash and cash equivalents at a level above that of the expected cash outflows for financial liabilities (apart from trade payables) during the next 60 days. As of December 31, 2020, approximately 25.0% of the Group’s interest-bearing liabilities mature in less than one year (2019: 27.2%) based on the carrying value of borrowings reflected in the financial statements. The decrease in the ratio is due to repayment of non-current bank loans in 2020. As of December 31, 2020, the expected cash inflows from trade and other receivables within two months amounts to approximately EUR 14,857k (2019: EUR 6,644k), which would be EUR 16,154k lower than the amount of trade payables due as of then.

The Company completed the IPO in November 2019. In July 2020, the Company completed a follow-on public offering of 3,500,000 common shares of the Company, consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of USD 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts, commissions and transaction costs, were EUR 22 million to the Company. As of December 31, 2020, the Group had cash and cash equivalent of EUR 48,156k (2019: EUR 41,095k). The cash and cash equivalents are deposited principally with financial institutions with investment grade credit ratings.

In addition to the cash and cash equivalent available as of December 31, 2020, the Group also has access to other sources of funding. As of December 31, 2020, the Group has secured credit lines totaling EUR 3,500k. These bear interest of 3.75% - 4.75% (2019: EUR 4,000k; 3.33% - 4.50%). EUR 1,538k were utilized as of December 31, 2020 (2019: EUR 2,636k).

The table below presents the remaining contractual terms of the financial liabilities on the reporting date, including estimated interest payments. The figures are undiscounted gross amounts, including estimated interest payments and interest on undrawn loan funds, but without showing the impact of offsetting.


		Contractually agreed cash flows
						More
Dec 31, 2019	Carrying		Less than	2 to 12	1 to 5	than
in EUR k	amount	Total	2 months	months	years	5 years
Bank overdrafts	2,636	2,636	2,636	—	—	—
Secured bank loans	1,770	1,866	12	848	1,006	—
Lease liabilities	21,704	25,934	755	3,034	9,574	12,571
Municipal Loans	860	1,022	—	327	695	—
Trade payables	8,554	8,554	6,871	1,683	—	—
	35,524	40,012	10,274	5,892	11,275	12,571


		Contractually agreed cash flows
						More
Dec 31, 2020	Carrying		Less than	2 to 12	1 to 5	than
in EUR k	amount	Total	2 months	months	years	5 years
Bank overdrafts	1,538	1,538	1,538	—	—	—
Secured bank loans	968	997	5	584	408	—
Other bank loans	387	394	—	394	—	—
Lease liabilities	21,205	24,897	716	3,580	9,861	10,740
Municipal Loans	—	—	—	—	—	—
Trade payables	31,736	31,525	31,011	514	—	—
	55,834	59,351	33,270	5,072	10,269	10,740

Reconciliation of liabilities arising from financing activities


			Non-cash changes
				Changes in
in EUR k	Jan 1, 2019	Cash flows	Additions	maturity	Dec 31, 2019
Non-current financial liabilities	14,627	(12,783)	18,910	(1,107)	19,647
Non-current portion of secured bank loans	12,055	(11,087)	—	—	968
Municipal loans	860	—	—	(250)	610
Non-current lease liabilities	1,712	(1,696)	18,910	(857)	18,069
Current financial liabilities	5,052	(1,614)	2,778	1,107	7,323
Current portion of secured bank loans	1,787	(985)	—	—	802
Bank overdrafts	1,915	721	—	—	2,636
Municipal loans	—	—	—	250	250
Current lease liabilities	1,350	(1,350)	2,778	857	3,635
Total	19,679	(14,397)	21,688	—	26,970


			Non-cash changes
				Changes in
in EUR k	Jan 1, 2020	Cash flows	Additions	maturity and FX	Dec 31, 2020
Non-current financial liabilities	19,647	(1,993)	2,029	(1,605)	18,078
Non-current portion of secured bank loans	968	—	—	(567)	401
Municipal loans	610	(610)	—	—	—
Non-current lease liabilities	18,069	(1,383)	2,029	(1,038)	17,677
Current financial liabilities	7,323	(5,520)	2,663	1,554	6,020
Current portion of secured bank loans	802	(865)	63	567	567
Bank loans	—	438	—	(51)	387
Bank overdrafts	2,636	(1,208)	110	—	1,538
Municipal loans	250	(250)	—	—	—
Current lease liabilities	3,635	(3,635)	2,490	1,038	3,528
Total	26,970	(7,513)	4,692	(51)	24,098

Currency risk

The Group is exposed to currency risk in cases where contracts are concluded in foreign currencies. The vast majority of goods delivered and services the Company provided, including those for international customers, are invoiced in euro.

The main functional currencies of group companies are the euro, USD, the Indian rupee and the Arab Emirates Dirham. The following table presents the net foreign currency exposure of the Group as of December 31, 2019 and 2020.


	Dec 31, 2019
in EUR k	USD	INR	AED
Trade receivables	4,275	36	(1)
Trade payables and other liabilities	(2,801)	(98)	(15)
Net exposure	1,474	(62)	(16)


	Dec 31, 2020
in EUR k	USD	INR	AED
Trade receivables	1,224	18	—
Trade payables and other liabilities	(3,631)	(55)	(17)
Net exposure	(2,407)	(37)	(17)

Sensitivity analysis relating to changes in exchange rates

Given the exposure to foreign currencies as presented above, the impact to the Group’s earnings before tax or equity from a 10% change in the US dollar exchange rate would not be material.

List of subsidiaries

12 Months Ended

Dec. 31, 2020

List of subsidiaries

List of subsidiaries

22 List of subsidiaries

The major subsidiaries of the Group are listed below.


		Equity interests (%)
	Country in which
	primary activities are
Name	pursued	Dec 31, 2019	Dec 31, 2020
Centogene GmbH	Germany	100	100
Centogene IP GmbH	Germany	100	100
Centogene Shared Service GmbH	Germany	100	100
Centogene FZ-LLC	United Arab Emirates	100	100
Centogene US, LLC	USA	100	100
Centogene GmbH	Austria	90	90
Centogene India Pvt. Ltd*	India	51	100
Centogene Switzerland AG	Switzerland	—	100
Centosafe B.V.	Netherlands	—	100
Centogene d.o.o Belgrade	Serbia	—	100
LPC GmbH**	Germany	51	—
Dr. Bauer Laboratoriums GmbH***	Germany	—	—

(*) The Group acquired the remaining 49% of Centogene India Pvt. Ltd. in 2020, previously accounted for as non-controlling interest.
(**)The Group disposed of its entire 51% interest in LPC GmbH (“LPC”) in 2020, previously accounted for as non-controlling interest.

(***)Centogene does not own any shares in Bauer GmbH. However, Centogene meets the criteria of the control model under IFRS 10 as it has exposure to variable returns and the ability to use power to affect returns (see note 4).

Non-controlling interests

12 Months Ended

Dec. 31, 2020

Non-controlling interests

Non-controlling interests

23 Non‑controlling interests

The table below shows information on each subsidiary of the Group with material, non‑controlling interests before intercompany eliminations. The Group acquired the remaining 49% of Centogene India Pvt. Ltd in 2020 and disposed of its entire 51% interest in LPC GmbH in 2020 (see note 8.2). The non-controlling interest in Dr. Bauer Laboratoriums GmbH relates to the share in the net result of Bauer GmbH that is included in the results of the Company’s COVID-19 testing business (see note 4).


Dec 31, 2019	Centogene India Pvt. Ltd	LPC GmbH
in EUR k
Net assets/(liabilities)	(1,263)	(546)
Carrying amount of non‑controlling interests	(619)	(268)
Revenue	687	0
Profit/(loss)	(311)	(56)
Profit/loss allocated to non‑controlling interests	(152)	(27)


Dec 31, 2020	Centogene GmbH, Vienna	Dr. Bauer Laboratoriums GmbH
in EUR k
Net assets/(liabilities)	(522)	148
Carrying amount of non‑controlling interests	(52)	—
Revenue	—	55,596
Profit/(loss)	(1)	122
Profit/loss allocated to non‑controlling interests	(0)	122

Commitments	12 Months Ended
Commitments	Dec. 31, 2020
Commitments
Commitments	24 Commitments Future payments for non-cancellable leases The Group has various lease contracts in relation to the expansion of the Rostock headquarters and leasing of the Frankfurt laboratory, Berlin Airport, Düsseldorf Airport, Frankfurt Airport and additional laboratory space in Hamburg. The future lease payments and utilities for these non-cancellable lease contracts are EUR 283k within one year, EUR 1,686k within five years and EUR 4,855k thereafter (December 31, 2019: EUR nil). The Group has various non-cancellable lease contracts of office equipment and storage spaces which had a lease term of less than 12 months or were related to leases of low-value assets, and therefore the short-term lease recognition exemption was applied to these contracts. The future lease payments for these non-cancellable lease contracts are EUR 33k within one year (December 31, 2019: EUR 72k) and EUR 9k within five years (December 31, 2019: EUR 36k). Future payment obligations During 2020, the Group concluded agreements with suppliers, for goods and services to be provided in 2021 with a total payment obligation of EUR 4,669k (2019: EUR 802k).

Related parties

12 Months Ended

Dec. 31, 2020

Related parties

Related parties

25 Related parties

Transaction with shareholders

In July 2020, we completed a follow-on public offering of 3,500,000 common shares of the Company (the “Follow-on Equity Offering”), consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of $14.00 per common share (i.e., €12.71 per share). Aggregate offering proceeds, net of underwriting discounts, commissions and transaction costs, to the Company were €22 million. We are not aware of any ordinary shares which were issued by the Company and sold in this transaction to related parties.

Based on a shareholder agreement from January 2016 the payment to the option holders of the VSOP 2016 will be reimbursed by the original shareholders to the Company at the same time when the obligation to pay the options holders arises. The payables by the Group to the holders of vested options were recorded as a liability with a carrying value of EUR 2,769k as of December 31, 2019 and a corresponding receivable against shareholders was recorded (see note 15). The shareholders agreement had a term until December 31, 2023. Upon completion of the July 2020 Offering, the relevant payables to the holders of vested options were settled mainly by the proceeds received from such original shareholders from the sale of their shares.

During 2020, the Company entered into a service contract with the former CEO, a major shareholder, to serve as an advisor during the transition period after his departure from the Company until December 31, 2020. For the year ended December 31, 2020, fees totaling EUR 11k were charged to profit or loss related to these services and the Group had payables of EUR 12k outstanding as of December 31, 2020.

Remuneration of management in key positions

Remuneration of members of key management personnel

Key management have been defined as the members of the management board and the Company’s other key executive officers.


in EUR k	2018	2019	2020
Short‑term employee benefits	2,354	3,313	4,273
Post‑employment pension and medical benefits	10	10	23
Termination benefits	—	—	565
Share‑based payment transactions	2,893	3,395	1,822
Total compensation to key management	5,257	6,718	6,683

Due to the departure of the former CEO, share-based payments include additional share-based expenses of EUR 468k for the accelerated vesting of outstanding equity awards and termination benefits include the severance payout of EUR 565k. As of December 31, 2020, the Group had amounts of EUR 1,325k (2019: EUR 769k) accrued for key management compensation.

There are no pension commitments for members of the management board.

During 2020, 154,925 share options and 1,033,600 RSUs were granted under the 2019 Plan to key management personnel which are recognized as share-based payment expenses in profit and loss (see notes 20(vi) and 20(vii)). In addition, as part of the employment agreement with the new CEO, he is entitled to awards of RSUs in an amount equal to CHF 1,400k to be granted on January 1, 2022 for which share-based payment expense is recognized in profit and loss during 2020 based upon an estimated grant date fair value over the requisite service period.

During 2019, 440,475 share options were granted under ESOP 2017 to key management personnel, allowing to purchase common shares of the Company, as a result of the replacement of previous cash-settled share-based transaction (see notes 20(v) and 20(viii)). The options are fully vested and exercisable after a lock-up period of 6 months after November 7, 2019. The exercise price of the share options is EUR 0.12, and the options expire in 2029.

As of December 31, 2020, the Group has receivables of EUR 561k (2019: EUR nil) recognized related to the exercise of options by key management personnel, including the former CEO who was a member of key management during the periods.

Remuneration of members of the Supervisory Board

The supervisory board received remuneration for its activities of EUR 603k in the reporting year (2019: EUR 499k; 2018: EUR 341k). In addition, as disclosed in note 20, certain members of the supervisory board received share-based awards under the 2019 Plan. For the year ended December 31, 2020, share-based payment expenses of EUR 2,172k (2019: EUR 704k; 2018: EUR nil) related to these awards were charged to profit and loss.

Transactions with members of management in key positions and other related parties

The Company purchased supplies used for COVID-19 testing from an entity related to a member of the supervisory board that joined the board in 2020. Expenses totaling EUR 65k were charged to profit and loss related to the period of service of the board member. As of December 31, 2020, the Group had payables of EUR 75k outstanding related to these purchases.

For the year ended December 31, 2020, revenues totaling EUR 127k in the year were recognized in profit and loss in relation to performance of COVID-19 testing services for entities related to members of the supervisory board. As of December 31, 2020, the Group had receivables of EUR 27k outstanding related to this entity.

For the year ended December 31, 2020, fees totaling EUR nil (2019: EUR 152k; 2018: EUR nil) were charged to profit or loss in relation to consulting services provided by a member of the supervisory board. For the year ended December 31, 2018, there were also consulting fees of EUR 64k relating to services provided by a member of the supervisory board and an entity controlled by a member of the supervisory board.

Contingent Liabilities	12 Months Ended
Contingent Liabilities	Dec. 31, 2020
Contingent Liabilities
Contingent Liabilities	26 Contingent liabilities In May 2016, the Company was informed in writing by the Universitair Medisch Centrum Utrecht ("UMCU") that a claim had been initiated against UMCU regarding a prenatal diagnostic test that the Company conducted at their request which failed to identify a specific mutation present in a patient. On October 1, 2018, the UMCU and Neon Underwriting Limited formally filed a legal claim in the local court in Rostock, Germany against the Company alleging that the Company’s negligence in performing the test resulted in the misdiagnosis of the patient. UMCU is seeking recovery for compensatory damages as a result of the alleged misdiagnosis. By court order of November 8, 2018, the Regional Court of Rostock set the amount in dispute at EUR 880k. On November 12, 2018, the Company submitted a notice to the Regional Court of Rostock of the intention to defend against the claim. On January 3, 2019, the Company filed a motion to dismiss in which the Company denied the merits of the claim. UMCU and Neon Underwriting Limited responded to this motion on March 15, 2019 with a statement of reply, and the parties made several court filings setting out their arguments since. By order dated June 3, 2019, the Regional Court of Rostock provided a first set of questions to be answered by an expert witness. Following a request by the Court, the Director of the Institute of Genetics at the University of Bonn recommended a professor for human genetics from the University of Aachen be appointed as an expert witness in this case. The Company agreed to such recommendation. As of December 31, 2020, the amount in dispute was EUR 1.3 million. The matter was assigned to a new judge, due to the illness of the prior judge, and the decision to appoint the recommended expert witness is still pending. The Company intends to continue to rigorously defend its position and considers that it is not probable the legal claim towards the Company will be successful and as a result has not recognized a provision for this claim as of December 31, 2020. In addition, in case a settlement would be required, the Company believes that the corresponding liability will be fully covered by the respective existing insurance policies. Certain of our original shareholders agreed to reimburse us for the payments that we make to option holders under the 2016 Plan. Upon completion of the Follow-on Equity Offering, the relevant payables to the holders of vested options were settled mainly by the proceeds received from such original shareholders from the sale of their shares in the Follow-on Equity Offering. We have received a demand from one such original shareholder that alleges that it should have paid less to us in connection with the settlement of such payables. We believe such demand to be baseless and, should such original shareholder institute formal legal proceedings against us, intend to defend our interests vigorously. The higher regional court of Rostock issued a final decision by which it has retroactively invalidated a contract entered into between Centogene GmbH (the “Company”) and the State of Mecklenburg-Western Pomerania (“MVP”) for COVID-19 testing, due to non-compliance by MVP with the public tender requirements of the German government. As a result of the invalidation, MVP now has a claim under German law against the Company for repayment of the full amount invoiced and received under the contract (EUR 2.3 million). The Company also has a claim against MVP for compensation for the value of services provided in expectation of the validity of the contract. In disputes of this kind, the amounts of these two claims would typically equal each other and could be offset against one another. However, definitive and formal assurance from MVP that it will take the view that the amount of its claim equals and offsets the amount of the Company's claim has not yet been provided in writing. To the extent that MVP's claim exceeds the Company's claim against MVP, Centogene may have a payment obligation, which could materially adversely affect the Group’s financial position and results of operations. The current understanding between MVP and Centogene is that the Company’s services were provided at market value and that despite the court’s invalidation of the contract, Centogene has a claim against MVP for EUR 2.3 million. A contractual agreement putting this understanding in writing has been finalized and is currently in the process of being signed.

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2020
Subsequent Events
Subsequent Events	27 Subsequent Events Grant of restricted stock units and options In 2021, 59,488 RSUs and 15,000 options were granted to management, subject to the terms of the 2019 Plan, the applicable award agreement and the terms specified in the authorization from the Supervisory Board for this purpose. The options awards and 30,000 RSUs will vest in three equal tranches over a three-year period and 29,488 RSUs will vest in four equal tranches over a four-year period starting January 1, 2022. These consolidated financial statements were approved by management on April 15, 2021.

Significant accounting policies (Policies)

12 Months Ended

Dec. 31, 2020

Significant accounting policies

Foreign currency and currency translation

(a)Foreign currency and currency translation

Transactions in foreign currency are translated into the respective entity’s functional currency at the spot rate prevailing on the date of the transaction.

The exchange rates used are presented in the following table:


	Average rate			Closing rate
				Dec 31,	Dec 31,	Dec 31,
	2018	2019	2020	2018	2019	2020
USD (EUR 1)	1.1779	1.1191	1.1412	1.1419	1.1234	1.2271
AED (EUR 1)	4.2713	4.0985	4.2091	4.1396	4.0795	4.5045
INR (EUR 1)	79.3177	78.7980	84.5737	78.5156	80.1870	89.6605

Revenues from contracts with customers

(b)Revenues from contracts with customers

(i)Pharmaceutical segment

-Revenue from the sale of CentoCards is recognized at a point in time when the control of the CentoCards has transferred to the customer, which typically occurs on delivery.

(ii)Diagnostics segment

(iii)COVID-19 segment

Contract balances

(i) Contract assets

(ii) Trade receivables

(iii) Contract liabilities

Finance income and finance costs

(c)Finance income and finance costs

Interest income and expenses are recognized in the period which they relate to through profit or loss using the effective interest rate method.

Current versus non-current classification

(d)Current versus non-current classification

The Group presents assets and liabilities in the statement of financial position based on current/non-current classification. An asset is current when it is:

-Expected to be realized or intended to be sold or consumed in the normal operating cycle

-Held primarily for the purpose of trading

-Expected to be realized within twelve months after the reporting period; or

-Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period

All other assets are classified as non-current.

A liability is current when:

-It is expected to be settled in the normal operating cycle

-It is held primarily for the purpose of trading

-It is due to be settled within twelve months after the reporting period; or

-There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period

The terms of the liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

The Group classifies all other liabilities as non-current.

Deferred tax assets and liabilities are classified as non-current assets and liabilities

Intangible assets

(e)Intangible assets

Research and development

Expenses for research activities are recognized through profit or loss in the period in which they are incurred.

Development expenditures on an individual project are recognized as an intangible asset from the date the Group can demonstrate:

-the product or process is technically and commercially feasible so that the asset will be available for use or sale

-the Group has the intention and its ability and intention to use or sell the asset

-a future economic benefit is probable

-the Group has sufficient resources to complete the development and

-the development costs can be measured reliably.

Capitalized development costs which are still under development are tested for impairment annually and when circumstances indicate that the carrying value may be impaired.

Other intangible assets

Intangible assets are amortized over their estimated useful life using the straight-line method and assessed for impairment whenever there is an indication that the intangible asset may be impaired.

The estimated useful lives are as follows:

Software, patents and trademarks: 3‑7 years

Corona Test Portal: 2 years

Capitalized development costs: 7 years

The useful lives and depreciation methods are reviewed annually to ensure that the methods and periods of depreciation are consistent with the expected economic benefit from the asset.

Property, plant and equipment

(f)Property, plant and equipment

Property, plant and equipment are carried at cost less any accumulated depreciation and any accumulated impairment losses.

Subsequent expenditure is only capitalized if it is probable that the future economic benefits associated with the expenditure will flow to the Group.

Freehold land is not depreciated

Buildings: 33 years and

Plant and other equipment, furniture and fixtures: 2‑15 years

The depreciation methods, useful lives and residual values are reviewed, and adjusted prospectively if appropriate, as of each reporting date.

Assets under construction are reported at cost and are allocated to property, plant and equipment until they are completed and put into operational use, from which point onwards they are depreciated.

Leases

(g)Leases

Assets from other leases are classified as operating leases and the respective lease expenses are recognised in profit or loss on a straight-line basis over the lease term.

Group as a lessee

(i)Right-of-use assets

-Buildings: 33 years

-Offices: 4 – 12 years and

-Plant and other equipment, furniture and fixtures: 2-15 years

The right-of-use assets are also subject to impairment. Refer to accounting policies of impairment of financial assets in note 5(n) “Financial instruments”.

(ii)Lease liabilities

(iii)Short-term leases and leases of low-value assets

(iv)Sale and leaseback transactions

•any below-market terms shall be accounted for as a prepayment of lease payments

•any above-market terms shall be accounted for as additional financing provided by the buyer-lessor to the seller-lessee

Impairment of non-financial assets

(h)Impairment of non-financial assets

Inventories

(i)Inventories

Inventories are measured at the lower of cost and net realizable value. Inventories are recognized at cost based on the first in first out (FIFO) method.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

Government grants

(j)Government grants

The release of deferred income related to either type of grant is presented as other operating income (see note 8).

Share-based payments

(k)Share-based payments

Equity settled transactions

Cash-settled transactions

Provisions

(l)Provisions

Income taxes

(m)Income taxes

Deferred tax assets and deferred tax liabilities are offset against each other if certain conditions are met.

Financial instruments

(n)Financial instruments

(i) Financial assets

The Group’s financial assets principally consist of those accounted for as receivables and contract assets.

Receivables and contract assets

Derecognition

A financial asset or a part of a financial asset is derecognized when the Group no longer has the contractual rights to the asset or the right to receive cash flows from the asset have expired.

Impairment

Further disclosures relating to impairment of trade receivables, including contract assets, are in note 21.

(ii) Financial liabilities

All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs.

The Group’s financial liabilities include trade and other payables (include contract liabilities), as well as loans and borrowings including bank overdrafts.

Loans and borrowings

Gains or losses are recognized through profit or loss at the time the liabilities are derecognized or disposed of.

Derecognition

A financial liability is derecognized when the obligation underlying the liability is discharged, canceled or expires.

Cash and cash equivalents

(o) Cash and cash equivalents

Significant accounting policies (Tables)

12 Months Ended

Dec. 31, 2020

Significant accounting policies

Schedule of exchange rates used


	Average rate			Closing rate
				Dec 31,	Dec 31,	Dec 31,
	2018	2019	2020	2018	2019	2020
USD (EUR 1)	1.1779	1.1191	1.1412	1.1419	1.1234	1.2271
AED (EUR 1)	4.2713	4.0985	4.2091	4.1396	4.0795	4.5045
INR (EUR 1)	79.3177	78.7980	84.5737	78.5156	80.1870	89.6605

Segment information and revenue from contracts with customers (Tables)

12 Months Ended

Dec. 31, 2020

Segment information and revenue from contracts with customers

Schedule of segment information and reconciliation of segment adjusted EBITDA to group loss for the period


	2018
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	17,307	23,171	—	40,478

Adjusted EBITDA	13,641	2,285	(15,836)	90

Capital Expenditures
Additions to property, plant and equipment	1,225	1,917	5,568	8,710
Additions to intangible assets	1,948	—	1,111	3,059

Other segment information
Depreciation and amortization	1,222	1,838	2,115	5,175
Research and development expenses	334	—	5,966	6,300


	2019
in EUR k	Pharmaceutical	Diagnostics	Corporate	Total
Total Revenues from contracts with external customers	21,522	27,258	—	48,780

Adjusted EBITDA	14,956	2,306	(22,949)	(5,687)

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	1,362	1,998	17,908	21,268
Additions to intangible assets	3,603	—	3,677	7,280

Other segment information
Depreciation and amortization	1,308	2,032	3,239	6,579
Research and development expenses	—	—	9,590	9,590


	2020
in EUR k	Pharmaceutical	Diagnostics	COVID-19(1)	Corporate	Total
Total Revenues from contracts with external customers	16,951	22,108	89,322	—	128,381

Adjusted EBITDA	6,194	(2,408)	37,215	(39,918)	1,083

Capital Expenditures
Additions to property, plant and equipment and right-of-use assets	333	602	9,113	2,682	12,730
Additions to intangible assets	3,183	—	1,672	1,802	6,657

Other segment information
Depreciation and amortization (including impairments)	6,769	2,289	1,400	4,670	15,128
Research and development expenses	—	—	—	14,935	14,935

(1)

Reconciliation of segment Adjusted EBITDA to Group loss for the period


in EUR k	2018	2019	2020
Reportable segment Adjusted EBITDA	15,926	17,262	41,001
Corporate expenses	(15,836)	(22,949)	(39,918)
	90	(5,687)	1,083
Share‑based payment expenses (Note 20)	(5,521)	(6,418)	(5,658)
Depreciation and amortization (including impairments)	(5,175)	(6,579)	(15,128)
Operating loss	(10,606)	(18,684)	(19,703)
Financial costs, net	(1,042)	(2,013)	(1,394)
Income taxes	310	(158)	(281)
Loss for the year	(11,338)	(20,855)	(21,378)

Schedule of geographical information


in EUR k	2018
	Pharmaceutical	Diagnostics	Total
Rendering of services	16,077	23,171	39,248
Sales of goods	1,230	—	1,230
Total Revenues from contracts with external customers	17,307	23,171	40,478

Recognized over time	12,077	23,171	35,248
Recognized at a point in time	5,230	—	5,230
Total Revenues from contracts with external customers	17,307	23,171	40,478

Geographical information
Europe	654	6,196	6,850
—Germany*	654	407	1,061
Middle East	—	12,401	12,401
—Saudi Arabia#	—	5,475	5,475
North America	16,653	1,460	18,113
—United States#	16,653	643	17,296
Latin America	—	2,185	2,185
Asia Pacific	—	929	929
Total	17,307	23,171	40,478


in EUR k	2019
	Pharmaceutical	Diagnostics	Total
Rendering of services	19,089	27,258	46,347
Sales of goods	2,433	—	2,433
Total Revenues from contracts with external customers	21,522	27,258	48,780

Recognized over time	17,159	27,258	44,417
Recognized at a point in time	4,363	—	4,363
Total Revenues from contracts with external customers	21,522	27,258	48,780

Geographical information
Europe	381	7,066	7,447
—Germany*	233	275	508
—Netherlands**	—	25	25
Middle East	122	13,977	14,099
—Saudi Arabia#	—	7,417	7,417
North America	20,896	2,380	23,276
—United States#	20,896	1,882	22,778
Latin America	123	2,864	2,987
Asia Pacific	—	971	971
Total	21,522	27,258	48,780


in EUR k	2020
	Pharmaceutical	Diagnostics	COVID-19	Total
Rendering of services	15,947	22,108	88,587	126,642
Sales of goods	1,004	—	735	1,739
Total Revenues from contracts with external customers	16,951	22,108	89,322	128,381

Recognized over time	15,947	22,108	24,684	62,739
Recognized at a point in time	1,004	—	64,638	65,642
Total Revenues from contracts with external customers	16,951	22,108	89,322	128,381

Geographical information
Europe	149	5,605	88,314	94,068
—Germany*#	—	186	80,879	81,065
—Netherlands**	—	3	6,572	6,575
Middle East	56	12,568	—	12,624
North America	16,711	1,576	978	19,265
—United States#	16,711	1,370	978	19,059
Latin America	35	1,851	2	1,888
Asia Pacific	—	508	28	536
Total	16,951	22,108	89,322	128,381

* country of the incorporation of Centogene GmbH

** country of the incorporation of Centogene N.V.

# countries contributing more than 10% of the Group's total consolidated revenues for the respective year ended December 31, 2018, 2019 and 2020

Schedule of contract balances


in EUR k	Dec 31, 2019	Dec 31, 2020
Trade receivables (note 15)	12,709	25,656
Contract assets (note 15)	3,884	3,543
Contract liabilities (note 19.2)	3,748	4,479

Other income and expenses (Tables)

12 Months Ended

Dec. 31, 2020

Other income and expenses

Schedule of other operating income


in EUR k	2018	2019	2020
Government grants	1,611	2,641	2,152
Gain on disposal of property, plant and equipment	—	532	2
Exchange rate gains	147	314	—
Income from the reversal of provisions	309	89	—
Others	239	205	240
Total other operating income	2,306	3,781	2,394

Schedule of other operating expenses


in EUR k	2018	2019	2020
Currency losses	250	192	10
Other	23	1,092	172
Total other operating expenses	273	1,284	182

Schedule of finance costs, net


in EUR k	2018	2019	2020
Interest expenses from loans	(922)	(1,690)	(173)
Currency losses	—	—	(362)
Unwinding of the discount on lease liabilities	(153)	(339)	(865)
Interest income from loans and receivables	33	16	6
Total	(1,042)	(2,013)	(1,394)

Schedule of employee benefits expense


in EUR k	2018	2019	2020
Wages and salaries	17,965	23,854	31,121
Social security contributions	2,492	3,212	4,095
Share‑based payments	5,521	5,714	3,486
Termination benefits	56	63	569
Total	26,034	32,843	39,271

Income taxes (Tables)

12 Months Ended

Dec. 31, 2020

Income taxes

Schedule of tax recognized through profit or loss


in EUR k	2018	2019	2020
Current tax expenses	(87)	(158)	(74)
Current year	(87)	(1)	(58)
Adjustments for prior periods	—	(157)	(16)
Deferred tax (expense)/income	397	—	(207)
Temporary differences	527	(514)	(182)
Tax losses	(130)	514	(25)
Total income tax (expenses)/benefit	310	(158)	(281)

Schedule of reconciliation of the effective tax rate to the statutory rate


in EUR k	2018	2019	2020
Loss before tax	(11,648)	(20,697)	(21,097)
Taxes on the basis of the Company’s domestic tax rate	3,623	6,445	6,570
Tax rate effect of foreign tax jurisdictions	406	412	65
Non‑deductible expenses	(105)	(441)	(903)
Current year losses for which no deferred tax assets were recognized	(3,528)	(6,416)	(5,792)
Tax income related to prior years	—	(157)	(137)
Other effects	(86)	(1)	(84)
Income tax (expenses)/ benefit	310	(158)	(281)

Schedule of breakdown of deferred taxes in the statement of financial position


	December 31, 2019		December 31, 2020
	Deferred	Deferred	Deferred	Deferred
in EUR k	tax assets	tax liabilities	tax assets	tax liabilities
Intangible assets	—	(3,013)	—	(2,934)
Property, plant and equipment	—	(156)	—	(133)
Right-of-use assets	—	—	—	(5,029)
Measurement of service contracts	—	(173)	—	(145)
Leasing liabilities	—	—	4,865	—
Government grants	2,051	—	1,903	—
Unused tax losses	1,291	—	1,266	—
Sum	3,342	(3,342)	8,034	(8,241)
Offset	(3,342)	3,342	(8,034)	8,034
Deferred Taxes	—	—	—	(207)

Intangible assets (Tables)

12 Months Ended

Dec. 31, 2020

Intangible assets

Summary of reconciliation of carrying amounts of intangible assets


	Internally
	generated	Internally	Purchased rights,
	/acquired	developed	licenses,
in EUR k	biomarkers	databases	software	Total
Cost
As of Jan 1, 2019	7,133	3,365	3,370	13,868
Reclass from property, plant and equipment (Note 12)	386	—	—	386
Reclass*	900	758	(1,658)	—
Additions	3,603	2,379	1,298	7,280
As of Dec 31, 2019	12,022	6,502	3,010	21,534
Additions	1,900	2,717	2,040	6,657
Deconsolidation	—	—	(151)	(151)
As of Dec 31, 2020	13,922	9,219	4,899	28,040

Accumulated amortization and impairment
As of Jan 1, 2019	2,660	1,047	1,366	5,073
Amortization	1,171	723	422	2,316
As of Dec 31, 2019	3,831	1,770	1,788	7,389
Amortization and impairment	6,917	943	508	8,368
Deconsolidation	—	—	(124)	(124)
As of Dec 31, 2020	10,748	2,713	2,172	15,633

Carrying amounts
As of Dec 31, 2019	8,191	4,732	1,222	14,145
As of Dec 31, 2020	3,174	6,506	2,727	12,407

Property, plant and equipment (Tables)

12 Months Ended

Dec. 31, 2020

Property, plant and equipment

Schedule of development of property, plant and equipment

Please refer to the following table for the development from January 1, 2019 to December 31, 2020:


				Other
				equipment,
				furniture
in EUR k	Land	Buildings	Plant	and fixtures	Total
Cost
As of Jan 1, 2019	2,149	24,891	16,011	4,856	47,907
Reclass to right-of-use assets*	—	—	(6,303)	(32)	(6,335)
Reclass to intangible assets (note 11)	—	—	—	(386)	(386)
Additions	—	—	22	274	296
Disposal (note 13.1)	(2,149)	(21,637)	—	—	(23,786)
As of Dec 31, 2019	—	3,254	9,730	4,712	17,696
Additions	—	105	1,295	8,490	9,890
Disposal***	—	—	—	(612)	(612)
Reclass from right-of-use assets**	—	—	3,099	—	3,099
As of Dec 31, 2020	—	3,359	14,124	12,590	30,073

Accumulated depreciation and impairment
As of Jan 1, 2019	—	612	6,178	2,002	8,792
Reclass to right-of-use assets*	—	—	(963)	(8)	(971)
Depreciation	—	737	940	779	2,456
Disposal (note 13.1)	—	(957)	—	—	(957)
As of Dec 31, 2019	—	392	6,155	2,773	9,320
Depreciation	—	194	993	1,913	3,100
Disposal***	—	—	—	(44)	(44)
Reclass from right-of-use assets**	—	—	1,107	—	1,107
As of Dec 31, 2020	—	586	8,255	4,642	13,483

Carrying amounts
As of Dec 31, 2019	—	2,862	3,575	1,939	8,376
As of Dec 31, 2020	—	2,773	5,869	7,948	16,590

Right-of-use assets (Tables)

12 Months Ended

Dec. 31, 2020

Right-of-use assets

Schedule of carrying amounts of right-of-use assets and movements during the period


			Plant and	Other	Motor
In EUR k	Buildings*	Offices	equipment	equipment	Vehicles	Total

As of January 1, 2019	—	391	5,340	24	12	5,767
Additions	13,456	4,288	2,824	386	18	20,972
Depreciation expenses	(330)	(272)	(1,175)	(20)	(10)	(1,807)
As of December 31, 2019	13,126	4,407	6,989	390	20	24,932
Additions	—	426	1,265	1,112	37	2,840
Reclass to property, plant & equipment**	—	—	(1,992)	—	—	(1,992)
Depreciation expenses	(1,121)	(657)	(1,675)	(187)	(20)	(3,660)
As of December 31, 2020	12,005	4,176	4,587	1,315	37	22,120

* As the lease of land and buildings are made through one contract, all the related right-of-use assets are allocated to Buildings.

** Reclass of leased assets to PP&E (note 12) represents purchased assets at the end of lease term.

Schedule of carrying amounts of lease liabilities and the movements during the period


in EUR k	2019	2020

As of January 1	3,465	21,704
Additions	20,946	3,654
Interest expenses	339	865
Payments	(3,046)	(5,018)
As of December 31	21,704	21,205

Current	3,635	3,528
Non-current	18,069	17,677

Schedule of amounts recognised in profit or loss related to leases


in EUR k	2019	2020
Depreciation expense of right-of-use assets	1,807	3,660
Interest expenses on lease liabilities	339	865
Rent expenses—short-term leases	185	1,695
Rent expense—leases of low-value assets	25	33
Total amounts recognized in profit or loss	2,356	6,253

Inventories (Tables)

12 Months Ended

Dec. 31, 2020

Inventories

Summary of inventories


in EUR k	Dec 31, 2019	Dec 31, 2020
Raw materials, consumables and supplies	1,644	11,167
Finished goods and merchandise	165	238
Inventories	1,809	11,405

Trade and other receivables and other assets (Tables)

12 Months Ended

Dec. 31, 2020

Trade and other receivables and other assets

Summary of trade receivables and other assets


in EUR k	Dec 31, 2019	Dec 31, 2020
Non‑current
Other assets—Rental deposits	1,948	1,867
Other assets—Others	—	100
	1,948	1,967
Current
Trade receivables	12,709	25,656
Contract assets	3,884	3,543
Receivables due from shareholders	2,766	—
Other assets	5,846	8,286
	25,205	37,485
Total non-current and current trade and other receivables and other assets	27,153	39,452

Equity (Tables)

12 Months Ended

Dec. 31, 2020

Equity.

Common shares issued and authorized


in thousands of shares	2019	2020
Common shares as of Jan 1, fully paid(1)	15,861	19,861
Issued shares	4,000	2,000
Exercise of options	—	256
Common shares issued as of Dec 31, fully paid	19,861	22,118

(1)

Common shares as of January 1, 2019, issued as a result of corporate reorganization


	as of	as of
in thousands of shares	Dec 31, 2019	Dec 31, 2020
Authorized common shares of EUR 0.12 each	79,000	79,000

Financial liabilities (Tables)

12 Months Ended

Dec. 31, 2020

Financial liabilities

Schedule of interest-bearing liabilities


in EUR k	Dec 31, 2019	Dec 31, 2020
Non‑current liabilities
Non‑current portion of secured bank loans	968	401
Municipal loans	610	—
Total non‑current loans	1,578	401
Lease liabilities	18,069	17,677
Total non‑current liabilities	19,647	18,078

Current liabilities
Current portion of secured bank loans	802	567
Other bank loans	—	387
Bank overdrafts	2,636	1,538
Municipal loans	250	—
Total current loans	3,688	2,492
Current portion of lease liabilities	3,635	3,528
Total current liabilities	7,323	6,020

Total non‑current and current liabilities	26,970	24,098

Schedule of outstanding interest-bearing liabilities


				Dec 31, 2019		Dec 31, 2020
		Nominal		Nominal	Carrying	Nominal	Carrying
in EUR k	Currency	interest rate	Maturity	amount	amount	amount	amount
Secured bank loan	EUR	2.95%	2017‑22	1,770	1,770	968	968
Other bank loan	USD	1%	2020-22	—	—	387	387
Municipal loan	EUR	8.25%; plus 1.5% profit-related; 0.75% on losses	2018-23	500	500	—	—
Municipal loan	EUR	8%; plus 1.5% profit-related; 0.75% on losses	2021	360	360	—	—
Bank overdrafts	EUR	4.75%	Rollover	476	476	498	498
Bank overdrafts	EUR	3.75%	Rollover	2,160	2,160	628	628
Bank overdrafts	EUR	4.50%	Rollover	—	—	412	412
Lease liabilities	EUR	2.1%-3.5%*, 5.4%-9.1%	2017-31	21,704	21,704	21,205	21,205
Total interest‑bearing financial liabilities				26,970	26,970	24,098	24,098

* represents the incremental borrowing rate of the Group at the commencement of the leases

Schedule of trade payables and other liabilities


in EUR k	Dec 31, 2019	Dec 31, 2020
Trade payables	8,554	31,736
Government grants (deferred income)	11,289	10,292
Liability for Virtual Stock Option Program	2,769	—
Contract liabilities	3,748	4,479
Others	5,258	13,483
Trade payables and other liabilities	31,618	59,990
Non‑current	9,941	8,950
Current	21,677	51,040

Share-based payments (Tables)

12 Months Ended

Dec. 31, 2020

Share-based payments

Schedule of total expenses arising from share‑based payment transactions


in EUR k	2018	2019	2020
Expenses arising from cash-settled share-based payment transactions	5,521	5,714	—
- 2016 VSOP	1,442	596	—
- 2017 VSOP (2019: including modification gain)	4,079	5,118	—
Expenses arising from equity-settled share-based payment transactions	—	704	5,658
- ESOP 2019, including replacement by RSUs		704	2,105
- 2020 grants to management board and employees		—	3,217
- 2020 grants to new CEO		—	269
- 2020 supervisory board grant		—	67
Total expenses arising from share‑based payment transactions	5,521	6,418	5,658

Virtual share option program 2016 (Cash settled)

Share-based payments

Schedule of share option activity


	2019
	Number	WAEP
Outstanding as of January 1	802,283	3.22
Exercised during the year	(802,283)	3.45
Outstanding as of December 31	—	—
Vested as of December 31	—	—
Exercisable as of December 31	—	—

Virtual share option program 2017 (Cash settled)

Share-based payments

Schedule of share option activity


	2019
	Number	WAEP
Outstanding as of January 1	10,496	1.0
Granted during the year	5,878	1.0
Cancelled during the year	(16,374)	1.0
Replacement awards granted during the year (note 20(iii))	805,308	0.12
Outstanding as of December 31	805,308	0.12
Vested as of December 31	805,308	0.12
Exercisable as of December 31	—	—

Equity share option 2017 and 2019

Share-based payments

Schedule of key assumptions used to derive the option value


	2019
	ESOP 2017	ESOP 2019
Exercise price (EUR)	0.12	12.58
Share price at grant date (EUR)	12.58	12.58
Volatility (%)	70	70
Risk‑free interest rate (%)	(0.7)	(0.7)
Dividend yield (%)	0	0
Option term (years)	10	10

Equity share option 2017 (Equity settled)

Share-based payments

Schedule of share option activity


	2020
	Number	WAEP
Outstanding as of January 1	805,308	0.12
Granted during the year	—	0.12
Cancelled during the year	—	0.12
Exercised during the year	(256,303)	0.12
Outstanding as of December 31	549,005	0.12
Vested as of December 31	549,005	0.12
Exercisable as of December 31	549,005	0.12

Equity share option 2019 (Equity settled)

Share-based payments

Schedule of share option activity


	2019		2020
	Number	WAEP (EUR)	Number	WAEP
Outstanding as of January 1	—	—	396,522	12.58
Cancelled during the year	—	—	(396,522)	12.58
Replacement awards granted during the year	—	—	300,000	—
Granted during the year	396,522	12.58	—	—
Exercised during the year	—	—	—	—
Outstanding as of December 31	396,522	12.58	300,000	—
Vested as of December 31	—	—	100,000	—
Exercisable as of December 31	—	—	100,000	—

2019 Plan

Share-based payments

Schedule of share option activity


	2020
	Options		RSUs
	Number	WAEP (USD)	Number	WAEP
Outstanding as of January 1	—	—	—	—
Granted during the year(1)	154,925	11.60	1,585,100	—
Exercised during the year	—	—	—	—
Outstanding as of December 31	154,925	11.60	1,585,100	—
Vested as of December 31	36,175	11.60	124,850	—
Exercisable as of December 31	36,175	11.60	124,850	—

Summary of Restricted Stock Units


	2020
	Options		RSUs
	Number	WAEP (USD)	Number	WAEP
Outstanding as of January 1	—	—	—	—
Granted during the year(1)	154,925	11.60	1,585,100	—
Exercised during the year	—	—	—	—
Outstanding as of December 31	154,925	11.60	1,585,100	—
Vested as of December 31	36,175	11.60	124,850	—
Exercisable as of December 31	36,175	11.60	124,850	—

Schedule of key assumptions used to derive the option value


	2020 Fair Value assumptions
	ESOP 2019	Options	Performormance
	Replacement		Based RSUs
Exercise price (USD)	14.00	11.60	n/a
Share price at grant date (USD)	12.02	11.05	12.54
Volatility (%)	75	75	88
Risk‑free interest rate (%)	1.0	0.8	0.2-0.3
Dividend yield (%)	0	0	0
Expected contractual life (years)	8.9	10	12.08-13.08
Weighted average fair value (USD)	12.02	6.20	8.23

Financial instruments—fair values and risk management (Tables)

12 Months Ended

Dec. 31, 2020

Financial instruments—fair values and risk management

Schedule of information regarding the credit risk exposure of trade receivables and contract assets


As of December 31, 2019
									Past due by
	Total Gross				Past due 1 -		Past due 31‑ 90		more than 90
in EUR k	amount		Not past due		30 days		days		days
Middle East	10,470		3,956		721		1,411		4,382
Europe	3,311		2,476		268		222		345
Latin America	811		611		53		42		105
North America	4,156		3,908		53		24		171
Asia Pacific	180		151		18		9		2
Total	18,928		11,102		1,113		1,708		5,005
Expected credit loss rate	12.3	%	0.3	%	1.0	%	1.2	%	45.4	%
Expected credit loss	2,335		31		11		21		2,272


As of December 31, 2020
									Past due by
	Total Gross				Past due 1 -		Past due 31‑ 90		more than 90
in EUR k	amount		Not past due		30 days		days		days
Middle East	10,515		3,338		486		385		6,306
Europe	20,017		19,193		706		113		5
Latin America	387		313		24		13		37
North America	2,870		1,205		994		262		409
Asia Pacific	178		136		18		24		—
Total	33,967		24,185		2,228		797		6,757
Expected credit loss rate	14	%	1.6	%	3.1	%	7.7	%	63.0	%
Expected credit loss	4,768		382		70		61		4,255

Schedule of development of impairment losses relating to trade and other receivables


in EUR k	2019	2020
As of January 1	1,633	2,355
Provision for expected credit losses	752	3,879
Write-off	(30)	(1,466)
As of December 31	2,355	4,768

Schedule of residual contractual terms of financial liabilities, including estimated interest payments


		Contractually agreed cash flows
						More
Dec 31, 2019	Carrying		Less than	2 to 12	1 to 5	than
in EUR k	amount	Total	2 months	months	years	5 years
Bank overdrafts	2,636	2,636	2,636	—	—	—
Secured bank loans	1,770	1,866	12	848	1,006	—
Lease liabilities	21,704	25,934	755	3,034	9,574	12,571
Municipal Loans	860	1,022	—	327	695	—
Trade payables	8,554	8,554	6,871	1,683	—	—
	35,524	40,012	10,274	5,892	11,275	12,571


		Contractually agreed cash flows
						More
Dec 31, 2020	Carrying		Less than	2 to 12	1 to 5	than
in EUR k	amount	Total	2 months	months	years	5 years
Bank overdrafts	1,538	1,538	1,538	—	—	—
Secured bank loans	968	997	5	584	408	—
Other bank loans	387	394	—	394	—	—
Lease liabilities	21,205	24,897	716	3,580	9,861	10,740
Municipal Loans	—	—	—	—	—	—
Trade payables	31,736	31,525	31,011	514	—	—
	55,834	59,351	33,270	5,072	10,269	10,740

Schedule of reconciliation of liabilities arising from financing activities


			Non-cash changes
				Changes in
in EUR k	Jan 1, 2019	Cash flows	Additions	maturity	Dec 31, 2019
Non-current financial liabilities	14,627	(12,783)	18,910	(1,107)	19,647
Non-current portion of secured bank loans	12,055	(11,087)	—	—	968
Municipal loans	860	—	—	(250)	610
Non-current lease liabilities	1,712	(1,696)	18,910	(857)	18,069
Current financial liabilities	5,052	(1,614)	2,778	1,107	7,323
Current portion of secured bank loans	1,787	(985)	—	—	802
Bank overdrafts	1,915	721	—	—	2,636
Municipal loans	—	—	—	250	250
Current lease liabilities	1,350	(1,350)	2,778	857	3,635
Total	19,679	(14,397)	21,688	—	26,970


			Non-cash changes
				Changes in
in EUR k	Jan 1, 2020	Cash flows	Additions	maturity and FX	Dec 31, 2020
Non-current financial liabilities	19,647	(1,993)	2,029	(1,605)	18,078
Non-current portion of secured bank loans	968	—	—	(567)	401
Municipal loans	610	(610)	—	—	—
Non-current lease liabilities	18,069	(1,383)	2,029	(1,038)	17,677
Current financial liabilities	7,323	(5,520)	2,663	1,554	6,020
Current portion of secured bank loans	802	(865)	63	567	567
Bank loans	—	438	—	(51)	387
Bank overdrafts	2,636	(1,208)	110	—	1,538
Municipal loans	250	(250)	—	—	—
Current lease liabilities	3,635	(3,635)	2,490	1,038	3,528
Total	26,970	(7,513)	4,692	(51)	24,098

Schedule of net foreign currency exposure


	Dec 31, 2019
in EUR k	USD	INR	AED
Trade receivables	4,275	36	(1)
Trade payables and other liabilities	(2,801)	(98)	(15)
Net exposure	1,474	(62)	(16)


	Dec 31, 2020
in EUR k	USD	INR	AED
Trade receivables	1,224	18	—
Trade payables and other liabilities	(3,631)	(55)	(17)
Net exposure	(2,407)	(37)	(17)

List of subsidiaries (Tables)

12 Months Ended

Dec. 31, 2020

List of subsidiaries

Schedule of major subsidiaries


		Equity interests (%)
	Country in which
	primary activities are
Name	pursued	Dec 31, 2019	Dec 31, 2020
Centogene GmbH	Germany	100	100
Centogene IP GmbH	Germany	100	100
Centogene Shared Service GmbH	Germany	100	100
Centogene FZ-LLC	United Arab Emirates	100	100
Centogene US, LLC	USA	100	100
Centogene GmbH	Austria	90	90
Centogene India Pvt. Ltd*	India	51	100
Centogene Switzerland AG	Switzerland	—	100
Centosafe B.V.	Netherlands	—	100
Centogene d.o.o Belgrade	Serbia	—	100
LPC GmbH**	Germany	51	—
Dr. Bauer Laboratoriums GmbH***	Germany	—	—

Non-controlling interests (Tables)

12 Months Ended

Dec. 31, 2020

Non-controlling interests

Schedule of information related to each subsidiary of the Group with material, non-controlling interests before intercompany eliminations

Dec 31, 2019	Centogene India Pvt. Ltd	LPC GmbH
in EUR k
Net assets/(liabilities)	(1,263)	(546)
Carrying amount of non‑controlling interests	(619)	(268)
Revenue	687	0
Profit/(loss)	(311)	(56)
Profit/loss allocated to non‑controlling interests	(152)	(27)


Dec 31, 2020	Centogene GmbH, Vienna	Dr. Bauer Laboratoriums GmbH
in EUR k
Net assets/(liabilities)	(522)	148
Carrying amount of non‑controlling interests	(52)	—
Revenue	—	55,596
Profit/(loss)	(1)	122
Profit/loss allocated to non‑controlling interests	(0)	122

Related parties (Tables)

12 Months Ended

Dec. 31, 2020


in EUR k	2018	2019	2020
Short‑term employee benefits	2,354	3,313	4,273
Post‑employment pension and medical benefits	10	10	23
Termination benefits	—	—	565
Share‑based payment transactions	2,893	3,395	1,822
Total compensation to key management	5,257	6,718	6,683

General company information (Details) € / shares in Units, € in Millions			1 Months Ended		12 Months Ended
	Nov. 07, 2019 $ / shares	Nov. 07, 2019 EUR (€) € / shares	Jul. 31, 2020 $ / shares	Jul. 31, 2020 EUR (€) € / shares shares	Dec. 31, 2020 EUR (€)
General company information
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs					€ 22.0
Common shares
General company information
Public offering price (in dollars per share) \| (per share)	$ 14.00	€ 12.58
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs		€ 42.0
Follow-on public offering \| Common shares
General company information
Public offering price (in dollars per share) \| (per share)			$ 14.00	€ 12.71
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs				€ 22.0
Follow-on public offering \| Common shares \| Major purchases of assets
General company information
Number of common shares issued (in shares) \| shares				3,500,000
Public offering price (in dollars per share) \| (per share)			$ 14.00	€ 12.71
Follow-on public offering \| Common shares \| Selling shareholders \| Major purchases of assets
General company information
Number of common shares issued (in shares) \| shares				1,500,000
Follow-on public offering \| Common shares \| The Company \| Major purchases of assets
General company information
Number of common shares issued (in shares) \| shares				2,000,000
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs				€ 22.0

Significant accounting policies (Details)	12 Months Ended
Significant accounting policies (Details)	Dec. 31, 2020 $ / €	Dec. 31, 2020 $ / €	Dec. 31, 2020 $ / € ₨ / €	Dec. 31, 2020 $ / € د.إ / €	Dec. 31, 2020 $ / € D	Dec. 31, 2019 $ / €	Dec. 31, 2019 $ / € ₨ / €	Dec. 31, 2019 $ / € د.إ / €	Dec. 31, 2018 $ / €	Dec. 31, 2018 $ / € ₨ / €	Dec. 31, 2018 $ / € د.إ / €	Dec. 31, 2020 ₨ / €	Dec. 31, 2020 د.إ / €	Dec. 31, 2019 ₨ / €	Dec. 31, 2019 د.إ / €	Dec. 31, 2018 ₨ / €	Dec. 31, 2018 د.إ / €
Foreign currency and currency translation
Average rate		1.1412	84.5737	4.2091		1.1191	78.7980	4.0985	1.1779	79.3177	4.2713
Closing rate	1.2271	1.2271	1.2271	1.2271	1.2271	1.1234	1.1234	1.1234	1.1419	1.1419	1.1419	89.6605	4.5045	80.1870	4.0795	78.5156	4.1396
Financial instruments
Number of days past due, to consider a financial asset as default					360
Buildings
Property, plant and equipment
Estimated useful life of property, plant and equipment	33 years
Leases
Estimated useful life of right-of-use assets	33 years
Offices \| Minimum
Leases
Estimated useful life of right-of-use assets	4 years
Offices \| Maximum
Leases
Estimated useful life of right-of-use assets	12 years
Plant and other equipment, furniture and fixtures Certain plant and machineries \| Minimum
Property, plant and equipment
Estimated useful life of property, plant and equipment	2 years
Leases
Estimated useful life of right-of-use assets	2 years
Plant and other equipment, furniture and fixtures Certain plant and machineries \| Maximum
Property, plant and equipment
Estimated useful life of property, plant and equipment	15 years
Leases
Estimated useful life of right-of-use assets	15 years
Software, patents and trademarks \| Minimum
Intangible assets
Estimated useful lives	3 years
Software, patents and trademarks \| Maximum
Intangible assets
Estimated useful lives	7 years
Corona Test Portal
Intangible assets
Estimated useful lives	2 years
Capitalized development costs
Intangible assets
Estimated useful lives	7 years

Accounting judgments and estimates (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Accounting judgments and estimates
Intangible assets other than goodwill	€ 12,407	€ 14,145
Gross carrying amount
Accounting judgments and estimates
Intangible assets other than goodwill	28,040	21,534	€ 13,868
Gross carrying amount \| Capitalized development costs
Accounting judgments and estimates
Intangible assets other than goodwill	€ 9,680	€ 12,923

Segment information and revenue from contracts with customers - Information by operating segments (Details) € in Thousands	12 Months Ended
	Dec. 31, 2020 EUR (€) segment	Dec. 31, 2019 EUR (€)	Dec. 31, 2018 EUR (€)
Segment information
Number of reportable segments \| segment	3
Total Revenues from contracts with external customers	€ 128,381	€ 48,780	€ 40,478
Adjusted EBITDA	1,083	(5,687)	90
Additions to property, plant and equipment			8,710
Additions to property, plant and equipment and right-of-use assets	12,730	21,268
Additions to intangible assets	6,657	7,280	3,059
Other segment information
Depreciation and amortization (including impairments)	15,128	6,579	5,175
Research and development expenses	14,935	9,590	6,300
Recognized over time
Segment information
Total Revenues from contracts with external customers	62,739	44,417	35,248
Recognized at a point in time
Segment information
Total Revenues from contracts with external customers	65,642	4,363	5,230
Pharmaceutical
Segment information
Total Revenues from contracts with external customers	16,951	21,522	17,307
Pharmaceutical \| Recognized over time
Segment information
Total Revenues from contracts with external customers	15,947	17,159	12,077
Pharmaceutical \| Recognized at a point in time
Segment information
Total Revenues from contracts with external customers	1,004	4,363	5,230
Pharmaceutical \| Pharmaceutical Partner
Segment information
Total Revenues from contracts with external customers	0	1,930	4,000
Diagnostics
Segment information
Total Revenues from contracts with external customers	22,108	27,258	23,171
Diagnostics \| Recognized over time
Segment information
Total Revenues from contracts with external customers	22,108	27,258	23,171
Covid-19
Segment information
Total Revenues from contracts with external customers	89,322
Adjusted EBITDA	37,215
Additions to property, plant and equipment and right-of-use assets	9,113
Additions to intangible assets	1,672
Other segment information
Depreciation and amortization (including impairments)	1,400
Covid-19 \| Recognized over time
Segment information
Total Revenues from contracts with external customers	24,684
Covid-19 \| Recognized at a point in time
Segment information
Total Revenues from contracts with external customers	64,638
Operating segment \| Pharmaceutical
Segment information
Total Revenues from contracts with external customers	16,951	21,522	17,307
Adjusted EBITDA	6,194	14,956	13,641
Additions to property, plant and equipment			1,225
Additions to property, plant and equipment and right-of-use assets	333	1,362
Additions to intangible assets	3,183	3,603	1,948
Other segment information
Depreciation and amortization (including impairments)	6,769	1,308	1,222
Research and development expenses			334
Operating segment \| Diagnostics
Segment information
Total Revenues from contracts with external customers	22,108	27,258	23,171
Adjusted EBITDA	(2,408)	2,306	2,285
Additions to property, plant and equipment			1,917
Additions to property, plant and equipment and right-of-use assets	602	1,998
Other segment information
Depreciation and amortization (including impairments)	2,289	2,032	1,838
Corporate
Segment information
Adjusted EBITDA	(39,918)	(22,949)	(15,836)
Additions to property, plant and equipment			5,568
Additions to property, plant and equipment and right-of-use assets	2,682	17,908
Additions to intangible assets	1,802	3,677	1,111
Other segment information
Depreciation and amortization (including impairments)	4,670	3,239	2,115
Research and development expenses	€ 14,935	€ 9,590	€ 5,966

Segment information and revenue from contracts with customers - Reconciliation of segment Adjusted EBITDA to Group Loss for the Period (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Segment information
Share-based compensation	€ (3,486)	€ (5,714)	€ (5,521)
Depreciation and amortization (including impairments)	(15,128)	(6,579)	(5,175)
Operating loss	(19,703)	(18,684)	(10,606)
Financial costs, net	(1,394)	(2,013)	(1,042)
Income taxes expenses	(281)	(158)	310
Loss for the year	(21,378)	(20,855)	(11,338)
Operating segment
Segment information
Reportable segment Adjusted EBITDA	41,001	17,262	15,926
Reportable segment Adjusted EBITDA after corporate expenses	1,083	(5,687)	90
Operating loss	(19,703)	(18,684)	(10,606)
Financial costs, net	(1,394)	(2,013)	(1,042)
Income taxes expenses	(281)	(158)	310
Loss for the year	(21,378)	(20,855)	(11,338)
Corporate
Segment information
Corporate expenses	(39,918)	(22,949)	(15,836)
Depreciation and amortization (including impairments)	(4,670)	(3,239)	(2,115)
Share‑based payment expenses
Segment information
Share-based compensation	(5,658)	(6,418)	(5,521)
Depreciation and amortization
Segment information
Depreciation and amortization (including impairments)	€ (15,128)	€ (6,579)	€ (5,175)

Segment information and revenue from contracts with customers - Geographical information (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of operating segments
Rendering of services	€ 126,642	€ 46,347	€ 39,248
Sales of goods	1,739	2,433	1,230
Total Revenues from contracts with external customers	128,381	48,780	40,478
—United States
Disclosure of operating segments
Total Revenues from contracts with external customers	19,059	22,778	17,296
Europe
Disclosure of operating segments
Total Revenues from contracts with external customers	94,068	7,447	6,850
Germany
Disclosure of operating segments
Total Revenues from contracts with external customers	81,065	508	1,061
—Netherlands
Disclosure of operating segments
Total Revenues from contracts with external customers	6,575	25
Middle East
Disclosure of operating segments
Total Revenues from contracts with external customers	12,624	14,099	12,401
—Saudi Arabia
Disclosure of operating segments
Total Revenues from contracts with external customers		7,417	5,475
North America
Disclosure of operating segments
Total Revenues from contracts with external customers	19,265	23,276	18,113
Latin America
Disclosure of operating segments
Total Revenues from contracts with external customers	1,888	2,987	2,185
Asia Pacific
Disclosure of operating segments
Total Revenues from contracts with external customers	536	971	929
Recognized over time
Disclosure of operating segments
Total Revenues from contracts with external customers	62,739	44,417	35,248
Recognized at a point in time
Disclosure of operating segments
Total Revenues from contracts with external customers	65,642	4,363	5,230
Pharmaceutical
Disclosure of operating segments
Rendering of services	15,947	19,089	16,077
Sales of goods	1,004	2,433	1,230
Total Revenues from contracts with external customers	16,951	21,522	17,307
Pharmaceutical \| —United States
Disclosure of operating segments
Total Revenues from contracts with external customers	16,711	20,896	16,653
Pharmaceutical \| Europe
Disclosure of operating segments
Total Revenues from contracts with external customers	149	381	654
Pharmaceutical \| Germany
Disclosure of operating segments
Total Revenues from contracts with external customers		233	654
Pharmaceutical \| —Netherlands
Disclosure of operating segments
Total Revenues from contracts with external customers	0
Pharmaceutical \| Middle East
Disclosure of operating segments
Total Revenues from contracts with external customers	56	122
Pharmaceutical \| North America
Disclosure of operating segments
Total Revenues from contracts with external customers	16,711	20,896	16,653
Pharmaceutical \| Latin America
Disclosure of operating segments
Total Revenues from contracts with external customers	35	123
Pharmaceutical \| Asia Pacific
Disclosure of operating segments
Total Revenues from contracts with external customers	0
Pharmaceutical \| Recognized over time
Disclosure of operating segments
Total Revenues from contracts with external customers	15,947	17,159	12,077
Pharmaceutical \| Recognized at a point in time
Disclosure of operating segments
Total Revenues from contracts with external customers	1,004	4,363	5,230
Diagnostics
Disclosure of operating segments
Rendering of services	22,108	27,258	23,171
Total Revenues from contracts with external customers	22,108	27,258	23,171
Diagnostics \| —United States
Disclosure of operating segments
Total Revenues from contracts with external customers	1,370	1,882	643
Diagnostics \| Europe
Disclosure of operating segments
Total Revenues from contracts with external customers	5,605	7,066	6,196
Diagnostics \| Germany
Disclosure of operating segments
Total Revenues from contracts with external customers	186	275	407
Diagnostics \| —Netherlands
Disclosure of operating segments
Total Revenues from contracts with external customers	3	25
Diagnostics \| Middle East
Disclosure of operating segments
Total Revenues from contracts with external customers	12,568	13,977	12,401
Diagnostics \| —Saudi Arabia
Disclosure of operating segments
Total Revenues from contracts with external customers		7,417	5,475
Diagnostics \| North America
Disclosure of operating segments
Total Revenues from contracts with external customers	1,576	2,380	1,460
Diagnostics \| Latin America
Disclosure of operating segments
Total Revenues from contracts with external customers	1,851	2,864	2,185
Diagnostics \| Asia Pacific
Disclosure of operating segments
Total Revenues from contracts with external customers	508	971	929
Diagnostics \| Recognized over time
Disclosure of operating segments
Total Revenues from contracts with external customers	22,108	€ 27,258	€ 23,171
Covid-19
Disclosure of operating segments
Rendering of services	88,587
Sales of goods	735
Total Revenues from contracts with external customers	89,322
Covid-19 \| —United States
Disclosure of operating segments
Total Revenues from contracts with external customers	978
Covid-19 \| Europe
Disclosure of operating segments
Total Revenues from contracts with external customers	88,314
Covid-19 \| Germany
Disclosure of operating segments
Total Revenues from contracts with external customers	80,879
Covid-19 \| —Netherlands
Disclosure of operating segments
Total Revenues from contracts with external customers	6,572
Covid-19 \| North America
Disclosure of operating segments
Total Revenues from contracts with external customers	978
Covid-19 \| Latin America
Disclosure of operating segments
Total Revenues from contracts with external customers	2
Covid-19 \| Asia Pacific
Disclosure of operating segments
Total Revenues from contracts with external customers	28
Covid-19 \| Recognized over time
Disclosure of operating segments
Total Revenues from contracts with external customers	24,684
Covid-19 \| Recognized at a point in time
Disclosure of operating segments
Total Revenues from contracts with external customers	€ 64,638

Segment information and revenue from contracts with customers - Contract balances (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Segment information and revenue from contracts with customers
Trade receivables (note 15)	€ 25,656	€ 12,709
Contract assets (note 15)	3,543	3,884
Contract liabilities (note 19.2)	€ 4,479	€ 3,748

Segment information and revenue from contracts with customers - Additional information (Details) € in Thousands	12 Months Ended
	Dec. 31, 2020 EUR (€) customer	Dec. 31, 2019 EUR (€) customer	Dec. 31, 2018 EUR (€) customer
Segment information
Share issue related cost	€ 779	€ 4,899	€ 0
Real estate transfer tax expenses		1,200	0
Property, plant and equipment	16,590	8,376
Right-of-use assets.	22,120	24,932	5,767
Revenue from contracts with customers	128,381	48,780	40,478
Provision for expected credit losses on contract assets	356	8
Revenues recognized for contract liabilities	2,516	3,748
Performance obligations	1,963	€ 0
Pharmaceutical Partner
Segment information
Percentage of revenue		24.30%
—United States
Segment information
Property, plant and equipment	516	€ 286	718
Right-of-use assets.	709	1,042	0
Revenue from contracts with customers	19,059	22,778	17,296
Germany
Segment information
Revenue from contracts with customers	81,065	508	1,061
Follow-on public offering
Segment information
Share issue related cost	278
IPO
Segment information
Share issue related cost		1,092
Pharmaceutical
Segment information
Revenue from contracts with customers	16,951	21,522	17,307
Pharmaceutical \| Pharmaceutical Partner
Segment information
Revenue from contracts with customers	€ 0	€ 1,930	€ 4,000
Percentage of revenue	8.60%	24.30%	27.30%
Number of customer in group \| customer	1	1	1
Pharmaceutical \| —United States
Segment information
Revenue from contracts with customers	€ 16,711	€ 20,896	€ 16,653
Pharmaceutical \| Germany
Segment information
Revenue from contracts with customers		€ 233	€ 654
Covid-19
Segment information
Revenue from contracts with customers	€ 89,322
Number of customer in group \| customer	2
Covid-19 \| Covid-19 Partner One
Segment information
Percentage of revenue	14.60%
Covid-19 \| Covid-19 Partner Two
Segment information
Percentage of revenue	13.50%
Covid-19 \| —United States
Segment information
Revenue from contracts with customers	€ 978
Covid-19 \| Germany
Segment information
Revenue from contracts with customers	80,879
Capitalized investment	10,800
Property Plant And Equipment \| Covid-19 \| Germany
Segment information
Capitalized investment	7,700
Right-of-use assets \| Covid-19 \| Germany
Segment information
Capitalized investment	1,400
Intangible assets \| Covid-19 \| Germany
Segment information
Capitalized investment	€ 1,700

Other income and expenses - Other operating income (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Other income and expenses
Government grants	€ 2,152	€ 2,641	€ 1,611
Gain on disposal of property, plant and equipment	2	532
Exchange rate gains		314	147
Income from the reversal of provisions		89	309
Others	240	205	239
Total other operating income	2,394	3,781	2,306
Employee benefits expense	39,271	32,843	26,034
Contributions to state pension scheme (defined contribution plan)	1,851	1,136	1,046
Supervisory board members
Other income and expenses
Employee benefits expense	€ 2,775	€ 1,203	€ 341

Other income and expenses - Other operating expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Other income and expenses
Ifrs Other operating expense	€ 182	€ 1,284	€ 273
Miscellaneous other operating expense	172	1,092	23
Net foreign exchange loss	10	192	250
Share issue related cost	€ 779	€ 4,899	€ 0

Other income and expenses - LPC GmbH (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Other income and expenses
Non‑controlling interests	€ 95	€ (938)
LPC GmbH
Other income and expenses
Proportion of ownership interest in subsidiary	51.00%	51.00%
Consideration for disposal of subsidiary	€ 213
Consideration to be paid over time	€ 200
Payment due period (in years)	4 years
Consideration outstanding	€ 150
Non‑controlling interests	(268)	€ 268
Profit/(loss) allocated to non-controlling interest	€ (101)	€ (27)

Other income and expenses - Financial costs, net (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Other income and expenses
Interest expenses from loans	€ (173)	€ (1,690)	€ (922)
Currency losses	(362)
Unwinding of the discount on lease liabilities	(865)	(339)	(153)
Interest income from loans and receivables	6	16	33
Financial costs, net	€ (1,394)	€ (2,013)	€ (1,042)

Other income and expenses - Employee benefits expense (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Other income and expenses
Wages and salaries	€ 31,121	€ 23,854	€ 17,965
Social security contributions	4,095	3,212	2,492
Share-based payment expenses	3,486	5,714	5,521
Termination benefits expense	569	63	56
Employee benefits expense	€ 39,271	€ 32,843	€ 26,034

Income taxes - Taxes recognized through profit or loss (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income taxes
Current tax expenses	€ (74)	€ (158)	€ (87)
Current year	(58)	(1)	(87)
Adjustments for prior periods	(16)	(157)
Deferred tax (expense)/income	(207)		397
Temporary differences	(182)	(514)	527
Tax losses	(25)	514	(130)
Income tax (expenses)/ benefit	(281)	(158)	310
Income taxes recognized directly in other comprehensive income	€ 0	€ 0	€ 0

- Definition

The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]

+ References + Details

Income taxes - Reconciliation of the effective tax rate to the statutory rate (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Line Items]
Statutory rate (as a percent)	31.10%	31.10%	31.10%
Loss before tax	€ (21,097)	€ (20,697)	€ (11,648)
Taxes on the basis of the Company’s domestic tax rate	6,570	6,445	3,623
Tax rate effect of foreign tax jurisdictions	65	412	406
Non-deductible expenses	(903)	(441)	(105)
Current year losses for which no deferred tax assets were recognized	(5,792)	(6,416)	(3,528)
Tax income related to prior years	(16)	(157)
Tax income related to prior years	(137)	(157)
Other effects	(84)	(1)	(86)
Income tax (expenses)/ benefit	€ (281)	€ (158)	€ 310
Domestic tax rate
Income Tax Disclosure [Line Items]
Statutory rate (as a percent)	31.10%	31.10%	31.10%
Corporate income tax rate (as a percent)	15.00%
Solidarity surcharge (as a percent)	5.50%
Trade tax rate (as a percent)	15.30%

Income taxes - Deferred Taxes (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income taxes
Deductible temporary differences, for which no deferred tax asset is recognized	€ 3,381
Temporary differences associated with investments for which no deferred tax liability has been recognized	4,313	€ 4,360	€ 3,049
Deferred tax assets	8,034	3,342
Deferred tax liabilities	(8,241)	(3,342)
Deferred tax assets, Offset	(8,034)	(3,342)
Deferred tax liabilities, Offset	8,034	3,342
Deferred Taxes	(207)
Deferred Taxes	207
Germany
Income taxes
Tax losses carryforwards for which no deferred tax assets were recognized	64,464	41,570	21,728
Other countries
Income taxes
Tax losses carryforwards for which no deferred tax assets were recognized	1,002	505	€ 788
Intangible assets
Income taxes
Deferred tax liabilities	(2,934)	(3,013)
Property Plant And Equipment
Income taxes
Deferred tax liabilities	(133)	(156)
Right-of-use assets
Income taxes
Deferred tax liabilities	(5,029)
Measurement of service contracts
Income taxes
Deferred tax liabilities	(145)	(173)
Lease liabilities
Income taxes
Deferred tax assets	4,865
Government grants
Income taxes
Deferred tax assets	1,903	2,051
Unused tax losses
Income taxes
Deferred tax assets	€ 1,266	€ 1,291

Loss Per Share (Details) - shares	12 Months Ended
Loss Per Share (Details) - shares	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Loss Per Share
Weighted average number of outstanding shares after adjusted for the effect of the corporate reorganization	20,909,673	16,409,285	14,112,841

Intangible assets (Details) - EUR (€) € in Thousands	12 Months Ended
Intangible assets (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Intangible assets
Balance, at the beginning of the year	€ 14,145
Additions		€ 7,280
Balance, at the end of the year	12,407	14,145
Biomarkers
Intangible assets
Impairment expense	4,700
Internally generated /acquired \| Biomarkers
Intangible assets
Balance, at the beginning of the year	8,191
Additions		3,603
Reclass		900
Balance, at the end of the year	3,174	8,191
Internally generated /acquired \| Database
Intangible assets
Balance, at the beginning of the year	4,732
Additions		2,379
Reclass		758
Balance, at the end of the year	6,506	4,732
Purchased \| Rights, licenses, software
Intangible assets
Balance, at the beginning of the year	1,222
Additions		1,298
Reclass		(1,658)
Balance, at the end of the year	2,727	1,222
Gross carrying amount
Intangible assets
Balance, at the beginning of the year	21,534	13,868
Additions	6,657
Reclass from property, plant and equipment		386
Deconsolidation	(151)
Balance, at the end of the year	28,040	21,534
Gross carrying amount \| Internally generated /acquired \| Biomarkers
Intangible assets
Balance, at the beginning of the year	12,022	7,133
Additions	1,900
Reclass from property, plant and equipment		386
Balance, at the end of the year	13,922	12,022
Gross carrying amount \| Internally generated /acquired \| Database
Intangible assets
Balance, at the beginning of the year	6,502	3,365
Additions	2,717
Balance, at the end of the year	9,219	6,502
Gross carrying amount \| Purchased \| Rights, licenses, software
Intangible assets
Balance, at the beginning of the year	3,010	3,370
Additions	2,040
Reclass	1,658
Deconsolidation	(151)
Balance, at the end of the year	4,899	3,010
Accumulated depreciation, amortization and impairment
Intangible assets
Balance, at the beginning of the year	(7,389)	(5,073)
Deconsolidation	124
Amortization and impairment	8,368	2,316
Balance, at the end of the year	(15,633)	(7,389)
Accumulated depreciation, amortization and impairment \| Internally generated /acquired \| Biomarkers
Intangible assets
Balance, at the beginning of the year	(3,831)	(2,660)
Amortization and impairment	6,917	1,171
Balance, at the end of the year	(10,748)	(3,831)
Accumulated depreciation, amortization and impairment \| Internally generated /acquired \| Database
Intangible assets
Balance, at the beginning of the year	(1,770)	(1,047)
Amortization and impairment	943	723
Balance, at the end of the year	(2,713)	(1,770)
Accumulated depreciation, amortization and impairment \| Purchased \| Rights, licenses, software
Intangible assets
Balance, at the beginning of the year	(1,788)	(1,366)
Deconsolidation	124
Amortization and impairment	508	422
Balance, at the end of the year	€ (2,172)	€ (1,788)

Property, plant and equipment (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, plant and equipment
Balance, at the beginning of the year	€ 8,376
Reclass from (to) right-of-use assets	1,992
Balance, at the end of the year	16,590	€ 8,376
Buildings
Property, plant and equipment
Balance, at the beginning of the year	2,862
Balance, at the end of the year	2,773	2,862
Plant
Property, plant and equipment
Balance, at the beginning of the year	3,575
Balance, at the end of the year	5,869	3,575
Other equipment, furniture and fixtures
Property, plant and equipment
Balance, at the beginning of the year	1,939
Balance, at the end of the year	7,948	1,939
Gross carrying amount
Property, plant and equipment
Balance, at the beginning of the year	17,696	47,907
Reclass from (to) right-of-use assets	3,099	(6,335)
Additions	9,890	296
Disposal	(612)	(23,786)
Reclass to intangible assets		(386)
Balance, at the end of the year	30,073	17,696
Gross carrying amount \| Land
Property, plant and equipment
Balance, at the beginning of the year		2,149
Disposal		(2,149)
Gross carrying amount \| Buildings
Property, plant and equipment
Balance, at the beginning of the year	3,254	24,891
Additions	105
Disposal		(21,637)
Balance, at the end of the year	3,359	3,254
Gross carrying amount \| Plant
Property, plant and equipment
Balance, at the beginning of the year	9,730	16,011
Reclass from (to) right-of-use assets	3,099	(6,303)
Additions	1,295	22
Balance, at the end of the year	14,124	9,730
Gross carrying amount \| Other equipment, furniture and fixtures
Property, plant and equipment
Balance, at the beginning of the year	4,712	4,856
Reclass from (to) right-of-use assets		(32)
Additions	8,490	274
Disposal	(612)
Reclass to intangible assets		(386)
Balance, at the end of the year	12,590	4,712
Accumulated depreciation, amortization and impairment
Property, plant and equipment
Balance, at the beginning of the year	(9,320)	(8,792)
Reclass from (to) right-of-use assets	(1,107)	971
Disposal	44	957
Depreciation	3,100	2,456
Balance, at the end of the year	(13,483)	(9,320)
Accumulated depreciation, amortization and impairment \| Buildings
Property, plant and equipment
Balance, at the beginning of the year	(392)	(612)
Disposal		957
Depreciation	194	737
Balance, at the end of the year	(586)	(392)
Accumulated depreciation, amortization and impairment \| Plant
Property, plant and equipment
Balance, at the beginning of the year	(6,155)	(6,178)
Reclass from (to) right-of-use assets	(1,107)	963
Depreciation	993	940
Balance, at the end of the year	(8,255)	(6,155)
Accumulated depreciation, amortization and impairment \| Other equipment, furniture and fixtures
Property, plant and equipment
Balance, at the beginning of the year	(2,773)	(2,002)
Reclass from (to) right-of-use assets		8
Disposal	44
Depreciation	1,913	779
Balance, at the end of the year	€ (4,642)	(2,773)
IFRS 16
Property, plant and equipment
Reclass from (to) right-of-use assets		€ 5,364

Right-of-use assets (Details) € in Thousands	1 Months Ended	12 Months Ended
Right-of-use assets (Details) € in Thousands	Jul. 31, 2019	Dec. 31, 2020 EUR (€) contract	Nov. 30, 2019 EUR (€)
Leases
Bank guarantee		€ 3,256
Short term deposits pledged as security		€ 1,628
Number of lease contracts containing termination options \| contract		0
Rostock headquarters building
Leases
Lease term	12 years	12 years
Short term deposits pledged as security			€ 1,500
Number of times the lease contract can be extended \| contract		2
Lease contract extension term		6 years
Rental expense		€ 1,400
Offices in Berlin
Leases
Lease term		12 years
Offices in Boston
Leases
Lease term		4 years
Plant and machinery
Leases
Lease term		2 years
Rental deposits		€ 115
Other equipment
Leases
Lease term		4 years
Motor vehicles
Leases
Lease term		3 years
Certain motor vehicles and premises \| Maximum
Leases
Lease term		12 months

Right-of-use assets - Carrying amounts of right-of-use assets and movements during the period (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases
Beginning balance	€ 24,932	€ 5,767
Additions	2,840	20,972
Reclass to property, plant & equipment	(1,992)
Depreciation expenses	(3,660)	(1,807)
Ending balance	22,120	24,932
Buildings
Leases
Beginning balance	13,126
Additions		13,456
Depreciation expenses	(1,121)	(330)
Ending balance	12,005	13,126
Offices
Leases
Beginning balance	4,407	391
Additions	426	4,288
Depreciation expenses	(657)	(272)
Ending balance	4,176	4,407
Plant and equipment
Leases
Beginning balance	6,989	5,340
Additions	1,265	2,824
Reclass to property, plant & equipment	(1,992)
Depreciation expenses	(1,675)	(1,175)
Ending balance	4,587	6,989
Other equipment
Leases
Beginning balance	390	24
Additions	1,112	386
Depreciation expenses	(187)	(20)
Ending balance	1,315	390
Motor vehicles
Leases
Beginning balance	20	12
Additions	37	18
Depreciation expenses	(20)	(10)
Ending balance	€ 37	€ 20

Right-of-use assets - Carrying amounts of lease liabilities and the movements during the period (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Right-of-use assets
Beginning balance	€ 21,704	€ 3,465
Additions	3,654	20,946
Interest expenses	865	339	€ 153
Payments	(5,018)	(3,046)
Ending balance	21,205	21,704	€ 3,465
Current lease liabilities	3,528	3,635
Non-current lease liabilities	€ 17,677	€ 18,069

Right-of-use assets - Amounts recognised in profit or loss (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Right-of-use assets
Depreciation expense of right-of-use assets	€ 3,660	€ 1,807
Interest expenses on lease liabilities	865	339	€ 153
Rent expenses - short-term leases	1,695	185
Rent expense - leases of low-value assets	33	25
Total amounts recognized in profit or loss	6,253	2,356
Total cash outflows for leases	€ 6,746	€ 3,256

Right-of-use assets - Sale and Leaseback transactions (Details) - EUR (€) € in Thousands	1 Months Ended			12 Months Ended
	Nov. 30, 2019	Jul. 31, 2019	Jun. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Leases
Real estate transfer tax expenses					€ 1,200	€ 0
Proceeds from sale of land and building					21,300
Loans repaid using the consideration from sale of land and building				€ 2,760	12,072	€ 2,851
Cash deposits provided as security for bank loans				€ 1,628
Grants refunded related to disposed property, plant and equipment	€ 358				358
Rostock headquarters building
Leases
Disposal of property			€ 22,829
Proceeds from sale of land and building		€ 24,000
Lease term		12 years		12 years
Loans repaid using the consideration from sale of land and building					10,776
Additional interest paid using the consideration from sale of land and building					1,159
Rental deposits made using the consideration from sale of land and building					3,000
Cash deposits provided as security for bank loans	€ 1,500
Gain on disposal of fixed assets					532
Decrease in property, plant and equipment					22,829
Increase in right-of-use assets					13,456
Increases in lease liabilities					€ 14,091

Inventories (Details) - EUR (€) € in Thousands	12 Months Ended
Inventories (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Inventories
Raw materials, consumables and supplies	€ 11,167	€ 1,644
Finished goods and merchandise	238	165
Inventories	11,405	1,809
Raw materials, consumables and changes in inventories of finished goods and work in process recorded as expenses	€ 41,594	€ 11,285	€ 9,473

Trade and other receivables and other assets (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Non-current
Other assets-Rental deposits	€ 1,867	€ 1,948
Other assets-Others	100
Trade receivables and contract assets and other assets non-current	1,967	1,948
Current
Trade receivables	25,656	12,709
Contract assets	3,543	3,884
Receivables due from shareholders		2,766
Payables due to holders of vested options		2,769
Other assets	8,286	5,846
Trade receivables and contract assets and other assets current	37,485	25,205
Total non-current and current trade receivables and contract assets and other assets	39,452	27,153
Credit loss rates in relation to the outstanding trade receivables and contract assets
Impairment of financial assets	3,738	752	€ 792
Cash deposits provided as security for bank loans	1,628
Bank guarantee	€ 3,256
Current value added tax receivables		1,311
Minimum
Current
Receivables payment terms	30 days
Maximum
Current
Receivables payment terms	90 days
Other assets
Credit loss rates in relation to the outstanding trade receivables and contract assets
Current value added tax receivables	€ 226	1,311
Prepaid expenses	4,431	3,481
Receivables from exercise of share based payments granted	1,253	0
Receivables from COVID 19 bank or credit card transactions	1,076	0
Receivables from grants	442	€ 409
Other assets \| Rostock headquarters building
Credit loss rates in relation to the outstanding trade receivables and contract assets
Cash deposits provided as security for bank loans	1,500
Bank guarantee	3,000
Other assets \| Berlin Offices
Credit loss rates in relation to the outstanding trade receivables and contract assets
Cash deposits provided as security for bank loans	128
Bank guarantee	257
Other assets \| Plant and other equipment, furniture and fixtures Certain plant and machineries
Non-current
Other assets-Rental deposits	190
Other assets \| LPC GmbH
Credit loss rates in relation to the outstanding trade receivables and contract assets
Consideration receivable for the sale of LPC	€ 100

Cash and short-term deposits (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Borrowings
Short term deposits pledged as security	€ 1,628
Secured bank loan
Borrowings
Short term deposits pledged as security	1,500	€ 1,500
Overdraft facility
Borrowings
Short term deposits pledged as security	1,000	0
Existing Overdraft facility
Borrowings
Short term deposits pledged as security	2,500	€ 2,500
Maximum borrowing capacity	2,500
Second Overdraft facility
Borrowings
Maximum borrowing capacity	500
Third Overdraft facility
Borrowings
Maximum borrowing capacity	€ 500

Equity - Issued capital and capital reserve (Details) - Common shares - € / shares		12 Months Ended
	Nov. 07, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Equity
Number of shares issued and fully paid, Beginning		19,861,340	15,861,000
Issued shares	4,000,000	2,000,000	4,000,000
Exercise of options		256,000
Number of shares issued and fully paid, Ending		22,117,643	19,861,340
Authorized common shares		79,000,000	79,000,000
Par value per share (in euros per share)	€ 0.12	€ 0.12	€ 0.12	€ 0.12

Equity - Common Shares (Details) € / shares in Units, € in Millions				1 Months Ended		12 Months Ended
	Nov. 12, 2019	Nov. 07, 2019 € / shares $ / shares	Nov. 07, 2019 EUR (€) € / shares shares	Jul. 31, 2020 $ / shares	Jul. 31, 2020 EUR (€) € / shares shares	Dec. 31, 2020 EUR (€) Vote € / shares shares	Dec. 31, 2019 € / shares shares	Dec. 31, 2018 € / shares shares
Disclosure of classes of share capital [line items]
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs \| €						€ 22.0
Common shares
Disclosure of classes of share capital [line items]
Common stock outstanding								15,861,340
Par value per share (in euros per share) \| € / shares		€ 0.12	€ 0.12			€ 0.12	€ 0.12	€ 0.12
Conversion ratio of common shares								33.2238
Increase (decrease) in number of ordinary shares issued			4,000,000			2,000,000	4,000,000
Public offering price (in dollars per share) \| (per share)		€ 14.00	€ 12.58
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs \| €			€ 42.0
Authorized but unissued share capital						6,826,000	7,097,000
Number of shares issued and fully paid						22,117,643	19,861,340	15,861,000
Preferred shares
Disclosure of classes of share capital [line items]
Par value per share (in euros per share) \| € / shares								€ 1.00
Conversion ratio of preferred shares								89.6125
Centogene GmbH \| Common shares
Disclosure of classes of share capital [line items]
Reverse share split ratio	33.2238%
Par value per share (in euros per share) \| € / shares								€ 1.00
Number of common shares converted								230,445,000
Centogene GmbH \| Preferred shares
Disclosure of classes of share capital [line items]
Reverse share split ratio	89.6125%
Number of voting rights per share \| Vote						1
Number of preferred shares converted								91,562
Follow-on public offering \| Common shares
Disclosure of classes of share capital [line items]
Total number of shares issued and sold in follow-on public offering					3,500,000
Number of shares offered by existing shareholders					1,500,000
Public offering price (in dollars per share) \| (per share)				$ 14.00	€ 12.71
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs \| €					€ 22.0
Follow-on public offering \| The Company \| Common shares
Disclosure of classes of share capital [line items]
Increase (decrease) in number of ordinary shares issued					2,000,000

Equity - Capital Reserves (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Capital reserve
Share premium included in capital reserve	€ 107,498	€ 90,297

Capital management - Additional Information (Details) € in Thousands	Dec. 31, 2020 EUR (€)
Capital management
Cash deposits provided as security for bank loans	€ 1,628

Financial liabilities - Interest-bearing loans (Details) € in Thousands, $ in Thousands	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Financial liabilities
Total non-current liabilities		€ 18,078	€ 19,647
Total current liabilities		6,020	7,323
Total non-current and current liabilities		24,098	26,970
Short term deposits pledged as security		1,628
Total loans
Financial liabilities
Total non-current liabilities		401	1,578
Total current liabilities		2,492	3,688
Secured bank loans
Financial liabilities
Total non-current liabilities		401	968
Total current liabilities		567	802
Short term deposits pledged as security		1,500	1,500
Other bank loans
Financial liabilities
Total current liabilities		387
Total non-current and current liabilities \| $	$ 387
Bank overdrafts
Financial liabilities
Total current liabilities		1,538	2,636
Municipal loans
Financial liabilities
Total non-current liabilities			610
Total current liabilities			250
Lease liabilities
Financial liabilities
Total non-current liabilities		17,677	18,069
Total current liabilities		3,528	3,635
Total non-current and current liabilities		€ 21,205	€ 21,704

Financial liabilities - Conditions and statement of liabilities (Details) € in Thousands, $ in Thousands	Dec. 31, 2020 USD ($)	Dec. 31, 2020 EUR (€)	Apr. 15, 2020 EUR (€)	Dec. 31, 2019 EUR (€)
Financial liabilities
Nominal amount		€ 24,098		€ 26,970
Carrying amount		55,834		35,524
Carrying amount		24,098		26,970
Financial assets pledged as collateral for liabilities or contingent liabilities		1,628
Bank overdrafts		910		476
Secured bank loans
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities		€ 1,500		1,500
Secured bank loans, bearing maturity period of 2017-25, three
Financial liabilities
Nominal interest rate (as a percent)	2.95%	2.95%
Nominal amount		€ 968		1,770
Carrying amount		€ 968		1,770
Other bank loans
Financial liabilities
Nominal interest rate (as a percent)	1.00%	1.00%
Nominal amount \| $	$ 387
Carrying amount \| $	$ 387
Municipal loans
Financial liabilities
Nominal amount				860
Municipal loan, 2018-2023
Financial liabilities
Nominal interest rate (as a percent)	8.25%	8.25%
Nominal interest rate profit (as a percent)	1.50%	1.50%
Nominal interest rate, on losses (as a percent)	0.75%	0.75%
Nominal amount				500
Carrying amount				500
Municipal loan, 2021, one
Financial liabilities
Nominal interest rate (as a percent)	8.00%	8.00%
Nominal interest rate profit (as a percent)	1.50%	1.50%
Nominal interest rate, on losses (as a percent)	0.75%	0.75%
Nominal amount				360
Carrying amount				360
Bank overdrafts, one
Financial liabilities
Nominal interest rate (as a percent)	4.75%	4.75%
Nominal amount		€ 498		476
Carrying amount		€ 498		476
Bank overdrafts, two
Financial liabilities
Nominal interest rate (as a percent)	3.75%	3.75%
Nominal amount		€ 628		2,160
Carrying amount		€ 628		2,160
Bank overdrafts, three
Financial liabilities
Nominal interest rate (as a percent)	4.50%	4.50%
Nominal amount		€ 412
Carrying amount		412
Lease liabilities
Financial liabilities
Nominal amount		21,205		21,704
Carrying amount		€ 21,205		21,704
Minimum \| Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	5.40%	5.40%
Nominal interest rate at commencement of leases	2.10%	2.10%
Maximum \| Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	9.10%	9.10%
Nominal interest rate at commencement of leases	3.50%	3.50%
Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities		€ 1,000		0
Short-term deposits, pledged as security		2,500	€ 500	2,500
Existing Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities		€ 2,500		€ 2,500

Financial liabilities - Trade payables and other liabilities (Details) - EUR (€) € in Thousands	1 Months Ended	12 Months Ended
	Nov. 30, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Disclosure of reconciliation of liabilities arising from financing activities
Trade payables		€ 31,736	€ 8,554
Government grants (deferred income)		10,292	11,289
Liability for Virtual Stock Option Program			2,769
Contract liabilities		4,479	3,748
Others		13,483	5,258
Trade payables and other liabilities		59,990	31,618
Non-current		8,950	9,941
Current		51,040	21,677
Grants received for investment in property, plant and equipment		390	793	€ 3,042
Provision for outstanding invoices		1,245	1,210
Personnel related liabilities for vacation and bonuses		4,032	2,264
VAT payable		4,578
VAT receivable			1,311
Liabilities for wage and church tax		1,988	376
Grants refunded related to disposed property, plant and equipment	€ 358		358
IPO
Disclosure of reconciliation of liabilities arising from financing activities
Costs relating to offering			565
Other assets
Disclosure of reconciliation of liabilities arising from financing activities
VAT receivable		€ 226	€ 1,311

Share-based payments - Virtual share option program 2016 (Cash settled) (Details) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2019 EUR (€) Options € / shares	Dec. 31, 2018 EUR (€)	Jul. 01, 2016 shares
WAEP
Payables due to holders of vested options \| €	€ 2,769
Virtual share option program 2016 (Cash settled)
Share-based payments
Number of authorized shares under the plan \| shares			1,000,000
Percentage of original shares represented by authorized share under the plan			5.00%
Number of original shares for authorization of share options \| shares			205,000
Number
Outstanding at January 1 \| Options	802,283
Exercised during the year \| Options	(802,283)
WAEP
Outstanding at January 1 \| € / shares	€ 3.22
Exercised during the year \| € / shares	€ 3.45
Payables due to holders of vested options \| €	€ 2,768	€ 2,170

Share-based payments - Virtual share option program 2017 (Cash settled) (Details) - Virtual share option program 2017 (Cash settled) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2019 EUR (€) Options € / shares shares	Dec. 31, 2017 shares
Share-based payments
Number of authorized shares under the plan \| shares		29,560
Percentage of original shares represented by authorized share under the plan		10.00%
Vesting period		3 years
Vesting percentage		33.33%
Number
Outstanding at January 1 \| Options	10,496
Granted during the year \| Options	5,878
Cancelled during the year \| Options	(16,374)
Replacement awards granted during the year \| Options	805,308
Outstanding at December 31 \| Options	805,308
Vested at December 31 \| shares	805,308
WAEP
Outstanding at January 1	€ 1.0
Granted during the year	€ 1.0
Cancelled during the year	1.0
Replacement awards granted during the year	€ 0.12
Outstanding at December 31	0.12
Vested at December 31	€ 0.12
Total accumulated liability prior to the modification date was reclassified to the capital reserve \| €	€ 10,038

Share-based payments - Equity share option 2017 (Equity settled) (Details) - Equity share option 2017 (Equity settled)	12 Months Ended
	Dec. 31, 2020 Options € / shares shares	Dec. 31, 2020 Options € / shares $ / shares shares	Dec. 31, 2019 Options € / shares shares
Share-based payments
Number of common shares per option granted \| shares			1
Exercise price of share options	€ 0.12
Lock-up period			180 days
Weighted average remaining contractual life of outstanding share options	9 years	9 years
Number
Outstanding at January 1 \| Options	805,308	805,308
Granted during the year \| Options			805,308
Exercised during the year \| Options	(256,303)	(256,303)
Outstanding at December 31 \| Options	549,005	549,005	805,308
Vested at December 31 \| shares	549,005	549,005
Exercisable at December 31 \| Options	549,005	549,005
WAEP
Outstanding at January 1	€ 0.12
Granted during the year	€ 0.12
Cancelled during the year	0.12	0.12
Exercised during the year \| (per share)	€ 0.12	$ 12.13
Outstanding at December 31	0.12		€ 0.12
Vested at December 31	0.12	$ 0.12
Exercisable at December 31	€ 0.12	$ 0.12

Share-based payments - Equity share option 2019 (Equity settled) (Details) € / shares in Units, € in Thousands			4 Months Ended	12 Months Ended
	Dec. 18, 2020 Options € / shares	Sep. 11, 2020 USD ($)	Apr. 15, 2021 Options $ / shares	Dec. 31, 2020 Options € / shares $ / shares shares	Dec. 31, 2020 EUR (€) Options USD ($) € / shares	Dec. 31, 2019 EUR (€) Options € / shares shares	Dec. 31, 2018 EUR (€)
Share-based payments
Share-based payment expense \| €					€ 1,822	€ 3,395	€ 2,893
Equity share option 2019 (Equity settled)
Number
Outstanding at January 1			300,000		396,522
Cancelled during the year					(396,522)
Replacement awards granted during the year					300,000
Granted during the year						396,522
Outstanding at December 31					300,000	396,522
Vested at December 31 \| shares				100,000
Exercisable at December 31				100,000
WAEP
Outstanding at January 1 \| € / shares					€ 12.58
Cancelled during the year \| € / shares				12.58
Granted during the year \| € / shares						€ 12.58
Outstanding at December 31 \| € / shares						€ 12.58
Equity share option 2019 (Equity settled) \| Member of the supervisory board
Share-based payments
Number of common shares per option granted \| shares						1
Vesting percentage						33.33%
Weighted average remaining contractual life of outstanding share options						10 years
Weighted average fair value of options outstanding \| € / shares						€ 9.08
Vesting period						3 years
Number
Granted during the year						396,522
WAEP
Granted during the year \| € / shares						€ 12.58
Equity share option 2019 (Equity settled) \| Key management personnel
Share-based payments
Vesting percentage						33.33%
2019 Plan
Share-based payments
Maximum amount of share-based award grants allowed under the plan (as a percent)					19.00%
Additional share-based award grants allowed under the plan (as a percent)					3.00%
RSUs granted \| $					1,585,100
Incremental fair value \| €					€ 135
Number
Outstanding at January 1			154,925
Granted during the year					154,925
Outstanding at December 31					154,925
Vested at December 31 \| shares				36,175
Exercisable at December 31				36,175
WAEP
Outstanding at January 1 \| $ / shares			$ 11.60
Granted during the year \| (per share)	€ 0			$ 11.60
Outstanding at December 31 \| $ / shares				11.60
Vested at December 31 \| $ / shares				11.60
Exercisable at December 31 \| $ / shares				$ 11.60
2019 Plan \| RSUs
Share-based payments
RSUs granted	300,000
Contractual life	10 years
2019 Plan \| RSUs \| Key management personnel
Share-based payments
RSUs granted \| $		75,000
2019 Plan \| Vest immediately \| RSUs
Share-based payments
Vesting percentage	33.00%
2019 Plan \| Vest in two equal annual instalments \| RSUs
Share-based payments
Vesting percentage	67.00%

Share-based payments - 2020 grant to management board and employees (Details) - 2019 Plan					12 Months Ended
	Dec. 18, 2020 Options	Dec. 01, 2020 USD ($)	Oct. 15, 2020 USD ($)	Sep. 11, 2020 Options USD ($) $ / shares	Dec. 31, 2020 Options USD ($)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted					154,925
RSUs granted \| $					1,585,100
Trading days				20 days
Exercise price \| $ / shares				$ 11.60
Chief Executive Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted					154,925
RSUs granted					1,033,600
Options \| Key management personnel
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted				87,500
Options \| Chief Executive Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted				36,175
Options \| Chief Financial Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted				16,250
Options \| Chief Information Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted				15,000
RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted	300,000
RSUs \| Key management personnel
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted \| $				75,000
RSUs \| Chief Executive Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted \| $		324,000		72,350
RSUs \| Chief Financial Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted \| $				32,250
RSUs \| Chief Information Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted \| $				30,000
RSUs \| Employees
Disclosure of terms and conditions of share-based payment arrangement [line items]
RSUs granted \| $			251,500
Tranche one
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting percentage				33.33%
Tranche two
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting percentage				33.33%
Tranche three
Disclosure of terms and conditions of share-based payment arrangement [line items]
Vesting percentage				33.33%

Share-based payments - 2020 grant to new CEO and supervisory board grant (Details) - 2019 Plan € / shares in Units, € in Thousands, SFr in Thousands					4 Months Ended	12 Months Ended
	Dec. 18, 2020 Options € / shares	Dec. 01, 2020 CHF (SFr) USD ($)	Dec. 01, 2020 $ / shares	Sep. 11, 2020 Options USD ($)	Apr. 15, 2021 Options USD ($) $ / shares	Dec. 31, 2020 CHF (SFr) Options USD ($)	Dec. 31, 2020 Options USD ($) $ / shares shares	Dec. 31, 2020 EUR (€) Options USD ($)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted during the year						1,585,100		1,585,100
Number
Outstanding at January 1 \| Options					154,925
Granted during the year \| Options						154,925		154,925
Outstanding at December 31 \| Options						154,925		154,925
Vested at December 31 \| shares							36,175
Exercisable at December 31 \| Options							36,175
WAEP
Outstanding at January 1 \| $ / shares					$ 11.60
Granted during the year \| (per share)	€ 0						$ 11.60
Outstanding at December 31 \| $ / shares							11.60
Vested at December 31 \| $ / shares							11.60
Exercisable at December 31 \| $ / shares							$ 11.60
Number
Outstanding as of January 1					1,585,100
Granted during the year						1,585,100		1,585,100
Outstanding as of December 31						1,585,100		1,585,100
Vested at December 31						124,850		124,850
Exercisable as of December 31							124,850
RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted during the year \| Options	300,000
Contractual life	10 years
Number
Granted during the year \| Options	300,000
Chief Executive Officer
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted during the year \| Options						1,033,600		1,033,600
Value of ordinary shares to be issued as per share based payment arrangement \| SFr		SFr 1,000
Value of other equity instruments granted under share based payment arrangement \| SFr		SFr 1,400				SFr 1,400
Contractual life		10 years
Number
Granted during the year \| Options						154,925		154,925
Number
Granted during the year \| Options						1,033,600		1,033,600
Chief Executive Officer \| RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted during the year		324,000		72,350
Number
Granted during the year		324,000		72,350
Chief Executive Officer \| Performance Based RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted during the year		500,000
Number
Granted during the year		500,000
Chief Executive Officer \| Options
Number
Granted during the year \| Options				36,175
Chief Executive Officer \| Volume weighted average stock price equals or exceeds USD 24 prior to January 1st, 2023
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of units vested during the period		200,000
Share hurdle price \| $ / shares			$ 24
Chief Executive Officer \| Volume weighted average stock price equals or exceeds USD 33 prior to January 1st, 2024.
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of units vested during the period		300,000
Share hurdle price \| $ / shares			$ 33
Supervisory board members
Disclosure of terms and conditions of share-based payment arrangement [line items]
Granted during the year						300,000		300,000
Contractual life						10 years		10 years
Value of equity ordinary shares \| €								€ 80,000
Maximum percentage of lost time injury						100.00%		100.00%
Period of tradings days						60 days		60 days
Number
Granted during the year						300,000		300,000
Supervisory board members \| RSUs
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of award constitutes RSU's						75.00%		75.00%
Supervisory board members \| Options
Disclosure of terms and conditions of share-based payment arrangement [line items]
Percentage of award constitutes stock options						25.00%		25.00%
Chairman
Disclosure of terms and conditions of share-based payment arrangement [line items]
Value of additional equity ordinary shares \| €								€ 60,000
Vice chairman
Disclosure of terms and conditions of share-based payment arrangement [line items]
Value of additional equity ordinary shares \| €								40,000
Chairman of audit committee
Disclosure of terms and conditions of share-based payment arrangement [line items]
Value of additional equity ordinary shares \| €								40,000
Chairman of compensation committee
Disclosure of terms and conditions of share-based payment arrangement [line items]
Value of additional equity ordinary shares \| €								€ 8,000

Share-based payments - Valuation of Options (Details) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2020 $ / shares	Dec. 31, 2020 EUR (€) Y	Dec. 31, 2019 EUR (€) Y € / shares	Dec. 31, 2018 EUR (€)
Options
Key assumptions used to derive other equity instruments value
Exercise price (USD) \| $ / shares	$ 11.60
Share price at grant date (USD) \| $ / shares	11.05
Volatility (%)		75.00%
Risk‑free interest rate (%)		0.80%
Dividend yield (%)		0.00%
Expected contractual life (years) \| Y		10
Weighted average fair value (USD) \| $ / shares	6.20
Performance Based RSUs
Key assumptions used to derive other equity instruments value
Share price at grant date (USD) \| $ / shares	12.54
Volatility (%)		88.00%
Dividend yield (%)		0.00%
Weighted average fair value (USD) \| $ / shares	8.23
Performance Based RSUs \| Minimum
Key assumptions used to derive other equity instruments value
Risk‑free interest rate (%)		0.20%
Expected contractual life (years) \| Y		12.08
Performance Based RSUs \| Maximum
Key assumptions used to derive other equity instruments value
Risk‑free interest rate (%)		0.30%
Expected contractual life (years) \| Y		13.08
Virtual share option program 2017 (Cash settled)
Expenses arising from share-based payment transactions
Expenses arising from cash-settled share-based payment transactions \| €			€ 5,118	€ 4,079
Virtual share option program 2016 (Cash settled)
Expenses arising from share-based payment transactions
Expenses offset by replacement equity-settled share-based payment transactions \| €			596	1,442
Equity share option 2017 and 2019
Expenses arising from share-based payment transactions
Expenses arising from cash-settled share-based payment transactions \| €			5,714	5,521
Expenses arising from equity-settled share-based payment transactions \| €		€ 5,658	704
Total expenses arising from share-based payment transactions \| €		5,658	€ 6,418	€ 5,521
Equity share option 2017 (Equity settled)
Key assumptions used to derive the option value
Exercise price \| € / shares			€ 0.12
Share price at grant date \| € / shares			€ 12.58
Volatility (%)			70.00%
Risk-free interest rate (%)			(0.70%)
Dividend yield (%)			0.00%
Option term (years) \| Y			10
Equity share option 2019 (Equity settled)
Key assumptions used to derive the option value
Exercise price \| € / shares			€ 12.58
Share price at grant date \| € / shares			€ 12.58
Volatility (%)			70.00%
Risk-free interest rate (%)			(0.70%)
Dividend yield (%)			0.00%
Option term (years) \| Y			10
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions \| €		€ 2,105	€ 704
2019 Plan
Key assumptions used to derive other equity instruments value
Exercise price (USD) \| $ / shares	14.00
Share price at grant date (USD) \| $ / shares	12.02
Volatility (%)		75.00%
Risk‑free interest rate (%)		1.00%
Dividend yield (%)		0.00%
Expected contractual life (years) \| Y		8.9
Weighted average fair value (USD) \| $ / shares	12.02
2019 Plan \| Management board and employees
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions \| €		€ 3,217
2019 Plan \| New CEO
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions \| €		269
2019 Plan \| Supervisory board members
Expenses arising from share-based payment transactions
Expenses arising from equity-settled share-based payment transactions \| €		€ 67
2019 Plan \| RSUs
Key assumptions used to derive other equity instruments value
Weighted average fair value (USD) \| $ / shares	$ 11.62

Financial instruments—fair values and risk management - Credit risk (Details) € in Thousands	12 Months Ended
	Dec. 31, 2020 EUR (€) customer	Dec. 31, 2019 EUR (€)	Dec. 31, 2018 EUR (€)	Dec. 31, 2020 EUR (€)	Dec. 31, 2019 EUR (€)	Dec. 31, 2018 EUR (€)	Dec. 31, 2017 EUR (€)
Credit risk exposure
Cash and cash equivalents				€ 48,156	€ 41,095	€ 9,222	€ 3,157
Development of impairment losses
Expected credit loss allowances on trade receivables	€ 3,738	€ 752	€ 792
Impairment loss on financial assets	3,738	752	792
Credit risk
Credit risk exposure
Cash and cash equivalents				48,156	41,095
Trade receivables and contract assets \| Specific bad debt allowances \| Credit risk
Credit risk exposure
Expected credit loss	4,768	2,355	1,633	4,768	2,355	€ 1,633
Development of impairment losses
As of January 1	2,355	1,633
Expected credit loss allowances on trade receivables	3,879	752
Write-off	(1,466)	(30)
As of December 31	4,768	2,355	€ 1,633
Trade receivables and contract assets \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				€ 33,967	€ 18,928
Expected credit loss rate				14.00%	12.30%
Expected credit loss	4,768	2,335		€ 4,768	€ 2,335
Development of impairment losses
As of January 1	2,335
As of December 31	4,768	2,335
Trade receivables and contract assets \| Middle East \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				10,515	10,470
Trade receivables and contract assets \| Europe \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				20,017	3,311
Trade receivables and contract assets \| Latin America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				387	811
Trade receivables and contract assets \| North America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				2,870	4,156
Trade receivables and contract assets \| Asia Pacific \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				178	180
Trade receivables and contract assets \| Not past due \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				€ 24,185	€ 11,102
Expected credit loss rate				1.60%	0.30%
Expected credit loss	382	31		€ 382	€ 31
Development of impairment losses
As of January 1	31
As of December 31	382	31
Trade receivables and contract assets \| Not past due \| Middle East \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				3,338	3,956
Trade receivables and contract assets \| Not past due \| Europe \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				19,193	2,476
Trade receivables and contract assets \| Not past due \| Latin America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				313	611
Trade receivables and contract assets \| Not past due \| North America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				1,205	3,908
Trade receivables and contract assets \| Not past due \| Asia Pacific \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				136	151
Trade receivables and contract assets \| Past due 1 to 30 day \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				€ 2,228	€ 1,113
Expected credit loss rate				3.10%	1.00%
Expected credit loss	70	11		€ 70	€ 11
Development of impairment losses
As of January 1	11
As of December 31	70	11
Trade receivables and contract assets \| Past due 1 to 30 day \| Middle East \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				486	721
Trade receivables and contract assets \| Past due 1 to 30 day \| Europe \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				706	268
Trade receivables and contract assets \| Past due 1 to 30 day \| Latin America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				24	53
Trade receivables and contract assets \| Past due 1 to 30 day \| North America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				994	53
Trade receivables and contract assets \| Past due 1 to 30 day \| Asia Pacific \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				18	18
Trade receivables and contract assets \| Past due 31-90 days \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				€ 797	€ 1,708
Expected credit loss rate				7.70%	1.20%
Expected credit loss	61	21		€ 61	€ 21
Development of impairment losses
As of January 1	21
As of December 31	61	21
Trade receivables and contract assets \| Past due 31-90 days \| Middle East \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				385	1,411
Trade receivables and contract assets \| Past due 31-90 days \| Europe \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				113	222
Trade receivables and contract assets \| Past due 31-90 days \| Latin America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				13	42
Trade receivables and contract assets \| Past due 31-90 days \| North America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				262	24
Trade receivables and contract assets \| Past due 31-90 days \| Asia Pacific \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				24	9
Trade receivables and contract assets \| Past due more than 90 days \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				€ 6,757	€ 5,005
Expected credit loss rate				63.00%	45.40%
Expected credit loss	4,255	2,272		€ 4,255	€ 2,272
Development of impairment losses
As of January 1	2,272
As of December 31	4,255	€ 2,272
Trade receivables and contract assets \| Past due more than 90 days \| Middle East \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				6,306	4,382
Trade receivables and contract assets \| Past due more than 90 days \| Europe \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				5	345
Trade receivables and contract assets \| Past due more than 90 days \| Latin America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				37	105
Trade receivables and contract assets \| Past due more than 90 days \| North America \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets				€ 409	171
Trade receivables and contract assets \| Past due more than 90 days \| Asia Pacific \| Gross carrying amount
Credit risk exposure
Trade receivables and contract assets					€ 2
Trade receivables \| Specific bad debt allowances \| Credit risk
Development of impairment losses
Impairment loss on financial assets	3,879
Trade receivables \| More than 365 days \| Specific bad debt allowances \| Credit risk
Development of impairment losses
Write-off	€ (1,466)
Diagnostics \| MENA \| Credit risk
Credit risk exposure
Number of top diagnostic customers \| customer	10
Percentage of overdue balances				90.00%

Financial instruments—fair values and risk management - Liquidity risk (Details) € / shares in Units, € in Thousands		1 Months Ended	12 Months Ended
	Nov. 07, 2019 EUR (€) shares	Jul. 31, 2020 € / shares shares	Dec. 31, 2020 EUR (€) shares	Dec. 31, 2019 EUR (€) shares	Jul. 31, 2020 $ / shares	Dec. 31, 2018 EUR (€)	Dec. 31, 2017 EUR (€)
Liquidity risk
Expected cash flows receivables with in two months			€ 16,154
Common per share \| (per share)		€ 12.71			$ 14.00
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs			22,000
Cash and cash equivalents			48,156	€ 41,095		€ 9,222	€ 3,157
Carrying amount			55,834	35,524
Total			59,351	40,012
Reconciliation of liabilities arising from financing activities
Beginning of year			26,970	19,679
Cash flows			(7,513)	(14,397)
Additions			4,692	21,688
Changes in maturity			(51)
End of year			24,098	26,970
Non-current financial liabilities
Reconciliation of liabilities arising from financing activities
Beginning of year			19,647	14,627
Cash flows			(1,993)	(12,783)
Additions			2,029	18,910
Changes in maturity			(1,605)	(1,107)
End of year			18,078	19,647
Non-current lease liabilities
Reconciliation of liabilities arising from financing activities
Beginning of year			18,069	1,712
Cash flows			(1,383)	(1,696)
Additions			2,029	18,910
Changes in maturity			(1,038)	(857)
End of year			17,677	18,069
Current financial liabilities
Reconciliation of liabilities arising from financing activities
Beginning of year			7,323	5,052
Cash flows			(5,520)	(1,614)
Additions			2,663	2,778
Changes in maturity			1,554	1,107
End of year			6,020	7,323
Non-current portion of secured bank loans
Reconciliation of liabilities arising from financing activities
Beginning of year			968	12,055
Cash flows				(11,087)
Changes in maturity			(567)
End of year			401	968
Municipal loans
Reconciliation of liabilities arising from financing activities
Beginning of year			610	860
Cash flows			(610)
Changes in maturity				(250)
End of year				610
Current portion of secured bank loans
Reconciliation of liabilities arising from financing activities
Beginning of year			802	1,787
Cash flows			(865)	(985)
Additions			63
Changes in maturity			567
End of year			567	802
Bank Loans
Reconciliation of liabilities arising from financing activities
Cash flows			438
Changes in maturity			(51)
End of year			387
Bank overdrafts
Reconciliation of liabilities arising from financing activities
Beginning of year			2,636	1,915
Cash flows			(1,208)	721
Additions			110
End of year			1,538	2,636
Municipal loans
Reconciliation of liabilities arising from financing activities
Beginning of year			250
Cash flows			(250)
Changes in maturity				250
End of year				250
Current lease liabilities
Reconciliation of liabilities arising from financing activities
Beginning of year			3,635	1,350
Cash flows			(3,635)	(1,350)
Additions			2,490	2,778
Changes in maturity			1,038	857
End of year			3,528	3,635
Less than 2 months
Liquidity risk
Total			33,270	10,274
2 to 12 months
Liquidity risk
Total			5,072	5,892
Within five years
Liquidity risk
Total			10,269	11,275
Later than 5 years
Liquidity risk
Total			10,740	12,571
Trade and other receivables due with in two months
Liquidity risk
Expected cash flows			14,857	6,644
Bank overdrafts
Liquidity risk
Carrying amount			1,538	2,636
Total			1,538	2,636
Bank overdrafts \| Less than 2 months
Liquidity risk
Total			€ 1,538	€ 2,636
Bank overdrafts \| 2 to 12 months
Liquidity risk
Interest-bearing loans will mature in less than one year (in percent)			25.00%	27.20%
Secured bank loans
Liquidity risk
Utilized amount of secured credit lines			€ 1,538	€ 2,636
Carrying amount			968	1,770
Secured bank loans			3,500	4,000
Total			€ 997	€ 1,866
Secured bank loans \| Minimum
Liquidity risk
Interest rate on secured credit lines			3.75%	3.33%
Secured bank loans \| Maximum
Liquidity risk
Interest rate on secured credit lines			4.75%	4.50%
Secured bank loans \| Less than 2 months
Liquidity risk
Total			€ 5	€ 12
Secured bank loans \| 2 to 12 months
Liquidity risk
Total			584	848
Secured bank loans \| Within five years
Liquidity risk
Total			408	1,006
Other bank loans
Liquidity risk
Carrying amount			387
Total			394
Other bank loans \| 2 to 12 months
Liquidity risk
Total			394
Lease liabilities
Liquidity risk
Carrying amount			21,205	21,704
Total			24,897	25,934
Lease liabilities \| Less than 2 months
Liquidity risk
Total			716	755
Lease liabilities \| 2 to 12 months
Liquidity risk
Total			3,580	3,034
Lease liabilities \| Within five years
Liquidity risk
Total			9,861	9,574
Lease liabilities \| Later than 5 years
Liquidity risk
Total			10,740	12,571
Municipal loans
Liquidity risk
Carrying amount				860
Total				1,022
Municipal loans \| 2 to 12 months
Liquidity risk
Total				327
Municipal loans \| Within five years
Liquidity risk
Total				695
Trade payables
Liquidity risk
Carrying amount			31,736	8,554
Total			31,525	8,554
Trade payables \| Less than 2 months
Liquidity risk
Total			31,011	6,871
Trade payables \| 2 to 12 months
Liquidity risk
Total			€ 514	€ 1,683
Common shares
Liquidity risk
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs	€ 42,000
Increase (decrease) in number of ordinary shares issued \| shares	4,000,000		2,000,000	4,000,000
Common shares \| Follow-on public offering
Liquidity risk
Total number of shares issued and sold in follow-on public offering \| shares		3,500,000
Number of shares offered by existing shareholders \| shares		1,500,000
The Company \| Common shares \| Follow-on public offering
Liquidity risk
Increase (decrease) in number of ordinary shares issued \| shares		2,000,000

Financial instruments—fair values and risk management - Currency risk (Details) - Currency risk - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
USD
Currency risk
Net exposure	€ 2,407	€ (1,474)
USD \| Trade receivables
Currency risk
Net exposure	1,224	4,275
USD \| Trade payables and other liabilities
Currency risk
Net exposure	3,631	2,801
INR
Currency risk
Net exposure	37	(62)
INR \| Trade receivables
Currency risk
Net exposure	18	36
INR \| Trade payables and other liabilities
Currency risk
Net exposure	55	98
AED
Currency risk
Net exposure	17	16
AED \| Trade receivables
Currency risk
Net exposure		(1)
AED \| Trade payables and other liabilities
Currency risk
Net exposure	€ 17	€ 15

List of subsidiaries (Details)	12 Months Ended
List of subsidiaries (Details)	Dec. 31, 2020	Dec. 31, 2019
Centogene GmbH
List of subsidiaries
Ownership interest in subsidiary (in percent)	100.00%	100.00%
Centogene IP GmbH
List of subsidiaries
Ownership interest in subsidiary (in percent)	100.00%	100.00%
Centogene Shared Service GmbH
List of subsidiaries
Ownership interest in subsidiary (in percent)	100.00%	100.00%
Centogene Fz Llc, United Arab Emirates
List of subsidiaries
Ownership interest in subsidiary (in percent)	100.00%	100.00%
Centogene US LLC, Burlington, USA
List of subsidiaries
Ownership interest in subsidiary (in percent)	100.00%	100.00%
Centogene GmbH, Vienna
List of subsidiaries
Ownership interest in subsidiary (in percent)	90.00%	90.00%
Centogene India Pvt. Ltd
List of subsidiaries
Ownership interest in subsidiary (in percent)	100.00%	51.00%
Proportion of additional ownership in subsidiary acquired	49.00%
Centogene Switzerland AG
List of subsidiaries
Ownership interest in subsidiary (in percent)	100.00%
Centosafe B.V.
List of subsidiaries
Ownership interest in subsidiary (in percent)	100.00%
Centogene d.o.o Belgrade
List of subsidiaries
Ownership interest in subsidiary (in percent)	100.00%
LPC GmbH
List of subsidiaries
Ownership interest in subsidiary (in percent)	51.00%	51.00%
Proportion of ownership interest in disposal	51.00%

Non-controlling interests (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Non-controlling interests
Non‑controlling interests	€ (95)	€ 938
Loss for the year	(21,378)	(20,855)	€ (11,338)
Centogene GmbH, Vienna
Non-controlling interests
Net assets/(liabilities)	(522)
Non‑controlling interests	(52)
Loss for the year	(1)
Profit/(loss) allocated to non-controlling interest	0
Dr. Bauer Laboratoriums GmbH
Non-controlling interests
Net assets/(liabilities)	148
Revenue	55,596
Loss for the year	122
Profit/(loss) allocated to non-controlling interest	€ 122
Centogene India Pvt. Ltd
Non-controlling interests
Proportion of additional ownership in subsidiary acquired	49.00%
Net assets/(liabilities)		(1,263)
Non‑controlling interests		(619)
Revenue		687
Loss for the year		(311)
Profit/(loss) allocated to non-controlling interest		(152)
LPC GmbH
Non-controlling interests
Proportion of ownership interest in disposal	51.00%
Net assets/(liabilities)		(546)
Non‑controlling interests	€ 268	(268)
Revenue		0
Loss for the year		(56)
Profit/(loss) allocated to non-controlling interest	€ (101)	€ (27)

Commitments (Details) - EUR (€) € in Thousands	12 Months Ended
Commitments (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019
Lease commitments
Total payment obligation	€ 4,669	€ 802
Rostock headquarters building
Lease commitments
Future lease payments to be made			€ 0
Rostock headquarters building \| Within one year
Lease commitments
Future lease payments to be made	283
Rostock headquarters building \| Within five years
Lease commitments
Future lease payments to be made	1,686
Rostock headquarters building \| Later than 5 years
Lease commitments
Future lease payments to be made	4,855
Office equipment and storage spaces \| Within one year
Lease commitments
Future lease payments to be made	33		72
Office equipment and storage spaces \| Within five years
Lease commitments
Future lease payments to be made	€ 9		€ 36

Related parties - Remuneration of members of key management (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Related parties
Short-term employee benefits	€ 4,273	€ 3,313	€ 2,354
Post-employment pension and medical benefits	23	10	10
Termination benefits	565
Share-based payment transactions	1,822	3,395	2,893
Total compensation paid to key management	€ 6,683	€ 6,718	€ 5,257

Related parties - Additional information (Details) € / shares in Units, € in Thousands, SFr in Thousands					1 Months Ended		12 Months Ended
	Dec. 18, 2020 € / shares	Dec. 01, 2020 CHF (SFr)	Nov. 07, 2019 $ / shares	Nov. 07, 2019 EUR (€) € / shares shares	Jul. 31, 2020 $ / shares	Jul. 31, 2020 EUR (€) € / shares shares	Dec. 31, 2020 CHF (SFr) Options USD ($) shares	Dec. 31, 2020 EUR (€) $ / shares	Dec. 31, 2020 EUR (€) Options USD ($) € / shares shares	Dec. 31, 2019 EUR (€) Options € / shares shares	Dec. 31, 2018 EUR (€)	Dec. 31, 2017 EUR (€)
Related parties
Share-based payment expenses									€ 3,486	€ 5,714	€ 5,521
Current receivables due from related parties										2,766
Payables due to holders of vested options										€ 2,769
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs									22,000
COVID Testing Supplies Purchases
Related parties
Payments for services									65
Payable for services								€ 75	75
COVID Testing Services
Related parties
Receivables of related to the exercise of options								€ 27	27
Revenues recognized in profit and loss									€ 127
Equity share option 2017 (Equity settled)
Related parties
Number of share options granted in share-based payment arrangement \| Options										805,308
Exercise price of share options \| € / shares									€ 0.12
2019 Plan
Related parties
Number of share options granted in share-based payment arrangement \| Options							154,925		154,925
Exercise price of share options \| (per share)	€ 0							€ 11.60
Number of other equity instruments granted in share-based payment arrangement \| $							1,585,100		1,585,100
Supervisory board members
Related parties
Share-based payment expenses									€ 2,172		704	€ 0
Supervisory board members \| Supervisory board activities
Related parties
Payments for services									€ 603		499	€ 341
Supervisory board members \| 2019 Plan
Related parties
Number of other equity instruments granted in share-based payment arrangement \| $							300,000		300,000
Member of the supervisory board \| Corporate strategy services
Related parties
Payments for services									€ 0	€ 152	0
Member of the supervisory board and an entity controlled by a member of the supervisory board \| Services
Related parties
Payments for services											€ 64
Key management personnel
Related parties
Additional share-based expenses									468
Severance payout									565
Accrued for key management compensation								€ 1,325	1,325	769
Receivables of related to the exercise of options								561	561	€ 0
Key management personnel \| Equity share option 2017 (Equity settled)
Related parties
Number of share options granted in share-based payment arrangement \| Options										440,475
Lock up period										6 months
Pension commitments for members of the management board								0	0
Exercise price of share options \| € / shares										€ 0.12
Former CEO And Major Shareholder [Member] \| Services
Related parties
Payments for services									11
Payable for services								€ 12	€ 12
Chief Executive Officer \| 2019 Plan
Related parties
Number of share options granted in share-based payment arrangement \| Options							154,925		154,925
Number of other equity instruments granted in share-based payment arrangement \| Options							1,033,600		1,033,600
Value of other equity instruments granted under share based payment arrangement \| SFr		SFr 1,400					SFr 1,400
Common shares
Related parties
Increase (decrease) in number of ordinary shares issued \| shares				4,000,000			2,000,000		2,000,000	4,000,000
Public offering price (in dollars per share) \| (per share)			$ 14.00	€ 12.58
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs				€ 42,000
Common shares \| Follow-on public offering
Related parties
Total number of shares issued and sold in follow-on public offering \| shares						3,500,000
Number of shares offered by existing shareholders \| shares						1,500,000
Public offering price (in dollars per share) \| (per share)					$ 14.00	€ 12.71
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs						€ 22,000
The Company \| Common shares \| Follow-on public offering
Related parties
Increase (decrease) in number of ordinary shares issued \| shares						2,000,000

Contingent Liabilities (Details) - EUR (€) € in Thousands	12 Months Ended
Contingent Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Nov. 08, 2018
Universitair Medisch Centrum Utrecht
Contingent Liabilities
Disputed amount	€ 1,300	€ 880
State of Mecklenburg-Western Pomerania ("MVP")
Contingent Liabilities
Disputed amount	2,300
Amounts received on invoices	€ 2,300

Subsequent Events (Details) - 2019 Plan		4 Months Ended	12 Months Ended
Subsequent Events (Details) - 2019 Plan	Dec. 18, 2020 Options	Apr. 15, 2021 tranche Options USD ($)	Dec. 31, 2020 Options USD ($)
Subsequent Event
RSUs granted \| $			1,585,100
Number of options granted \| Options			154,925
RSUs
Subsequent Event
RSUs granted \| Options	300,000
RSUs \| Management \| Grant of RSUs
Subsequent Event
RSUs granted \| $		59,488
Options \| Management \| Grant of Options
Subsequent Event
Number of options granted \| Options		15,000
Vesting in three tranches \| RSUs \| Management \| Grant of RSUs
Subsequent Event
RSUs granted \| $		30,000
Number of tranches		3
Vesting period		3 years
Vesting in three tranches \| Options \| Management \| Grant of Options
Subsequent Event
Number of tranches		3
Vesting period		3 years
Vesting in four tranches \| RSUs \| Management \| Grant of RSUs
Subsequent Event
RSUs granted		29,488
Number of tranches		4
Vesting period		4 years